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ABSTRACT OF THE DISSERTATION 
Defining the roles of outer membrane proteins and host cathelicidins in uropathogenic 
Escherichia coli infection 
by 
Elizabeth Sarah Danka 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2015 
Associate Professor David A. Hunstad, Chair 
 
The Gram-negative bacterium uropathogenic Escherichia coli (UPEC) is the causative 
agent of up to 85% of community-acquired urinary tract infections (UTIs). This thesis work 
aimed to better define interactions between UPEC and host antimicrobial peptides (AMPs). The 
bacterial outer membrane is constantly interacting with the external environment, and contains 
many integral proteins with defined roles in pathogenesis. The E. coli outer membrane protein 
OmpA is a highly conserved, integral beta-barrel membrane protein with four extracellular loops. 
We found that the loops of OmpA individually influence binding and invasion of UPEC during 
infection. Loop 2 appears to be essential for binding to the host epithelium. These effects are 
seen in vitro as well as in a murine model of UTI, where the pathogenic cascade is severely 
interrupted when loop 2 is absent. The loop 2 mutant forms very few intracellular bacterial 
communities (IBCs, a hallmark of UPEC UTI) and fails to cause robust acute infection. These 
phenotypes are not due to alterations in membrane permeability, growth, or the indispensable 
adhesive virulence organelle termed type 1 pili.  
xi 
 
AMPs are small proteins expressed by innate immune cells and epithelial cells, including 
those of the urinary tract. Although we predicted that the murine cathelicidin, termed CRAMP, 
would play an important role in urinary tract defense against UPEC, we instead found that 
CRAMP-deficient mice exhibit attenuated UTIs. These mice have lower bladder bacterial loads 
at all examined time points, fewer IBCs, less inflammation and inflammation-related bladder 
damage, and resolve infection faster. Early differences in bacterial binding to wild-type and 
mutant bladders are not attributable to modifications in bacterial adhesive factors, instead 
pointing to altered host uroepithelium in CRAMP-deficient mice. Furthermore, cathelicidin does 
not appear to be expressed within the urinary tract at concentrations necessary to cause bacterial 
cell death in vitro. We conclude that cathelicidin is essential for normal maintenance of the 
uroepithelium and for the promotion of innate immune responses to UPEC. We will continue to 
examine this potential role for CRAMP as a driver of the immune response during UTI. 
Finally, we were surprised to find that UPEC growth is augmented after exposure to sub-
lethal concentrations of CRAMP, and UPEC specifically upregulate a defined set of genes in this 
response. While these genes are also encoded by non-pathogenic E. coli, the same transcriptional 
response is not observed. Most interestingly, the majority of these genes are involved in small 
molecule transport or metabolism, implying that UPEC are actively sensing the peptide, 
upregulating pathways that may allow for uptake of the AMP, and perhaps converting acquired 
AMP into useful product. This model is consistent with the increased UPEC growth seen after 
exposure to CRAMP, and suggests that UPEC are better adapted to strategically utilize 
molecules in order to thrive in a limiting environment. Future experiments will characterize the 
roles of these regulated genes in vitro after exposure of UPEC to other AMPs, and during 
infection. 
CHAPTER ONE 
INTRODUCTION TO THE DISSERTATION 
 
Urinary Tract Infections  
 Urinary tract infections (UTIs) occur when bacteria grow within the lower urinary tract 
(comprised of the urethra and bladder) or the upper urinary tract (comprised of paired ureters and 
kidneys) [1]. The most common form of UTI is cystitis, or bladder infection, although infection 
of one or both kidneys, termed pyelonephritis, can occur [1]. UTIs are most common in women, 
occurring at an incidence of 3-13% [2, 3]. Over her lifetime, a woman’s risk of UTI is over 60% 
[4]. Of the women that develop a UTI, 30-50% will have a second infection within 6 months [1]. 
While UTIs are rarely deadly in developed countries, these infections represent a significant 
healthcare burden. In 2007, these infections resulted in nearly 11 million physician visits in the 
United States, and UTI-associated costs approached $4 billion [5, 6]. Even though these 
infections can be naturally cleared by the immune system, each year physicians write millions of 
antibiotic prescriptions for UTI patients, which contribute to the current crisis of antibiotic-
resistant bacteria [7]. A thorough understanding of the pathogenesis of UTI can direct the 
development of alternative therapies to treat these infections.  
 
Risk factors for UTI 
 The strongest risk factor for UTI is being female. This sex-specific susceptibility is due to 
the shorter urethra in women, and to the highly colonized periurethral area [1]. Other important 
risk factors for UTI among otherwise healthy adults include frequent sexual activity, recent 
condom use, and recent spermicide use [1]. The link between multiple sexual encounters and 
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UTI is so strong that it is often referred to as “honeymoon cystitis.” Familial predisposition to 
recurrent UTIs has been noted since the late 1970s [8-10]. The vast majority of genetic factors 
that alter UTI risk affect the innate immune system [11]. For example, polymorphisms in 
chemokines CCL2 and CCL5 as well as in the chemokine receptor CXCR1 have been shown to 
increase UTI risk and risk of acute pyelonephritis [12, 13]. Decreased expression of the 
transcription factor IRF3 has also been linked to increased risk of acute pyelonephritis [14]. 
Recent work has determined that TLR4 polymorphisms can have widely varying effects on the 
development of cystitis and can increase or decrease risk of cystitis, recurrent cystitis, and 
pyelonephritis [15, 16]. Other studies have suggested that blood group (with respect to P1 
antigen and secretor status) can also increase risk of acute pyelonephritis [17-19].  
Congenital abnormalities of the urinary tract, such as obstructions, ureteral duplication, or 
other malformations can also result in a predisposition to UTI [20]. Significant vesicoureteral 
reflux (VUR), or reflux of urine from the bladder into the kidneys, increases the chances of 
developing pyelonephritis. Premature babies and uncircumcised males also have increased risk 
for UTI [20]. In adults, diabetes, obesity, and vaginal infections have all been linked to increased 
UTI risk [21, 22]. Catheter placement represents the largest risk factor for developing a UTI. 
Reports since 1980 suggest that the incidence of UTI in male and female patients with urinary 
catheters is between 1.1-6.5% [23]. Risk of UTI increases with prolonged catheter use; overall, 
an indwelling catheter is thought to increase risk 4-fold [1]. 
 
Symptomology and diagnosis 
As the severity of UTI can vary, patients can present with a range of symptoms. The most 
common symptoms are urgency, increased frequency, pain while urinating, cloudy urine, and 
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suprapubic abdominal pain [1, 20]. Some patients also detect a foul odor from their urine. 
Progression to pyelonephritis can result in renal abscess formation, and in rare cases, sepsis. 
Patients with pyelonephritis may experience the symptoms of cystitis, in addition to fever, 
nausea, vomiting, and back and flank pain [1]. A diagnosis of UTI is most commonly achieved 
through culture of mid-stream urine (with >10
5
 bacteria/mL), urine dipstick test for leukocyte 
esterase, and leukocyturia. Many UTIs are diagnosed on the basis of symptoms alone, so as to 
minimize the delay before starting treatment. Although uncomplicated UTIs are self-limiting and 
can be cleared by the immune system in ~5 days, many physicians prescribe oral antibiotics to 
help the patient resolve the infection more quickly [7, 24].  
 
Asymptomatic bacteriuria 
Asymptomatic bacteriuria (ASB) is diagnosed when a urine culture yields >10
5
 CFU/mL 
of a known uropathogen, but the patient does not present with symptoms of UTI. ASB has an 
overall prevalence of 3.5% in women, although prevalence in teens is closer to 1% and increases 
with age [25]. The prevalence of ASB has made correct diagnosis of UTI difficult, and new 
criteria have recently been developed to better differentiate the two. PCR- and sequencing-based 
methods are much more sensitive than culture-based methods, and detect a wide variety of flora 
within the urine [26]. This has led to the concept of a urinary microbiome, although more work 
needs to be done to distinguish bacteria that have truly colonized the bladder from contaminants. 
The periurethral area and distal urethra are known to be colonized by bacteria, so it is likely that 
some organisms detected by these very sensitive methods arise from this area and not the bladder 
specifically [26]. Future research will delineate the effects of ASB on health and on the 
development of UTI.  
3
 UPEC 
 Uropathogenic Escherichia coli (UPEC) represent the most common cause of 
community-acquired UTI, accounting for up to 85% of cases [27]. Various species of Klebsiella, 
Pseudomonas, Enterococcus, and Staphylococcus are also frequently isolated from ambulatory 
patients [1, 27]. However, nosocomial infections are more commonly caused by strains other 
than UPEC. Species such as Proteus mirabilis, Klebsiella pneumoniae, and Enterococcus are 
each isolated in approximately one in ten nursing home patients with UTI, more than double the 
incidence of these strains in ambulatory patients [27]. Up to 30% of catheter-associated UTIs are 
caused by Enterococcus faecalis or E. faecium, although UPEC infections are also very common 
[28]. 
UPEC and neonatal meningitis-causing E. coli (NMEC) are two classifications that are 
included within the extraintestinal pathogenic E. coli pathotype (ExPEC) [29]. As the name 
implies, most UPEC strains are thought to be strains that originated from the gut [30]. The 
expression of certain virulence factors likely aids in the development of infection when these 
bacteria are exposed to the urinary tract. UPEC strains isolated from patients have proven to be 
highly genomically diverse [29, 31, 32]. While there are specific UPEC virulence factors, a set of 
factors that can be used to define UPEC or potential uropathogens has not been specified [33]. 
Many factors can partially contribute to UPEC virulence, although there is much variation 
among strains.  
 
Murine Model of UTI 
Method of infection 
4
 A murine model of UTI was created to investigate contributions of both host and 
bacterial factors during infection. This simple and reliable method of inducing infection delivers 
UPEC to the bladder via catheter, which is then removed [34]. Due to the technical difficulty of 
catheterizing male mice, female mice have been used for the vast majority of UTI studies. Most 
infection models inoculate the bladder with approximately 10
7
 CFU of UPEC in a volume of 50 
µL to ensure reliable infections [34, 35]. Larger volumes often result in VUR, but can be used to 
force the development of pyelonephritis. If desired, control mice can be mock-infected with 
sterile phosphate-buffered saline (PBS) and harvested in parallel to quantify changes in the 
bladder due to catheterization and delivery of the inoculum. 
 
Common downstream methodology to characterize UPEC infection 
Urine can be collected to monitor the progress of the infection through the enumeration 
of colony-forming units (CFU) of bacteria. The presence of immune and uroepithelial cells in the 
urine can be examined by microscopy of urines spun onto slides and stained, or enumerated 
using a hemacytometer. Bladder and kidney tissues are harvested after sacrifice and 
homogenized in sterile PBS to determine bacterial load at various time points post-infection. 
Cytokine expression in tissue homogenates can be quantified through antibody-based multiplex 
assays or ELISA. Expression of the enzyme myeloperoxidase (MPO) within tissue homogenates 
can be used as a proxy for neutrophil recruitment to the tissue [36]. Blood and serum can be 
collected during infection or after sacrifice to screen for sepsis (via blood culture) or to measure 
global cytokine expression. 
Whole tissue studies can also provide information about the state of infection state within 
the animal. Intracellular bacterial communities (IBCs) in the bladder (e.g., 6, 16, or 24 hours 
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post-infection [hpi]) can be quantified by bisecting the bladder after harvest and exploiting the 
lacZ expression of UPEC to stain IBCs in situ within the tissue. We can also visualize IBC 
structure and approximate the number of IBCs by infecting mice with GFP-expressing bacteria 
and examining the bladder tissue by confocal microscopy at the desired time points. Nuclear 
stains or host cell membrane stains help to localize UPEC within the tissue. Differences in the 
size of IBCs can be quantified using 3D reconstruction techniques [37]. Additionally, we can fix 
and stain whole tissues for histological analyses such as hematoxylin and eosin staining or 
scoring of immune cell recruitment and inflammation. Unstained slides can be used for 
immunofluorescence microscopy studies. Although these methods only provide a snapshot of 
what was happening in the bladder at the time of harvest, different parts of the bladder can be 
visualized at one time. To supplement histology and immunofluorescence microscopy, we 
developed immunoblot assays to quantify uroplakins present in bladder homogenates; these were 
used to approximate the amount of uroepithelial exfoliation that had occurred [37].  
 
Effects of host genetics on development of UTI 
Multiple groups have explored the effects of genetic background on development of UTI 
[38-41]. The inbred mouse strains C57Bl/6 and C3H/HeN are commonly used to study acute and 
chronic UTIs. There are many knock-out and conditional expression lines available in the 
C57Bl/6 background, making these mice excellent tools to examine the contribution of host 
factors to the development or resolution of UTI. In the C57Bl/6 background, UPEC infection is 
often limited to an acute infection that is largely cleared from the bladder by 48 hpi [42]. These 
mice rarely develop kidney infection, although quiescent bacteria do form reservoirs within the 
deeper epithelium of the bladder [43]. C3H/HeN mice are commonly used to examine chronic 
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phenotypes, as 20-30% of these mice develop chronic cystitis after infection with 10
7
 UPEC 
[38]. Experiments using C3H/HeJ mice, which have a mutation in TLR4, have helped discern the 
role of TLR4 in both host uroepithelial cells and immune cells [44, 45]. 80% of C3H/HeJ mice 
go on to develop chronic infections [38]. Another C3H subtype, C3H/HeOuJ, develops chronic 
cystitis in 90% of infected mice [38]. Meanwhile, C3H-related strains CBA/J and DBA/2J show 
an intermediate phenotype, with 20-40% of these mice developing chronic cystitis [38]. 
Downstream studies can further elucidate factors that contribute to these differences, and will 
contribute to the understanding of patient susceptibility to UTI. 
 
UPEC Infections 
Binding and invasion to the host cell epithelium 
 Upon introduction to the bladder, UPEC must first resist being washed from the urinary 
tract by the flow of urine. Most UPEC strains accomplish this by binding to the surfaces of host 
uroepithelial cells using the adhesive organelle type 1 pili (Figure 1) [46]. This binding requires 
a specific interaction of the tip adhesin FimH with mannosylated proteins (uroplakins) on the 
surfaces of superficial epithelial cells [47]. UPEC strains that do not express type 1 pili are 
severely attenuated in the mouse model of cystitis [48, 49]. The interaction of FimH with 
mannose has been shown to be greatly enhanced when the protein is bound to the chaperone 
FimC and adopts an elongated conformation [50]. The expression of the fim operon is under the 
regulation of an invertible switch element, which has been shown to be affected by a wide 
variety of factors [51, 52].  
 Once bound to host uroepithelium, a subset of UEPC are internalized into the host cells 
within a membrane-bound vacuole (Figure 1) [46]. This internalization is controlled by 
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microtubule destabilization and integrin-mediated interactions with actin filaments that cause 
actin rearrangement and uptake of the bacteria into vacuoles [53-55]. An unknown percentage of 
the bacteria-containing vacuoles re-fuse with the cell membrane, releasing the bacteria back into 
the bladder lumen. This exocytosis is regulated by increases in intracellular cAMP 
concentrations, which are triggered upon TLR4 activation by bacterial LPS [56, 57]. Therefore, 
UPEC must escape into the cytoplasm from the vacuole to avoid being expelled. UPEC that 
successfully invade the uroepithelium and escape into the cytoplasm are protected from 
components of the innate immune system, the mechanical shear force of urine, and antibiotics. 
 
Intracellular growth 
 The superficial facet cell cytoplasm provides a rich medium for UPEC growth. The 
availability of nutrients allows division to occur more frequently, and results in many of the 
bacteria becoming coccoid (Figure 1) [58]. These rapidly dividing bacteria form large, tightly 
cohesive structures known as intracellular bacterial communities (IBCs; Figure 1) [59, 60]. Each 
IBC may contain up to 10
5
 bacteria, and can take up the majority of the cell’s cytoplasm [60]. 
Indeed, when viewed from the lumen, uroepithelial cells harboring mature IBCs bulge outward 
[34, 59]. IBCs have similarities to biofilms, as polysaccharides, outer membrane vesicles, and 
type 1 pili are highly expressed within the structure [49, 59, 60]. Mutations in genes (e.g., those 
encoding pili, curli, flagella, antigen 43) with known roles in biofilm formation limit the ability 
of UPEC to form IBCs and to propagate an acute infection [46, 49, 60]. After a yet undetermined 
signal, UPEC will slow their division to create long filaments and flux out of the host cell 
(Figure 1) [58]. These filaments are resistant to phagocytosis and killing by neutrophils [61-63]. 
This survival mechanism allows the filaments to infect neighboring epithelial cells to repeat the 
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cycle of infection. IBCs and filamentous bacteria are found in the urines of children and adults 
with UTI [64, 65]. 
 
Clearance of UPEC 
 UTIs are usually self-limiting infections that can be cleared from an otherwise-healthy 
host in 5 days. The exfoliation and shedding of infected uroepithelial cells represent one 
mechanism by which UPEC are cleared from the bladder (Figure 1) [46]. Although exfoliation 
can quickly rid the bladder of large numbers of bacteria, this mechanism also leaves the 
underlying cells exposed and susceptible to infection by UPEC [46]. The expression of cytokines 
from infected cells activates components of the innate immune system, largely neutrophils or 
polymorphonuclear cells (PMNs), to respond to the infection [66]. While a few PMNs are 
already present in the tissue, the majority of the response is due to circulating PMNs leaving 
nearby vessels and localizing to IBC-containing cells (Figure 1) [66]. Although PMNs cannot 
penetrate into healthy uroepithelial cells, PMNs can phagocytose the exposed bacteria once the 
host cell membrane has been compromised. Leukocyturia in patients reflects the PMNs that have 
responded to the infection being lost in the urine.    
 Two main pathologies develop within the bladder as an infection is cleared. The infection 
of underlying host cells can lead to the development of small collections of UPEC within the 
epithelium known as quiescent intracellular reservoirs (QIRs) [43]. Although thought to be 
metabolically inactive, these collections can be triggered to reemerge and cause a new infection. 
While antibiotics and intensive epithelial exfoliation have been shown to trigger reemergence of 
bacteria from QIRs, the molecular mechanisms behind this activation are not well understood 
[67]. Recent work has also been exploring the development of chronic infections within the 
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urinary tract. These infections are characterized by persistent bacterial titers >10
4
 CFU/mL in the 
urine, along with high levels of uroepithelial exfoliation, and high bladder titers at 2-4 weeks 
post-infection [38]. Strong inflammatory responses during the early stages of infection are 
predictive of chronic cystitis development, and mice that have experienced chronic cystitis are 
more susceptible to a subsequent episode [38, 68]. However, the distinct differences in host or 
bacterial physiology that lead to the development of QIRs instead of chronic infections and vice 
versa are not known. Future studies can explore these differences, and determine if QIR 
formation also occurs in patients that have cleared a UTI, or in patients that are susceptible to 
recurrent cystitis. 
 
Antimicrobial Peptides 
 Antimicrobial peptides (AMPs) are small, 12-100 amino acid sequences that are 
produced by all kingdoms of life. Most of these peptides contain lysine and/or arginine residues, 
which results in an overall positive charge. AMPs are also amphipathic, which promotes 
interaction with bacterial membranes to cause cell death [69]. AMPs function as defensive 
mechanisms for living organisms that range from bacteria, to insects, to vertebrates, and are 
thought to represent one of the earliest branches of innate immunity [69]. Gram-positive and -
negative bacteria utilize these molecules, termed bacteriocins, for narrow (same species) or 
broad-spectrum self-defense and competition within various environments [70]. In mammals, 
AMPs are often part of the defense of epithelial surfaces, and are expressed by both epithelial 
cells and innate immune cells [71]. In addition to activity against Gram-positive and -negative 
bacteria, AMPs have been shown to be effective against viruses and fungi [69]. While expression 
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of these peptides can be upregulated, constitutive expression provides a strong front line of 
defense that potential pathogens must resist in order to establish infection [71-73].  
 
Cathelicidins and other urinary tract AMPs 
 Within the urinary tract, the most highly-expressed AMPs are α- and β-defensins, RNase 
7, hepcidin, and cathelicidin [71, 74-78]. While humans encode at least 30 defensins, 
cathelicidins are not as diverse [79]. Humans and mice each express a single cathelicidin, 
although other mammals encode multiple different cathelicidins (e.g., pigs, sheep, horses, and 
cows) [80-82]. Cathelicidins share a four-exon, three-intron gene structure, with the mature 
peptide encoded in exon 4 [82, 83]. Expression of the gene results in a pre-pro-peptide that is 
cleaved once intracellularly to create a pro-peptide which must be secreted and cleaved again 
extracellularly to form the mature peptide [82]. Conserved, signature patterns have been 
identified within the pro-region of the peptide, but there is much variability within the amino 
acid sequence of the mature peptide (Figure 2A) [82]. This sequence variability results in at least 
three major classes of structures for the peptides: α-helical, hairpin-like, and more linear forms 
containing proline- or tryptophan-rich sequences [82]. Human cathelicidin maintains an α-helical 
structure (Figure 2B) [84]. Regardless of sequence and structure, cathelicidins are expressed by 
many different cells types, including epithelial cells, neutrophils, monocytes, macrophages, and 
B- and T-cells [73].  
 Recent work supports a role for cathelicidin in the defense of the urinary tract. Although 
constitutively expressed, epithelial expression of cathelicidin can be upregulated in response to 
bacterial infection. This has been demonstrated in culture using renal epithelial cells, 
uroepithelial cells, and healthy human renal cortex sections [78]. LL-37 concentrations in the 
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urines of patients with active UTI are higher than those of patients that have resolved an 
infection or of control patients, supporting increased expression of the peptide during bacterial 
infection [78, 85]. Furthermore, control samples had higher concentrations of LL-37 than 
patients that had resolved an infection, suggesting that patients with low expression of 
cathelicidin may have increased risk of UTI [85]. These findings, namely upregulation of an 
AMP in response to bacterial infection and increased bacterial infection in AMP-deficient mice, 
mirror previous work with various defensins [86-88]. It should be noted that while human β-
defensin-1 is upregulated during infection, the concentration reached in the urine is too low to 
directly kill potential pathogens [76]. Much of this work has focused on the expression and 
activity of AMPs within the upper urinary tract. The effects of AMPs within the bladder, where 
urine is stored for long periods of time, have been largely unexplored.  
 
Alternative applications of AMPs 
 Interestingly, some AMPs and AMP derivatives have been tested for therapeutic 
potential. The synthetic peptide omiganan pentahydrochloride mimics the bovine AMP indolicin 
and is highly bactericidal and fungicidal [89]. Incorporation of this analogue into venous 
catheters as a mechanism to prevent blood-stream infections has been pursued through phase III 
clinical trials [90]. Multiple cecropin peptides isolated from insects have been shown to kill 
Chlamydia trachomatis isolates [91]. Relevant to this work, human and bovine lactoferrins and 
shorter synthetic lactoferrin derivatives have been shown to decrease bacterial titers in the 
bladders and kidneys of mice infected with a pyelonephritis-derived UPEC isolate [92]. These 
peptides were delivered to the mice orally 30 min after infection with 10
8
 bacteria, and titers 
were determined 24 hpi [92]. Together, these data indicate that natural and synthetic AMPs 
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independently suppress bacterial infection, including within niches where they are not normally 
expressed. 
 Sequence- or structural-based studies are often used to identify AMPs, and in vitro 
studies are subsequently used to confirm antimicrobial activity. Downstream studies have 
identified alternative functions for many cationic AMPs. In addition to antimicrobial roles, the 
peptide hepcidin has been shown to regulate iron levels in multiple niches including the serum, 
liver, intestine and macrophages [93, 94]. Hepcidin can directly bind to the iron transporter 
ferroportin and limit iron export from cells [95, 96]. Both defensins and cathelicidins have been 
shown to regulate components of the innate and adaptive immune systems in addition to 
functioning as antimicrobials [97]. These peptides can induce and augment the expression of 
cytokines, act as chemokines to enhance immune cell recruitment, and promote mast cell 
degranulation [97]. Defensins and cathelicidins can stimulate angiogenesis and wound healing, 
and defensin expression is important for proper sperm function in males [98, 99]. Cathelicidins 
and defensins have even been shown to play roles in promoting invasion by cancer cells [98, 
100-102]. Although these are but a few examples, AMPs undoubtedly mediate diverse and 
complex roles in the innate immune system. 
 
Summary and Prospectus 
UTIs are very common bacterial infections that affect millions of people annually and 
result in a significant burden on the healthcare system. As the vast majority of UTIs are caused 
by UPEC, much work has been done to investigate the mechanisms of pathogenesis responsible 
for these infections. A murine model of cystitis has greatly expanded our understanding of UPEC 
infection and complements in vitro work with bacterial strains. The work described here aimed 
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to better define the roles of specific factors expressed by the host and by the pathogen. 
Specifically, we investigated the roles that UPEC outer membrane proteins play in promoting the 
establishment of an infection within the urinary tract. The expression of AMPs in the urinary 
tract by host uroepithelial cells and innate immune cells represents a first line of defense against 
potential pathogens. Therefore, we investigated the effects of host cathelicidin on the 
development of UPEC infection in vivo. We also surveyed the bacterial responses to sub-lethal 
cathelicidin exposure in vitro. Taken together, these data allow us to profile the effects of 
cathelicidin exposure on the host and on the pathogen during UPEC infection. Future 
experiments will continue to define the roles of UPEC factors during infection.  
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Tables and Figures 
 
 
 
Figure 1: UPEC pathogenic cascade and IBC cycle. The major steps in the development of a 
UTI are displayed as: attachment of UPEC to host epithelial cells (top center), invasion of UPEC 
into the epithelial cells (top right), early IBC formation and recruitment of PMNs (bottom right), 
development of a mature IBC (bottom center), bacterial filamentation and egress from the host 
cell (top left), and exfoliation of IBC-containing epithelial cells (left center). Representative 
15
microscopy images are shown to support the information relayed in the schematic. (adapted from 
Mulvey et al, 1998; Mysorekar et al, 2006; Rosen et al, 2007; Hunstad and Justice, 2010)  
  
16
  
Figure 2: Cathelicidin sequence comparison and LL-37 structure. (A) Alignments of the 
mature peptide sequences for LL-37 (human), mCRAMP (mouse), rCRAMP (rat), CAP18 
(rabbit), and RL-37 (Rhesus monkey) reveal much variability between species. Residues in red 
are homologous to the LL-37 peptide. (B) Structure of the α-helical peptide LL-37 in micelles 
[84]. DOI: 10.1074/jbc.M805533200  
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CHAPTER TWO 
EXTRACELLULAR LOOPS OF UPEC OUTER MEMBRANE PROTEIN A SPECIFICALLY 
PROMOTE URINARY TRACT INFECTION 
 
Abstract 
 The major outer membrane protein OmpA of uropathogenic E. coli (UPEC) does not 
have a single, defined function, although it has been proposed to have many roles in both 
pathogenic and non-pathogenic E. coli isolates. Here, we investigate the importance of the four 
extracellular loops of OmpA with respect to the pathogenesis of UPEC in vitro and in vivo. We 
find that UPEC cells expressing OmpA lacking loop 1 are unaffected in most assays, although 
there is a mild impact on invasion into uroepithelial cells. More importantly, UPEC that only 
express a mutant OmpA lacking loop 2 exhibit impaired binding and invasion in vitro, and are 
cleared from the bladder more efficiently in a murine model of cystitis. Finally, the loop 2 
mutant is dominant over the full-length protein in wild-type cells, and results in impaired binding 
and invasion in vitro when cells co-express both proteins. These data are consistent with UPEC 
OmpA acting as a binding cofactor during invasion of uroepithelial cells. Specifically, 
extracellular loop 1 is dispensable for this interaction, while loop 2 is required. Although it is 
unknown if these phenotypes are due to a direct interaction or due to secondary effects, future 
experiments will define the binding partner(s) that exist on host uroepithelial cells.  
 
Introduction 
 Outer membrane protein A (OmpA) is an abundantly expressed, integral outer membrane 
protein (OMP) in E. coli and other Gram-negative bacteria [1, 2]. The ompA sequence is highly 
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conserved, and expression of OmpA is tightly regulated during translation by mRNA structure 
and the small RNA micA [1]. Full-length ompA mutants are viable, but complementation must be 
carefully controlled, as overexpression of OmpA is lethal [3]. The ompA gene encodes a 35 kDa 
protein with two major domains. The N-terminal domain of OmpA forms a β-barrel made of 
eight, antiparallel, transmembrane β-sheets, including four extracellular loops and three short 
periplasmic turn regions [1, 4, 5]. The extracellular loops of OmpA vary in length (7-17 aa), and 
the sequences suggest that some loops may be more flexible than others. The C-terminal domain 
of the protein extends into the periplasm and has been implicated in binding to peptidoglycan, 
providing structural stability to the cell [1, 6, 7]. Many other roles have ben posited for OmpA in 
E. coli. With respect to pathogenesis, OmpA has been shown to mediate serum resistance within 
potential hosts, and Prasadarao and colleagues demonstrated that neonatal meningitis-causing E. 
coli (NMEC) use OmpA to bind and invade cultured brain microvascular endothelial cells and to 
cross the blood-brain barrier in mice [8-10]. Furthermore, expression of OmpA has been shown 
to be critical for biofilm formation in some systems [11, 12]. Not all OmpA interactions benefit 
the bacterium, though. OmpA is targeted by the phagocyte-produced enzyme neutrophil elastase, 
is recognized by the immune system as a pathogen-associated molecular pattern (PAMP), and its 
extracellular loops are important for binding of bacteriophage, bacteriocin, and attacin binding 
[13-16].  
 Uropathogenic E. coli (UPEC) are the most common cause of cystitis (bacterial infection 
of the urinary bladder) especially in women of child-bearing age [17]. Although uncommon, 
bacteria from the bladder can also ascend up the ureters to cause a more severe infection in the 
kidneys, known as pyelonephritis, or can disseminate into the bloodstream [17]. Clinical reports 
estimate that 75-85% of all urinary tract infections (UTIs) are caused by UPEC [17, 18]. Cystitis 
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is diagnosed by detection in the urine of bacteria (bacteriuria) and immune cells (pyuria), 
particularly neutrophils [17].  Symptoms of cystitis include suprapubic abdominal pain, dysuria 
(pain while urinating), and increased urgency [17, 19]. Many women visit their physician and are 
prescribed antibiotics, even though the infection is self-limiting in many cases [19]. Up to 50% 
of patients will have a second infection within six months of their original infection, and a small 
percentage will develop chronic cystitis, characterized by ongoing symptoms and consistently 
high levels of bacteria in the urine [17, 18, 20].  
 The UPEC infection cascade and important virulence factors have been detailed over the 
past two decades using both in vitro methods and a murine model of cystitis. Upon introduction 
to the bladder, type 1 pili on the surfaces of UPEC bind to mannosylated uroplakin proteins 
decorating the luminal face of the uroepithelium [21-23]. Once bound, these bacteria can be 
internalized into the superficial uroepithelial cells (facet cells), where they escape from an initial 
Lamp1
+
 vacuole into the cytoplasm of the cell [24, 25]. The bacteria rapidly replicate in the 
cytoplasm, forming a dense cluster of cells known as an intracellular bacterial community (IBC) 
within 6-16 hours [26]. An IBC may contain as many as 10
5
 UPEC cells, and can fill the 
majority of the volume of the cell. This will often cause the facet cell to rupture, releasing 
bacteria into the lumen of the bladder, where they can spread to naïve epithelial cells and repeat 
the infection cycle [27]. UPEC contained within epithelial cells are protected from the 
mechanical shear force of urine flow, innate immune components such as neutrophils and 
antimicrobial peptides, and the action of antibiotics [27]. Many infected epithelial cells will be 
exfoliated and shed in the urine as a means of clearing the infection, and phagocytes will attack 
and kill bacterial cells that have emerged from epithelial cells [27]. Some bacterial cells will 
form quiescent clusters deeper within bladder tissue, and can emerge weeks to months later to 
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cause a new infection [25, 28]. A more thorough understanding of the mechanism that allows 
UPEC to enter the uroepithelial cell and gain access to its cytoplasm may help define new 
therapies that can prevent establishment of infection, and also protect against repeated 
pathogenic cycles and recurrent infections.  
 Previously, UPEC OmpA was shown to be important for chronic infection in a murine 
model of cystitis in C3H/HeN mice [3]. In those studies, binding, invasion, and acute bladder 
titers were similar between wild-type and OmpA mutant bacteria [3]. However, OmpA mutant 
bacteria subsequently formed only sparse and rudimentary IBCs by confocal microscopy [3]. 
Further, relative to the starting inoculum, wild-type UPEC highly upregulated ompA expression 
while in the bladder [3]. This may be due in part to the fact that the inoculum consists of bacteria 
in stationary phase, and ompA has been shown to be downregulated during stationary phase [29]. 
Here, we present data demonstrating that ompA mutant bacteria cause less robust infection in 
C57Bl/6 mice. We sought to define the interactions of OmpA with the host during infection, and 
to identify specific regions of the protein that are most important in these interactions. 
 We hypothesized that the extracellular loops represent a way for UPEC to directly 
interact with the surrounding environment, and may be responsible for some of the phenotypes 
observed in an OmpA mutant. Here, we present data characterizing the effects of two of the 
extracellular loops of OmpA. We found that OmpA loop mutants had distinct phenotypes during 
infection. Although loop 1 was largely dispensable during infection, loop 2 mutant bacteria 
showed severely limited binding and invasion in vitro, and were quickly cleared from the bladder 
in vivo without progressing through the IBC cycle. These data indicate that OmpA may function 
as a co-factor during binding to the uroepithelium, and that loop 2 is mediating this interaction. 
Future experiments will identify a binding partner or partners, and will investigate if loop 2 is 
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directly interacting with these partners, or is indirectly influencing the binding of UPEC to the 
uroepithelium. 
 
Materials and Methods 
Bacterial strains and cloning  
The cystitis-derived UPEC strain UTI89 was inoculated from frozen stock directly into Luria-
Bertani broth (LB) for all experiments [26]. Chloramphenicol or kanamycin was added at 100 
µg/mL where indicated. A UTI89 ompA::cat strain was previously created by lambda red 
mutagenesis, and the chloramphenicol marker was excised with Flp recombinase to yield the 
UTI89 ΔompA strain used in all experiments [3, 30]. The entire ompA gene, including a 60 bp 
region upstream thought to include the promoter, was cloned into the low-copy number plasmid 
pACYC184. This plasmid was used to complement the ompA mutant strain. This plasmid was 
further mutated to create and express the individual loop mutants used in the present 
experiments, based on mutants previously created by Ralf Koebnik [31]. Briefly, the majority of 
the amino acids composing each surface loop were deleted and replaced with 1-2 amino acid (aa) 
linkers. This was accomplished by using complementary forward and reverse internal loop KO 
primers containing approximately 4 aa before the deletion, and 11 aa after the deleted region that 
correspond to the matching full-length plasmid template (Table 1). These primers were used with 
a forward or reverse OmpA primer that contained a restriction enzyme site to create two products 
for each mutant (Table 1). These products were amplified a second time with the OmpA forward 
and reverse primers using the sewing method of PCR to create a final product with a single loop 
mutation. These products were sequenced, and clones without unintended mutations were 
screened for protein expression by SDS-PAGE gel. UTI89fimH::kan (kind gift from S. Hultgren) 
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lacks the type 1 pilus tip adhesin FimH and does not produce pili. UTI89 surA::kan lacks the 
periplasmic chaperone SurA and is deficient in many major outer membrane proteins, including 
OmpA [32]. The loop 2 KO plasmid was re-derived and transformed into UTI89 and 
the ompA mutant to create a second clone. UTI89 was also transformed with a plasmid encoding 
an HA-labelled OmpA lacking loop 2. UTI89, UTI89 ΔompA, and the loop mutants were also 
transformed with a GFP-containing plasmid for confocal microscopy studies. 
 
Mouse infections 
Age-matched, 8-10 week old female C57Bl/6 mice (Jackson Laboratories) were infected by 
transurethral catheterization with approximately 10
7
 colony-forming units (CFU) of UPEC in 50 
µL of phosphate-buffered saline (PBS) as previously described [22]. Bladders and kidneys were 
harvested using sterile technique after the infection was allowed to develop for the indicated 
intervals, homogenized in PBS, serially diluted, and plated on LB agar (with antibiotics when 
appropriate) to determine CFU per organ. Remaining homogenates were stored at -80˚C for use 
in downstream applications. 
 
Immunoblotting 
Lysed whole cells, cell supernatants, cell fractions, or mouse bladder lysates were separated by 
SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes, and probed with 
antibodies to detect bacterial and murine proteins. A polyclonal rabbit antibody was generated 
using UTI89 OmpA. The antibody was mixed 1:1 with UTI89 ΔompA cell lysate for 30 min on 
ice and centrifuged at 14,000 × g for 10 min. The supernatant was used at 1:10-25,000 for 
immunoblotting with minimal background. HA-tagged proteins were detected with an anti-HA 
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primary antibody (1:1000, Zymed). A primary antibody for GroEL was used as a cytoplasmic 
marker (1:40,000; Sigma), and sera from mice that had been inoculated with SurA was used as a 
periplasmic marker (1:5000). The FimH protein was detected using sera from rabbits that had 
been inoculated with the FimH protein (1:5000). A primary antibody specific to the murine 
mitochondrial marker CoxIV was used as a loading control in bladder lysates (1:2000; Cell 
Signaling). Anti-rabbit and anti-mouse alkaline phosphatase-tagged secondary antibodies were 
used at 1:2000-2500 (Sigma). Blots were developed with Tropix CDP-STAR (Applied 
Biosystems). 
 
Cell fractionation 
Overnight cultures of the indicated strains were sub-cultured into fresh LB at 1:100 and grown 
under shaking conditions at 37°C to an OD600 = 0.8. Cultures were centrifuged at 5000 × g for 20 
min and the resulting pellets were weighed and frozen overnight. Thawed pellets were 
resuspended in 10mM Tris pH 8.0 with 100 μg/mL of RNase and DNase (4mL/g of pellet). Cells 
were lysed twice in a Stansted Cell Pressure Homogenizer, and residual whole cells were 
removed by centrifugation at 2000 × g for 15 min. The resulting supernatant was ultracentrifuged 
at 82500 × g for 80 min to separate the soluble fraction from the pellet of the cell membranes. 
The soluble fraction was decanted and saved at -20°C for future analysis. The membrane-
containing pellet was resuspended in 50mM Tris pH 8.0 with 1% sarkosyl and ultracentrifuged at 
82500 × g for 80 min to separate the inner and outer membranes. The soluble inner membrane 
fraction was saved at -20°C, and the pellet containing the outer membrane was fully resuspended 
in 10mM Tris pH 8.0 before being stored at -20°C. 
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Transmission electron microscopy (TEM) 
For negative-stained samples, overnight static cultures were pelleted, fixed in 1% glutaraldehyde, 
and adsorbed to flow-discharged formvar/carbon-coated copper grids for 2 min. Grids were 
washed with water, stained for 1 min with 1% aqueous uranyl acetate (Ted Pella, Redding, CA), 
and air-dried. Immunolabelled and negative-stained samples were adsorbed to formvar/carbon-
coated nickel grids for 10 min, washed in PBS, and blocked with 1% fetal bovine serum (FBS) 
for 20 min. Anti-FimH antibody (1:200) was applied for 30 min before grids were washed with 
1% FBS and incubated with goat anti-rabbit secondary antibody conjugated to 18 nm colloidal 
gold (1:10; Jackson ImmunoResearch, Laboratories, Inc., West Grove, PA) for 30 min. Grids 
were washed with PBS, fixed in 1% glutaraldehyde for 10 min, and washed with dH2O before 
being stained with uranyl acetate and air dried. Samples were viewed on a JEOL 1200EX 
transmission electron microscope (JEOL USA, Peabody, MA). 
 
Bacterial growth curves 
Overnight cultures grown in LB, with antibiotics when appropriate for plasmid maintenance, 
were sub-cultured 1:100 into fresh LB and grown under shaking conditions to an OD600 = 1. 
These cultures were diluted 1:5000 into fresh media, plated in triplicate, and grown at 37°C. The 
optical density was read every 40 min for 16 h in a temperature-controlled microplate reader 
(Synergy 2, Biotek). The experiment was repeated at least three times for each strain. 
 
Novobiocin susceptibility assay 
Overnight, shaking cultures grown in LB broth were sub-cultured 1:100 in LB and grown to an 
OD600 = 1. These cultures were diluted 1:10 with PBS before a sterile cotton swab was dipped 
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into each culture and spread evenly across a single LB agar plate. The moisture was allowed to 
absorb for 5 min, and then two discs impregnated with novobiocin (30 ug/disc, Sensi-Disc, BD 
BBL) were placed on each plate, and the plates were incubated at 37°C overnight. The next 
morning, the diameter of the zone of inhibition around each disc was measured. The experiment 
was repeated three times. 
 
Confocal microscopy 
Mice were infected as usual with GFP-expressing strains [33]. After 16 h, bladders were 
harvested, splayed, and fixed with 2.5% paraformaldehyde in PBS for 1 h. Bladders were 
washed, permeabilized with 0.1% Triton X-100, and stained with the nuclear stain Syto 61 
(1:1000 in PBS; Life Technologies). Bladders were washed three times in PBS and mounted 
with antifade reagent (ProLong Gold, Life Technologies) before imaging on an inverted confocal 
microscope (LSM510, Zeiss). 
 
IBC enumeration by lacZ staining 
Mice were infected with the indicated strains for 16 h, before the mice were sacrificed, and the 
bladders were harvested, bisected, stretched, and gently washed twice with PBS. Bladders were 
fixed for 1 h at 4°C (0.2% glutaraldehyde, 50 mM EGTA, 100 mM MgCl2 in PBS, washed three 
times (2mM MgCl2, 0.01% deoxycholic acid sodium salt, 0.02% IGEPAL CA-630 in PBS), and 
stained (1 mg/mL X-gal, 114 mM potassium ferrocyanide, 97mM potassium ferricyanide in 
wash buffer) for 6 h at 30°C. After staining, tissues were washed three times with PBS and 
stored at 4C until IBCs were counted under a dissecting microscope. 
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Hemagglutination assays 
Static 20 mL overnight cultures of indicated strains grown in LB were diluted to an OD540 = 1 
with LB broth. Cells were concentrated 10-fold in PBS, and duplicate cultures were prepared 
with 2% mannose in PBS. Concentrated cells were serially diluted in an equal volume of PBS or 
PBS with 2% mannose in 96-well V-bottom plates (Costar). Guinea pig red blood cells 
(Colorado Serum Company) were washed 2-3 times with sterile PBS and resuspended to an 
OD640 = 2.0. An equal volume of diluted red blood cells was added to each well of the plates. 
The plates were gently tapped to ensure mixing and were covered with sealing tape. The last well 
in which hemagglutination occurred was determined visually after overnight incubation at 4°C 
(this is the HA titer). The experiment was repeated three times. 
 
In vitro binding and invasion assays 
Human bladder carcinoma cells (5637 cells; ATCC HTB-9) were maintained in RPMI with 10% 
fetal bovine serum (Sigma) in a humidified incubator at 37°C with 5% CO2. Triplicate wells of 
confluent 5637 cells were prepared for each bacterial strain in 24-well tissue culture plates 
(TPP). Before infection, existing medium was aspirated, cells were washed once with sterile 
PBS, and 1 mL of fresh medium was added to each well. Overnight static cultures of the 
indicated bacterial strains were centrifuged and resuspended in sterile PBS to OD600 = 1. Ten 
microliters of the desired bacterial suspension was added to each well. Plates were spun at 325 × 
g for 3 min at room temperature and returned to the incubator. Binding and input plates were 
removed from the incubator after 30 min. Supernatants were removed from the binding wells, 
and cells were washed five times with PBS before lysis (PBS with 0.1% Triton X-100) at room 
temperature for 15 min. Input wells were not washed before lysis with 10 µL of 10% Triton X-
38
100. Each well was scraped and examined under the microscope to ensure that all cells were 
released. Lysates were serially diluted and plated on LB agar plates to enumerate CFU. Invasion 
plates were removed from the incubator after 60 min and wells were washed once with PBS. 
Gentamicin (10 mg/mL in medium) was added to each well and the plate was returned to the 
incubator for 90 min. After gentamicin treatment, wells were washed three times with PBS 
before lysis, scraping, dilution, and plating as above. LB agar plates were incubated overnight at 
37°C, and colonies were enumerated the following day. 
 
Results 
UTI89 ΔompA is less virulent in a murine model of cystitis. 
 Previous work has established that UTI89 ΔompA cannot cause chronic infections in 
C3H/HeN mice, unlike the parent strain UTI89. However, the virulence of UTI89 ΔompA in the 
C57Bl/6 mouse, a strain that has a more robust immune response and many available genetic 
tools, was unknown. We found that UTI89 ΔompA was cleared from the bladder faster than wild-
type UTI89, and that bacterial loads of UTI89 ΔompA were significantly lower by 24 hpi 
(Figure 1). Kidney infections are not prominent in C57Bl/6 mice, a strain that does not exhibit 
significant vesicoureteral reflux; we did not find any difference in the (low) frequency of kidney 
infection between UTI89 and UTI89 ΔompA (data not shown). 
 
Creation of extracellular OmpA loop mutants. 
 We hypothesized that one or more of the extracellular loops of OmpA could be necessary 
for interacting with the host environment during infection, and that we could identify this 
interaction by creating individual loop mutants. Each extracellular loop of UPEC OmpA is a 12-
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14 amino acid sequence that connects two of the transmembrane domains that comprise the β-
barrel of OmpA. We created mutants that have each loop replaced by a 1-2 amino acid linker, 
while the rest of the OmpA protein (i.e., the barrel and the periplasmic domain) is unchanged 
[31]. Low-copy plasmids encoding the loop mutant proteins are then used to complement UTI89 
ΔompA. We refer to each loop mutant strain as LP n KO. By immunoblot with an OmpA-
specific antibody, each loop mutant strain expresses its OmpA variant at levels similar to that of 
wild-type OmpA in UTI89 (Figure 2A). To ensure that the loop mutant proteins localize to the 
outer membrane, we fractionated cultures into outer membrane, inner membrane, and soluble 
fractions. The vast majority of each protein variant was detected in the outer membrane fraction 
(Figure 2B). We conclude that the loop mutant proteins are stable and are expressed at levels 
similar to that of wild-type in the outer membrane.  
 
Mutation of loops does not affect growth rate or outer membrane permeability. 
 We next investigated if the mutant proteins had deleterious effects on the cells. 
Transmission electron microscopy (TEM) did not reveal any differences in the physical 
appearance of the bacterial strains (Figure 3A). We compared the growth of the loop mutant 
strains to UTI89 and UTI89 ΔompA in rich media and found no differences (Figure 3B). The 
small lag in growth of the loop mutants is likely due to chloramphenicol (included in the media 
to maintain the plasmid), as this lag also observed in cells carrying the empty vector (Figure 
3B). Novobiocin, an antibiotic that cannot permeate the outer membrane of healthy Gram-
negative cells, was used to determine if the loop mutant proteins affected permeability of the 
outer membrane. Novobiocin disc diffusion assays demonstrated no significant differences in 
outer membrane permeability between the loop mutants and UTI89 or UTI89 ΔompA (Figure 
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3C). UTI89 surA::kan does not express the periplasmic chaperone SurA, which is responsible 
for correct insertion of many OMPs, and serves as a positive control for increased outer 
membrane permeability (Figure 3C).  
 
Mutation of OmpA does not affect the expression of type 1 pili. 
 It is possible that mutation of OmpA or individual extracellular loops alters the 
expression of the major adhesive organelle involved in UPEC binding to epithelial cells, namely 
type 1 pili. However, when negative-stained cells were examined by TEM, pili were observed on 
UTI89, ΔompA, LP 1 KO, and LP 2 KO cells (Figure 4A). Immunogold labeling using an 
antibody specific to FimH confirmed that the pili decorating the cells of all four strains were type 
1 pili (Figure 4A). The negative control UTI89 fimH::kan exhibited severely stunted pili 
(Figure 4A). An immunoblot of whole cells further confirmed equivalent expression of FimH 
across wild-type, ΔompA, LP 1 KO, and LP 2 KO strains (Figure 4B). Finally, hemagglutination 
(HA) assays were used to confirm that these pili function as expected. Minimal variation was 
observed in the HA titers of LP 1 KO and LP 2 KO cells (Figure 4C). 
 
Deletion of loop 2 limits virulence in a mouse model of cystitis. 
 To investigate the effects of loop mutation in the context of in vivo infection, we used the 
loop mutant strains in an established mouse model of cystitis and quantified bladder titers 24 hpi. 
While LP 1 KO titers were equivalent to those of UTI89 ΔompA, the LP 2 KO bacteria were 
almost completely cleared from the bladder by 24 hpi (Figure 5A). As detailed above, the 
intracellular bacterial community (IBC) is an important step in the propagation of cystitis. By 
confocal microscopy, we found that UTI89, UTI89 ΔompA, and LP 1 KO cells were all able to 
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form mature IBCs by 16 hpi (Figure 5B). However, no IBCs were observed in the bladders of 
mice that had been infected with LP 2 KO. This block in the infection cascade likely accounts for 
the deficient titers observed with LP 2 KO 24 hpi. We next quantified numbers of IBCs in the 
bladders of mice using a lacZ-based staining method. The confocal data provided an excellent 
snapshot of what was happening in the bladders, as bladders infected with LP 2 KO bacteria 
harbored significantly fewer IBCs than the other three strains (Figure 5C). Furthermore, mice 
infected with ΔompA also harbored significantly fewer IBCs than UTI89-infected mice, which 
likely accounts for the difference in bacterial titer at 24 hpi (Figure 5C). 
 
Loop 2 is required for host cell binding and internalization. 
To identify if the loss of loop 2 affects UPEC binding to of invasion of the uroepithelium, 
we employed in vitro binding and invasion assays with cultured 5637 bladder epithelial cells. 
Binding and invasion in the ompA mutant were equivalent to wild-type UTI89 (Figure 6A, B). 
The LP 1 KO strain showed a small, non-significant decrease in binding, but a significant 
decrease in invasion (Figure 6A, B). Meanwhile, LP 2 KO cells bound and invaded uroepithelial 
cells at a significantly lower rate than wild-type or ΔompA cells (Figure 6A, B). A second, 
independent clone of the LP 2 KO displayed the same phenotype (“new LP 2 KO” in Figure 6A, 
B). 
We further discovered that this is a dominant effect. The LP 2 KO plasmid (with or 
without an HA tag) was transformed into wild-type UTI89, and the resulting strains were used 
for binding and invasion assays. Cells expressing both wild-type and mutant forms of OmpA 
exhibited impaired binding and invasion into 5637 cells (Figure 6A, B). Importantly, we 
42
confirmed that both the native and OmpA variant proteins were expressed at approximately 
equal levels (Figure 6C).  
 
Discussion 
 The major outer membrane protein OmpA has been shown to be important in the 
development of chronic cystitis in C3H/HeN model hosts [3]. Here, we demonstrate that OmpA 
is required for high-titer acute cystitis in C57Bl/6 mice. We hypothesized that the extracellular 
loops of OmpA may be driving this phenotype, and created individual loop mutants that allowed 
us to explore the roles of these structures during infection. This work focuses on the impacts of 
extracellular loops 1 and 2 during in vitro and in vivo infection.  
Although the expression of OmpA proteins with mutations in the extracellular loops did 
not affect cell shape, growth, permeability, or type 1 pili expression, we observed that mice 
infected with LP 2 KO bacteria had significantly lower bladder titers in C57Bl/6 mice 24 hpi 
when compared to wild-type bacteria. Further, this strain was unable to form mature IBCs, which 
resulted in significantly fewer IBCs 16 hpi. In vitro binding and invasion of uroepithelial cells by 
LP 2 KO strains was significantly worse than both wild-type and ompA mutant cells. Binding to 
host cells was not affected by the LP 1 KO, although invasion was modestly impacted, which 
may account for the lower numbers of IBCs observed 16 hpi. Surprisingly, LP 2 KO OmpA 
proteins exerted a dominant effect over the wild-type protein, as UTI89 cells expressing both 
native and LP 2 KO OmpA also exhibited sharply limited binding and invasion.  
Together, these data indicate that UPEC OmpA may directly interact with a molecule on 
or in uroepithelial cells, and that LP 2 is necessary for promoting this interaction. Our studies 
suggest that this interaction could be necessary for binding, internalization, or for preventing the 
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expulsion of bacteria-containing vacuoles. Work in other infectious E. coli systems hints at 
potential mechanisms to investigate. The role of OmpA in neonatal meningitis-causing E. coli 
(NMEC) has been extensively studied within the context of binding to human microvascular 
brain endothelial cells (HBMECs). In this system, NMEC OmpA can interact with the protein 
Ecgp (also known as gp96, Grp94, or HSP90B1) on the surfaces of HBMECs to promote 
internalization [9, 34, 35]. Although Ecgp contains a KDEL endoplasmic reticulum-localization 
sequence, this protein appears to be expressed in the cell membrane [35, 36]. Further, Prasadarao 
and colleagues have also utilized OmpA LP KO strains, and found that NMEC bacteria with 
mutant loop 1 or loop 2 are severely attenuated in a meningitis model [37, 38]. 
To determine if Ecgp is important for binding and invasion during UPEC cystitis, future 
experiments will examine the expression and localization of Ecgp in 5637 human bladder 
epithelial cells before and after exposure to UPEC, and will determine if there are differences in 
expression after exposure to full-length or loop mutant bacteria. Similar experiments can also be 
conducted in the murine model of cystitis to examine expression levels and localization of Ecgp 
before and after infection with wild-type and ompA mutant UPEC. Furthermore, confocal 
microscopy studies with cultured cells or in the murine host can be used to examine 
colocalization of UPEC and Ecgp. Additionally, several Ecgp blocking antibodies have been 
identified, and it may be possible to test these as a therapeutic to impair the infectious cycle that 
occurs during acute UTI, and to prevent the development of chronic cystitis [34]. These 
experiments will help determine if Ecgp is important for promoting binding and invasion of 
bacteria into host cells, a critical step in the development of acute UTI. 
More broadly, we can use purified native OmpA protein and our OmpA antibody in 
immunoprecipitation and Far Western experiments to probe host cell lysates or fractions for 
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potential binding partners and co-factors. Structural modeling studies have identified multiple 
putative binding pockets within the extracellular loops of OmpA [39, 40]. When a variety of 
sugars are modeled against these binding pockets, chitobiose shows the strongest affinity for 
binding [36, 40]. This is of particular interest, as chitobiose has also been shown to be important 
for the interaction of the type 1 pili adhesin FimH with glycoproteins on the surface of the 
bladder [41]. It is possible that OmpA and type 1 pili function cooperatively during UPEC 
infection. A similar cooperative interaction is important for NMEC invasion into brain 
microvascular endothelial cells, where binding of both FimH and OmpA results in an increase in 
intracellular Ca
2+
 levels, which promotes the actin rearrangement necessary for bacterial invasion 
[42-44]. Future studies will determine if type 1 pili and OmpA work together to facilitate binding 
in UPEC pathogenesis.  
An alternative explanation is that OmpA forms a homodimer to promote binding and 
invasion, and that mutation of loop 2 disrupts this dimerization. Alternatively, loop 2 may be 
required for OmpA to interact with a separate outer membrane protein, and this interaction may 
enhance binding to the host cell. Preliminary studies to determine if there are alterations in outer 
membrane proteins other than OmpA when the loop mutants are expressed did not identify any 
changes (data not shown). In these models, binding would be driven by type 1 pili alone when 
OmpA is mutated, leading to decreased binding to the host in vivo, although this decrease is 
harder to detect in vitro, potentially due to limited expression of uroplakins on 5637 cells (data 
not shown).  
Finally, we can also utilize the UTI89 strain that also expresses both native and LP 2 KO 
forms of OmpA in our mouse model of UTI to see if the dominant in vitro binding and invasion 
defects are also evident during in vivo infection. These experiments can help us identify which in 
45
vitro phenotypes are most important for UPEC infection, and lend direction to future in vivo 
studies. We have demonstrated that the extracellular loops of UPEC OmpA promote binding of 
bacterial cells to the host to enhance infection. The future experiments outlined here will dissect 
the specific roles of the loops during infection to further define how OmpA promotes UPEC 
pathogenesis during cystitis. We hope that this information will help direct the development of 
new methods for treating UTI. 
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Tables and Figures 
Table 1: Primers used to make UPEC OmpA extracellular loop mutants 
Primer name Sequence (5’ to 3’)* 
LP1SDM_4-10B-F CTGGTCCCAGTACTCTCGCGAAAACCAACTGGGCGCTGGTGCTTTTGGTGGTTAC 
LP1SDM_4-10-R CAGTTGGTTTTCGCGAGAGTACTGGGACCAGCCCAGTTTAGCACCAGTGTAC 
LP2SDM_5-10B-F GGTCGTATGCCTAGGAAAGCTCAGGGCGTTCAGCTGACCGCTAAACTGGG 
LP2SDM_5-10B-R CGCCCTGAGCTTTCCTAGGCATACGACCTAACCAGTCATAACCCATTTC 
OmpA Xba1-F CGTGTCTAGATTTCCTTGCGGAGGCTTGTCTGAAGCGGTTTC 
OmpA HindIII-R ACCCAAGCTTAACTTAAGCCTGCGGCTGAGTTACAACGTC 
* Membrane/non-surface exposed loops in red, surface exposed loops that are not deleted 
are bold, connectors replacing surface exposed loops underlined, matching spots in primer 
design green 
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Figure 1: OmpA is required to cause robust acute infection in C57Bl/6 mice. C57Bl/6 mice 
were transurethrally infected with approximately 10
7
 bacteria, either UTI89 (circles) or UTI89 
ΔompA (squares). Bladder titers (colony-forming units, CFU) are shown for the indicated time 
points (hours or weeks post infection). Each point represents a single mouse; horizontal bar 
indicates the geometric mean. Significance, as determined by Mann-Whitney U test, is denoted 
by asterisks; *** p < 0.0001. 
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Figure 2: Individual OmpA loop mutants express and localize correctly. (A) Immunoblot 
showing expression of OmpA in UTI89, UTI89 ΔompA (ΔompA), UTI89 ΔompA/LP 1 KO (LP 1 
KO), and UTI89 ΔompA/LP 2 KO (LP 2 KO) cells. The cytoplasmic protein GroEL is used as a 
loading control. (B) Representative immunoblots showing expression of the OmpA, periplasmic 
SurA, and cytoplasmic GroEL in whole bacterial cells, outer membrane fractions, and soluble 
fractions (cytoplasm and periplasm). U = UTI89, A = UTI89 ΔompA, 1 = LP 1 KO, 2 = LP 2 
KO. 
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Figure 3: Expression of loop mutant OmpA does not cause overt phenotypic differences. 
(A) Overnight cultures of UTI89, ΔompA, LP 1 KO, and LP 2 KO do not show any differences 
in overall morphology, as assessed by TEM. Representative pictures are shown. Scale bar 
represents 500 nm. (B) Growth of wild-type and mutant strains in LB media. pACYC is the 
empty vector. Lower growth in the strains carrying a plasmid is likely due to the inclusion of 
chloramphenicol in the media for plasmid maintenance. A representative plot is shown. (C) 
Mutant strains do not exhibit increased membrane permeability, as tested by a novobiocin disc 
diffusion assay.  50
  
Figure 4: Pili expression is not disrupted in OmpA loop mutants. (A) Immuno-gold TEM 
using a primary antibody directed against FimH tip adhesin. Secondary antibody is conjugated to 
18nm gold particle. Representative images are shown. Scale bar represents 500 nm. (B) 
Immunoblot for the type 1 pilus tip adhesin FimH shows approximately equivalent levels 
between strains. (C) Hemagglutination titers are modestly lower in bacteria expressing loop 
mutants. SurA mutant and FimH mutant bacteria are included as controls. Mean and standard 
deviation are shown. * p < 0.05; *** p < 0.0005; **** p < 0.001. 
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Figure 5: OmpA loop 2 mutant UPEC are severely attenuated in vivo. (A) Bladder titers 24 
hpi with wild-type or mutant bacteria in C57Bl/6 mice. Mice were infected with approximately 
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10
7
 UTI89 (circles), ΔompA (squares), LP 1 KO (diamonds), or LP 2 KO (diamonds) bacteria (n 
= 9-10 mice/strain). Geometric mean is indicated by the horizontal line. (B) Confocal 
microscopy to examine IBC formation 16 hpi in C57Bl/6 mice. DNA is stained red, and UTI89, 
LP 1 KO, and LP 2 KO UPEC express GFP. Representative images are shown. (C) Enumeration 
of IBCs in the bladders of C57Bl/6 mice 16 hpi as determined by lacZ stain (n = 11-13 
mice/strain). Geometric mean is indicated by the horizontal line; dashed line indicates the limit 
of detection. * p < 0.05; ** p < 0.005;  *** p < 0.001; **** p < 0.0001. 
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Figure 6: Loop 2 mutant UPEC display severe binding and invasion defects. (A) Binding to 
human bladder uroepithelial cells, displayed as percent bound of input. FimH mutant bacteria are 
54
included as a negative control. (B) Invasion into host cells, displayed as percent of bound. 
Average and standard deviation are shown in (A) and (B). * p < 0.05; ** p < 0.005;  *** p < 
0.001; **** p < 0.0001. (C) UTI89 cells transformed with LP 2 mutant-expressing plasmids 
express both native and variant forms of OmpA, as determined by immunoblot with anti-OmpA 
polyclonal antibody. The cytoplasmic protein GroEL is used as a loading control. Representative 
blot is shown. 
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Abstract 
 Cathelicidin is a proposed defender of the urinary tract via its antimicrobial properties, 
but its activity has not been delineated in a dedicated cystitis model. Female C57Bl/6 mice, wild-
type or deficient in CRAMP (ortholog of the sole human cathelicidin, LL-37), were infected 
transurethrally with the cystitis-derived uropathogenic Escherichia coli (UPEC) strain UTI89. 
Infection course was evaluated by bladder titers, intracellular bacterial community (IBC) 
quantification, and histology; immune responses and resolution were characterized through 
cytokine profiling, microscopy, and quantitation of epithelial recovery from exfoliation. 
CRAMP-deficient mice exhibited significantly lower bladder bacterial loads and fewer IBCs 
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during acute cystitis. Through differences in bacterial titers were evident as early as 1 hour post 
infection, CRAMP-deficient mice showed no baseline alterations in immune activation, 
uroepithelial structure, apical expression of uroplakins (which serve as bacterial receptors), or 
intracellular bacterial growth rate. CRAMP-deficient hosts demonstrated less intense cytokine 
responses, diminished neutrophil infiltration, and accelerated uroepithelial recovery. Mice 
lacking the antimicrobial peptide CRAMP suffered less severe infection than wild-type mice in a 
well-establish model of cystitis. Though CRAMP exhibits in vitro antibacterial activity against 
UPEC, it may enhance UPEC infection in the bladder by promoting epithelial receptivity and 
local inflammation. 
 
Introduction 
 Urinary tract infections (UTIs) are common worldwide, predominantly affecting young, 
premenopausal women. Over 80% of UTIs are caused by uropathogenic E. coli (UPEC), among 
which many strains have acquired significant antibiotic resistance [1]. A thorough understanding 
of both host and bacterial factors affecting the progression of UTIs is necessary to devise new 
treatment methods. Complicating this effort, UPEC comprise an array of strains that, by virtue of 
different genetic attributes and virulence factors, are adapted to colonization and virulence in 
distinct niches within and outside the urinary tract [2]. For example, the cystitis-derived UPEC 
strain UTI89 attaches via type 1 pili to mannosylated uroplakins on the luminal surface of 
bladder epithelial cells and is internalized [3, 4]. Intracellular organisms, protected from immune 
effectors and antibiotic therapies, replicate into biofilm-like structures termed intracellular 
bacterial communities (IBCs) [5, 6]. Exfoliation of the superficial epithelium is one host strategy 
to eliminate invasive bacteria, while a cytokine response recruits phagocytes (predominantly 
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neutrophils and macrophages) to the infected bladder [3, 7-10]. Host strain-dependent attributes 
specify additional influences on the progress and outcomes of experimental infection. In healthy 
C57Bl/6 mice, UPEC undergo multiple IBC cycles within the first 24 h, but pathogen control 
and diminishing bacterial titer are evident by 48 h post-infection (hpi) [11]. In other susceptible 
host strains (e.g., C3H/HeN), a dose-dependent proportion of infected animals maintains high-
titer chronic cystitis for weeks following inoculation [12]. 
 While exfoliation and urine flow represent mechanical defenses that protect the bladder, 
molecules including lysozyme, lipocalin, lactoferrin, and antimicrobial peptides also make the 
luminal environment less hospitable for pathogens [13]. Antimicrobial peptides (AMPs) 
comprise a diverse group of 12-50 amino acid chains produced by a wide variety of organisms. 
In humans, the chief classes of AMPs are cathelicidins and defensins; both have been implicated 
in defense of epithelial surfaces against infectious agents [14]. Humans and mice each express a 
single cathelicidin, termed LL-37 in humans and cathelin-related antimicrobial peptide 
(CRAMP) in mice [14, 15]. Though their antimicrobial domains vary in primary sequence, both 
LL-37 and CRAMP form amphipathic α-helices with demonstrated activity against Gram-
positive and -negative bacteria, fungi, and viruses [14]. Cathelicidin is constitutively expressed at 
low levels by epithelial cells in many tissues, including the urogenital tract, skin, lungs, and gut; 
pathogen recognition can rapidly induce local production of the peptide [15-18]. Beyond its 
antimicrobial properties, cathelicidin can recruit immune cells to sites of infection and stimulate 
production of pro-inflammatory cytokines [14, 19]. Recruited neutrophils can also produce 
cathelicidin to aid in controlling infection [15, 20]. 
 Uroepithelial expression of cathelicidin has been described as an important innate 
defense mechanism in the urinary tract. Higher cathelicidin levels are detected in urine during 
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human UTI, while post-infection levels fall below those of controls, suggesting that patients with 
naturally lower levels of cathelicidin may be more susceptible to UTI [17]. Chromek and 
colleagues examined UTI in CRAMP-deficient mice on a 129/SvJ genetic background using a 
UPEC strain, CFT073, isolated from the blood of a patient with pyelonephritis [16]. These 
authors observed more severe infections in CRAMP-deficient mice, evidenced by augments 
bacterial binding to renal proximal tubule cells and higher kidney bacterial loads 48 hpi [16]. 
 To further specify the role of cathelicidin during the most common form of human UTI, 
cystitis, we employed the cystitis-derived UPEC isolate UTI89 and CRAMP-deficient C57Bl/6 
mice. Although CRAMP effectively limited UPEC growth in vitro, its role during UTI was 
revealed as more complex than previously appreciated. Contrary to expectation, we found that 
CRAMP-deficient mice demonstrated lower bacterial loads at multiple time points and recovered 
more quickly from cystitis. CRAMP-deficient mice exhibited an attenuated immune response to 
infection and less tissue damage, correlating with accelerated epithelial restoration. Our data 
indicate that CRAMP may confer benefits to both host and pathogen in distinct ways within the 
urinary tract. 
 
Materials and Methods 
Bacterial strains and culture 
For infections, the cystitis-derived UPEC isolate UTI89 [21] was inoculated into Luria-Bertani 
broth (LB; 20 mL) directly from frozen stock and grown statically at 37°C for 16 h. Overnight 
cultures were centrifuged at 5000 × g for 10 min, resuspended in sterile phosphate-buffered 
saline (PBS) to OD600nm 1.0, and diluted 1:1 in PBS for inoculation.  
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In vitro CRAMP resistance assay 
CRAMP (mCRAMP, Anaspec, Fremont, CA) was resuspended in water to a final concentration 
of 2 mg/mL. Aliquots were stored at -80°C until use. Bacteria were prepared as described above. 
50 µl of bacterial suspension was added to 150 µl of sterile PBS with varying concentrations of 
CRAMP in a 96-well plate, briefly mixed, and incubated at 37°C for 2 h. Treated cultures were 
serially diluted and plated on LB agar to determine survival. Each concentration of CRAMP was 
tested in triplicate, and the experiment was repeated three times. 
 
Mice and infections 
Female mice aged 8-10 weeks were used for all experiments; animal procedures were approved 
in advance by the Animal Studies Committee at Washington University. Homozygous CRAMP-
deficient mice in a C57BL/6 background (kind gift of R. Gallo [22]) were bred on site. Mice 
were genotyped with PCR on tail DNA with primers specific to the third and fourth exons of the 
Cnlp gene [23]. C57Bl/6J mice (bred on site and purchased from Jackson Laboratories, Bar 
Harbor, ME) were used as comparators. Cystitis was induced by transurethral inoculation of 50 
μL of bacterial suspension in PBS (~107 CFU) as previously described [3].  
 
Organ and urine bacterial titers 
Urine collected from mice 1 hpi was serially diluted and plated to LB agar. Bladders and kidneys 
were harvested sterilely at specific time points (1, 6, 16, 24, 48 hpi, or 2 weeks post-infection 
[wpi]), homogenized in sterile PBS (Bullet Blender, Next Advance, Averill Park, NY), and 
plated to LB agar. Remaining homogenates were stored at -80C for use in uroplakin 
immunoblotting and soluble analyses as described below.   
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 Confocal microscopy and IBC volume determination 
Mice were infected with UTI89/pcomGFP [24] and bladders harvested at 16 hpi. Bladders were 
bisected and stretched with fine forceps and mounting pins. Bladder halves were fixed in 2.5% 
paraformaldehyde, permeabilized with Triton X-100, and stained with Syto 61 (1:1000, Life 
Technologies, Grand Island, NY). Bladder halves were imaged using a Zeiss LSM510 inverted 
confocal microscope; Z-stacks of individual IBCs were collected and volumes quantified using 
Volocity 6.3 software (PerkinElmer, Shelton, CT). 
 
IBC enumeration 
Bladders were harvested 16 hpi, bisected, stretched, and gently washed twice with PBS, then 
fixed for 1 h at 4°C (0.2% glutaraldehyde, 50 mM EGTA, 100 mM MgCl2 in PBS) and stained 
as previously described until IBCs could be clearly visualized [25]. After staining, tissues were 
washed three times with PBS. Stained tissues were stored at 4C in PBS until IBCs were counted 
under a dissecting microscope [25]. 
 
In vivo binding and invasion assays 
Bladders were harvested 1 hpi, partially bisected, and washed three times with 500 μL PBS with 
gentle rocking; washes were plated to LB agar to enumerate lumenal bacteria. Washed bladders 
were incubated in 100 µg/mL gentamicin at 37°C for 90 min; this gentamicin wash was plated to 
confirm death of extracellular bacteria. Bladders were then homogenized in sterile PBS and 
plated to enumerate intracellular bacteria.  
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Electron microscopy of CRAMP-treated cultures 
Overnight bacterial cultures were pelleted, resuspended to OD600 = 1.0, and treated with 10 
µg/mL CRAMP or PBS for 1 h at 37°C. Cultures were fixed (1% glutaraldehyde) before bacteria 
were adsorbed to glow-discharged formvar/carbon-coated copper grids for 2 min. Grids were 
washed in water and stained for 1 min with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, 
CA).  Air-dried samples were viewed on a JEOL 1200EX transmission electron microscope 
(JEOL USA, Peabody, MA). 
 
Immunoblotting 
Bladder homogenates were thawed, vortexed, and separated on 12% SDS-PAGE gels. Proteins 
were transferred to PVDF membranes and blocked in 2% powdered milk + 2% BSA in blocking 
buffer (0.5% Tween-20, 0.5M NaCl, 0.01M Tris base; pH 8.2). Membranes were incubated with 
either rabbit anti-uroplakin IIIa (UPIIIa; 1:5000, sc-33570, Santa Cruz Biotechnology, Dallas, 
TX) or goat anti-uroplakin Ia (UPIa; 1:250, sc-15173, Santa Cruz Biotechnology), and the 
control rabbit anti-CoxIV (1:2000, #4844, Cell Signaling Technology, Danvers, MA). Alkaline 
phosphatase-conjugated anti-rabbit IgG (1:2500, Sigma, A3812) or anti-goat IgG (1:2000, 
Sigma, A4187) was used as secondary antibody. Blots were incubated with Tropix CDP-STAR 
(Life Technologies) and exposed to film. Band densities were quantified using ImageJ, and 
uroplakin levels were normalized to the loading control CoxIV. All homogenates (3 uninfected 
mice/strain, 5 infected mice/strain/time point) were run adjacently on three separate gels and 
blots, with independent quantification.   
 
cAMP quantification 
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Bladders were harvested sterilely 30 min post-infection, everted (with two pairs of fine forceps, 
one securing the superior end and the other everting the tissue from the cut inferior end), and 
incubated in 0.1 M HCl for 30 min at room temperature (RT). Lysates were cleared by 
centrifugation at 20,000 × g for 10 min and stored at -20°C, then acetylated and used in the 
cAMP Enzyme Immunoassay Kit (Sigma, CA201) according to manufacturer’s instructions. 
Comparator C57Bl/6 mice were administered 10 mg/kg forskolin (Sigma) intraperitoneally plus 
100 μM forskolin transurethrally [26], or DMSO vehicle control 30 min before processing.  
 
Tissue histology 
The bladder and left kidney of two (C57Bl/6) or three (CRAMP-deficient) mice were harvested 
and fixed in methacarn (6:3:1 solution of methanol:chloroform:glacial acetic acid). Bladders and 
kidneys were bisected and set in 2% agar. Agar blocks were paraffin embedded, and 5-μm 
sections were stained with hematoxylin and eosin, then imaged using an Olympus DP25 camera 
and BX40 light microscope. 
 
Immunofluorescence microscopy 
Unstained sections from uninfected C57Bl/6 and CRAMP-deficient bladders were deparaffinized 
in mixed xylenes, rehydrated in isopropanol, washed in water, then boiled 30 min in 10 mM 
sodium citrate. Sections were blocked for 1 h in PBS with 1% BSA and 0.3% Triton X-100 at 
RT, and incubated with rabbit anti-UPIIIa (1:100) overnight at 4°C. AlexaFluor 488-conjugated 
goat anti-rabbit IgG (1:500, Life Technologies) and Syto 61 (1:10,000) were added for 1 h at RT 
before mounting and visualization. 
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Cytokine analysis 
Cytokines in bladder homogenates were quantified using a 23-plex magnetic bead cytokine array 
(Bio-Plex Pro, Mouse Group I; Bio-Rad, Hercules, CA). Homogenates were thawed on ice and 
cleared by centrifugation at 20,000 × g for 10 min. Individual samples (3 uninfected mice/strain, 
5 infected mice/strain/time point) were assayed in duplicate, and data were analyzed per the 
manufacturer’s instructions. 
 
Tissue myeloperoxidase assay 
Myeloperoxidase (MPO) activity was quantified as a measure of neutrophils present in bladder 
tissue [27]. Cleared lysates from bladder homogenates were analyzed with the Fluoro MPO kit 
(Cell Technology, Mountain View, CA) per the manufacturer’s instructions. 
 
Bacterial killing by murine bone marrow-derived neutrophils 
Bone marrow from C57Bl/6 and CRAMP-deficient mice was isolated in parallel; each sample 
was placed in PBS containing 0.1% bovine serum albumin (BSA; Sigma, St. Louis, MO) and 1% 
glucose (termed PBS-BG) before centrifugation at 100 × g for 10 min at 4°C. The pellet was 
resuspended in 45% Percoll and layered on top of a gradient comprised of 81%, 62%, 55% and 
50% Percoll layers. Gradients were centrifuged at 600 × g for 30 min at 4°C without brake. 
Neutrophils were collected from the interface between the 81% and 62% layers and washed once 
with PBS-BG, and the red cells were lysed. The neutrophils were washed again with PBS-BG 
and resuspended in RPMI to 10
7
 neutrophils/mL. Neutrophils were incubated with bacteria at a 
multiplicity of infection of 10 for 1 h in a tissue culture incubator (37˚C, 5% CO2), before lysis 
with Triton X-100 (final concentration 0.1%). Lysates were serially diluted and plated to 
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enumerate CFU, expressed as a percentage of input bacteria. The experiment was repeated 3 
times, with 5 samples per treatment (RPMI, C57Bl/6 or CRAMP-deficient) at 0 and 60 min. 
 
Statistical analysis 
All data were analyzed using the Mann-Whitney U test in GraphPad Prism software. P values < 
0.05 were considered significant. 
 
Results 
CRAMP-deficient mice display less severe cystitis. 
 We confirmed the in vitro antimicrobial properties of CRAMP against the cystitis-
derived UPEC strain UTI89 (Figure 1). We therefore expected CRAMP-deficient mice to 
display more extensive infection in the urinary tract. Instead, CRAMP-deficient mice exhibited 
significantly lower bladder bacterial loads as early as 1 hpi and at all time points through 48 hpi 
(p<0.005 at 1, 6, and 48 hpi, p<0.05 at 16 and 24 hpi; Figure 2A). Kidney infection was 
infrequently observed in either host strain (data not shown). Wild-type C57Bl/6 mice rarely 
progress to chronic high-titer cystitis [12], and similarly, CRAMP-deficient bladders did not 
harbor elevated bacterial loads 2 wpi (Figure 2B). 
 
Intracellular growth and IBC formation are unaffected in the absence of CRAMP. 
 The IBC represents a key phenotypic stage in the development of murine cystitis [5, 6, 
28, 29]. Thus, we asked whether defective IBC formation in CRAMP-deficient mice might 
correlate with the lower bladder titers observed in these hosts. Confocal microscopy revealed 
early and mature IBCs, as well as filamentous forms, in C57Bl/6 and CRAMP-deficient mice 
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(Figure 3A). Neutrophils properly located infected epithelial cells in both strains of mice 
(Figure 3A, right column). Quantification of IBC volumes did not reveal differences (Figure 
3B), but CRAMP-deficient bladders bore significantly fewer IBCs than did wild-type mice 
(p=0.002; Figure 3C). Together, these data indicate that while the IBC pathway is intact in 
CRAMP-deficient mice, diminished IBC numbers point to an early alteration in the infectious 
process (e.g., impaired initiation of infection, accelerated clearance of bacteria, increased 
exfoliation) in these hosts. 
 
Epithelial binding and invasion are diminished in CRAMP-deficient mice. 
 Given that bladder bacterial loads differed as early as 1 hpi, we investigated binding, 
invasion, and other processes occurring within this interval. Using in vivo binding and invasion 
assays, we recovered significantly fewer bacteria from both the luminal and intracellular 
compartments 1 hpi in CRAMP-deficient mice (p<0.001 and p<0.05, respectively; Figure 4A), 
implicating bacterial binding and invasion in the defective pathogenesis observed in these hosts. 
Corroborating this finding, CRAMP-deficient mice liberated significantly more bacteria in the 
urine 1 hpi (p<0.05; Figure 4B). 
 Because type 1 pili represent the primary determinant of UPEC binding to bladder 
epithelium, we tested whether CRAMP might represent a stimulus for bacterial expression of 
these organelles. However, no alteration in piliation was observed by electron microscopy upon 
CRAMP exposure in vitro (84.8% vs 78.2%; Figure 4C). Bladder UPIIIa content (by 
immunoblot of tissue homogenates) was also equivalent between wild-type and CRAMP-
deficient mice 1 hpi, indicating that accelerated uroepithelial exfoliation does not underlie 
decreased bacterial loads in CRAMP-deficient bladders (Figure 4D).  
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 Abraham and colleagues have shown that TLR4-dependent surges in epithelial cell 
cAMP result in expulsion of internalized UPEC [26, 30, 31]. In addition, cathelicidin may bind 
to and mask recognition of bacterial lipopolysaccharide (LPS), thereby down-regulating TLR4-
dependent immune signaling [32]. Consequently, we hypothesized that in CRAMP-deficient 
mice, TLR4 hyperactivation due to unmasked LPS may drive increased epithelial expulsion of 
internalized bacteria. However, cAMP activation in superficial epithelium in response to UTI89 
infection was equivalent in wild-type and CRAMP-deficient mice (Figure 4E). 
 
CRAMP deficiency does not impart inherent epithelial changes. 
 In further considering attenuated UPEC binding and invasion in CRAMP-deficient mice, 
we reasoned that these hosts might show baseline differences in epithelial structure or surface 
receptors (e.g., uroplakins). By immunoblot, UPIa and UPIIIa were equivalently expressed in 
bladder homogenates from the two mouse strains; this was corroborated by immunofluorescence 
microscopy for UPIIIa of uninfected bladder sections (Figure 5A). By histology, uninfected 
bladders of wild-type and CRAMP-deficient mice were similar in size and in tissue structure and 
organization (Figure 5B and C).  
 Cathelicidin expression can stimulate cytokine release from epithelial cells and promote 
immune cell recruitment to infected tissues [19, 33]. To investigate whether CRAMP influences 
soluble and cellular immune constituents in the bladder environment at baseline, we compared 
expression of 23 cytokines in uninfected C57Bl/6 and CRAMP-deficient bladders, finding no 
significant differences; six representative cytokines relevant to host response in cystitis are 
shown (Figure 5D; complete data in Table 1). We also found no difference in bladder neutrophil 
content (as measured by myeloperoxidase [MPO] activity) in the two uninfected host strains 
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(Figure 5E). These data indicate that UPEC pathogenicity in the CRAMP-deficient host is not 
influenced by pre-infection alterations in the resting immunologic state of the bladder. 
 
CRAMP-deficient mice show attenuated inflammatory responses to infection. 
 We next investigated whether CRAMP deficiency altered the inflammatory response to 
UPEC introduction into the bladder. By histology, luminal bacteria and areas of epithelial 
exfoliation were evident in both host strains by 6 hpi. Bladders from both hosts displayed mild 
edema and inflammatory cellular infiltrates (Figure 6A and B). While histologic differences at 
this time point were modest, analysis of bladder homogenates 6 hpi revealed significantly higher 
levels of 16 inflammatory cytokines in wild-type compared with CRAMP-deficient mice 
(representative cytokines shown in Figure 6C; complete data in Table 1). As inflammation and 
associated tissue damage may promote sustained UPEC infection [2, 11, 12], we repeated these 
analyses 24 hpi; at this subsequent interval, bladders of CRAMP-deficient mice displayed 
epithelial restoration and minimal edema, while wild-type bladders remained notably edematous, 
with widespread epithelial exfoliation (Figure 6A and B). Meanwhile, tissue cytokines remained 
generally higher in wild-type mice 24 hpi, though these differences did not retain statistical 
significance (Figure 6D and Table 1). Similarly, bladder MPO content was significantly higher 
in CRAMP-deficient hosts 6 hpi, but this difference had resolved by 24 hpi (p=0.016; Figure 6E 
and F, respectively). 
 These contrasts in inflammatory response were also reflected in recovery of the 
superficial epithelium. Though bladder uroplakin content at baseline and 1 hpi was equivalent 
between host strains, (Figure 4D), significantly more exfoliation was evident 6 and 24 hpi in 
wild-type mice (p=0.0317; Figure 6G). More striking, by 48 hpi, infected CRAMP-deficient 
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mice had restored the superficial epithelium fully, while wild-type bladder UPIIIa levels 
remained low, about one third of baseline (p=0.0089; Figure 6G). In combination, these data 
suggest significant alterations in the immune response to UPEC cystitis in CRAMP-deficient 
mice.  
 
Discussion 
 Cathelicidin antimicrobial peptides have been implicated in defense of multiple epithelial 
surfaces, including the skin, lungs, and urinary tract. Within the murine urinary tract, the 
expression and protective capacity of cathelicidin have been described in relation to kidney 
infection in 129/SvJ mice inoculated with 10
8
 CFU of UPEC strain CFT073 [16]. Here, we 
employed an established murine cystitis model, notably different from prior studies in host 
strain, bacterial strain, infectious dose, and the organ of focus. Our findings in this model system 
suggest that CRAMP exerts a complex influence on the progression and outcome of infection. 
 Though in vitro assays showed antimicrobial activity of CRAMP against UTI89, 
CRAMP was not essential for uroepithelial defense in our in vivo cystitis model. Instead, as 
indicated by significantly lower IBC numbers and bladder bacterial loads throughout infection, 
hosts lacking CRAMP resolved infections more efficiently. Diminished IBC formation in 
CRAMP-deficient hosts results from very early alterations in pathogenesis, specifically in 
epithelial binding and invasion by UPEC; we found no differences in several molecular 
determinants of these processes. Of note, cathelicidin has also been shown to enhance the 
bactericidal capacity of human and murine neutrophils, by stimulating ROS production in 
response to bacterial components and by augmenting bacterial engulfment. Specifically, bone 
marrow-derived neutrophils from CRAMP-deficient 129/SvJ mice showed diminished killing of 
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Gram-negative and -positive bacteria compared with wild-type neutrophils, and cathelicidin may 
alter gene expression in neutrophils [34, 35]. In contrast, we found normal UPEC-killing ability 
in bone marrow-derived neutrophils from CRAMP-deficient C57Bl/6 mice (Figure 7). In total, 
our data instead indicate important activities for cathelicidin during UTI that are independent of 
its direct antimicrobial activity and support of phagocyte killing. Future studies of cathelicidin in 
epithelial defense should account for these multiple biological activities that occur during host-
pathogen interactions, and should examine both epithelial and hematopoietic sources of the 
peptide.  
 Consonant with recent transcriptional profiling data [36, 37] and other prior studies (e.g., 
[7, 38]), we observed a sharp pro-inflammatory cytokine response in infected wild-type C57Bl/6 
mice by 6 hpi, with subsequent resolution. However, CRAMP-deficient hosts exhibited 
significantly reduced pro-inflammatory cytokine expression, edema, and neutrophil influx by 6 
hpi (Figure 6 and Table 1). Our findings support a model in which CRAMP participates in 
activation and development of the host immune response to UPEC within the bladder, a response 
that helps to control but may also facilitate UPEC infection [2]. Of note, a similar function for 
cathelicidin has been demonstrated in studies with cultured human lung epithelial cells and with 
human and murine peripheral monocytes [39, 40]. Consistent with an immunostimulatory role, 
cathelicidin concentrations during human UTI are on the order of other immunomodulators but 
well below concentrations necessary for bactericidal activity [16, 17] (Figure 1). While the 
bactericidal activity of AMPs may be impaired in high-salt conditions, it is unknown how such 
conditions (as may occur in urine) may influence its immunostimulatory properties. During 
experimental cystitis, absence of CRAMP may dampen inflammatory cytokine responses and 
exfoliation, processes that in wild-type hosts produce the significant epithelial damage that offers 
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UEPC access to naïve cells in deeper uroepithelial layers [41]. Though bladder instillation of 
concentrated cathelicidin can elicit edema and leukocytic infiltrates, enhanced IBC formation in 
wild-type mice may also drive augmented inflammation [42]. Indeed, multiple studies indicate 
that the degree of intracellular invasion and IBC formation predicts the intensity of inflammatory 
response in the bladder, and that increased inflammation in turn facilitates persistence of UPEC 
infection [2, 11, 12]. Thus, the development and outcome of uroepithelial infection depend on 
ongoing interplay between invasive bacterial populations and the soluble and cellular immune 
components of the host milieu.  
 Finally, cathelicidin is among multiple AMPs that could influence the progression of 
UTIs. For example, α-defensins produced by infiltrating neutrophils, as well as renally-expressed 
β-defensins, function to kill uropathogens and promote innate responses in infected tissue [43]. 
Uroepithelial expression of RNase 7 also increases during infection to yield urinary 
concentrations inhibitory to uropathogens [44, 45]. Additionally, AMPs have been shown to 
signal to other types of epithelial cells through surface receptors of upon internalization [39, 46]. 
Beyond potential signaling roles in host epithelial or hematopoietic cells, cathelicidin and other 
AMPs, might also elicit transcriptional programs (e.g., envelope stress responses) in bacteria. 
Cross-talk and/or redundancy likely occur among urinary AMPs and would complicate the 
development of a complete model detailing the effects of an individual AMP on the course of 
UTI. Our data also do not exclude the possibility that CRAMP-deficient mice might have 
alterations in intracellular events that follow bacterial internalization. However, the field 
presently lacks detailed molecular and cell-biological knowledge of these events, including a 
mechanism for presumed UPEC escape from the endocytic vacuole into the epithelial cell 
cytoplasm. Further exploration of potential influences of cathelicidin on UTI pathogenesis and 
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accompanying immune responses may reveal avenues for modulating these host responses in 
order to mitigate progression, chronic infection, and recurrence. 
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Tables and Figures 
 
 
 
Figure 1: CRAMP has antimicrobial activity against UPEC strain UTI89 in vitro. Dose-
dependent inhibition of bacterial viability is seen after 2 h treatment with CRAMP. Survival is 
shown as a percentage of input bacteria after 2 h. The mean and standard error are shown for 
each treatment concentration. 
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Figure 2: CRAMP-deficient mice have significantly lower bladder bacterial loads. (A) 
Bladder bacterial loads in wild-type C57Bl/6 mice (filled circles) were significantly higher than 
in CRAMP-deficient mice (open circles) at 1, 6, 16, 24, and 48 hpi (*p<0.05, **p<0.005). Bar 
represents the geometric mean. (B) C57Bl/6 and CRAMP-deficient mice show equivalent and 
minimal bladder bacterial loads at 2 wpi. Each point represents a single mouse. 
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Figure 3: Intracellular bacterial growth is similar between host strains, although wild-type 
mice have more IBCs. (A) Early and mature IBCs can be found in the bladder epithelial cells of 
both C57Bl/6 and CRAMP-deficient mice after infection with GFP-expressing UTI89. 
Filamentous bacteria were identified in both host strains of mice, as well as neutrophils that 
localize to IBC-bearing epithelial cells. DNA (host cell and bacterial) is stained red. 
Representative pictures are shown. (B) IBC volumes were equivalent between the two host 
strains, as quantified by Volocity software (all IBCs from 3 C57Bl/6 and 4 CRAMP-deficient 
mice). (C) IBC numbers, measured by lacZ staining, were significantly higher in wild-type mice 
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(***p<0.001; n = 13-15 mice per strain). Bars in (B) and (C) represent the geometric mean. Each 
point represents a single mouse. 
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Figure 4: Epithelial binding and invasion is less efficient in CRAMP-deficient mice. (A) 
Bacterial titers in the luminal and intracellular (gentamicin-protected) compartments at 1 hpi 
were both significantly lower in CRAMP-deficient mice (*p<0.05, ***p<0.001; n = 5 
mice/strain/experiment). (B) CRAMP-deficient mice liberate increased bacterial CFU in the 
urine at 1 hpi (*p<0.05). Dashed line represents the limit of detection and bars represent the 
geometric mean in (A) and (B). (C) Proportion of bacteria, either untreated or after 1 h exposure 
to 10 µg/mL CRAMP, that were piliated as determined by electron microscopy (n = 
100/condition x 5 separate experiments). (D) Densitometric quantification by immunoblot of 
UPIIIa in 1 hpi bladder homogenates as a measure of epithelial exfoliation showed no difference 
between host strains. Mitochondrial enzyme CoxIV was used to normalize the amount of protein 82
in each sample. (E) cAMP expression in the bladder uroepithelium of C57Bl/6 and CRAMP-
deficient mice at 30 min post-infection (n = 6-7 mice/strain). Negative and positive controls, 
respectively (white bars), included vehicle-only (DMSO) and forskolin-treated C57Bl/6 bladders 
(n = 2 mice/treatment). Mean and SEM are indicated in (C), (D), and (E). 
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Figure 5: Uninfected mice do not have inherent differences in the uroepithelium. (A) 
Densitometric analysis of immunoblots for UPIa and UPIIIa in uninfected bladder homogenates 
showed no significant differences (UPIa, p=0.1354; UPIIIA, p=0.1). Mitochondrial enzyme 
CoxIV was used to normalize the amount of protein in each sample. Mean and SEM are 
indicated. At right are representative fluorescence images of uninfected bladders sections (UPIIIa 
shown in green, nuclei shown in red; scale bar, 20 µm). (B and C) Sections of uninfected 
84
C57Bl/6 (B) and CRAMP-deficient (C) bladders were stained with hematoxylin and eosin 
(H&E) for morphological analysis. Whole bladders are shown on the left (scale bar, 400 µm), 
and magnified epithelial views are shown on the right (scale bar, 100 µm). Representative 
images are shown. (D) Cytokine profiles of uninfected bladder homogenates from C57Bl/6 and 
CRAMP-deficient mice. (E) Myeloperoxidase (MPO) activity, a surrogate for tissue neutrophil 
content, in uninfected whole bladder homogenates from the two host strains (n = 6 C57Bl/6 
mice, 11 CRAMP-deficient mice). Mean and SEM are indicated in (D) and (E). 
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Figure 6: Bladder from CRAMP-deficient mice recover faster after infection with UPEC. 
Sections of C57Bl/6 (A) and CRAMP-deficient bladders (B) 6 and 24 hpi were stained with 
H&E for morphological analysis. Whole bladder sections (left panels; scale bar, 400 µm) show 
substantially increased edema in wild-type mice at both time points. Acute cystitis is evident in 
both host strains 6 hpi (right panels; scale bar, 40 µm). However, at 24hpi, the infected wild-type 
bladder remains edematous and completely exfoliated, while CRAMP-deficient bladders reflect 
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resolved inflammatory changes and recovery of the superficial epithelial layer. (C) Expression of 
six representative cytokines is significantly lower in CRAMP-deficient bladder homogenates 6 
hpi (*p<0.05, **p<0.01). (D) At 24 hpi, only GM-CSF was significantly lower in CRAMP-
deficient mice, among 23 cytokines measured (*p=0.032; data not shown). Whole bladder MPO 
activity is significantly lower in CRAMP-deficient mice 6 hpi (E); this difference was no longer 
significant 24 hpi (F). (G) Densitometric analysis of bladder UPIIIa expression indicates more 
rapid epithelial recovery in CRAMP-deficient mice (white bars) than in wild-type mice (black 
bars) (*p<0.05, **p<0.01). Mean and SEM are indicated in (C-G). 
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Table 1: Pro- and anti-inflammatory cytokine levels in bladder homogenates
a
 
 Uninf 
C57Bl/6 
Uninf 
CRAMP 
6 hpi C57Bl/6 6 hpi CRAMP 24 hpi 
C57Bl/6 
24 hpi 
CRAMP 
IL-1α 15.87 ± 1.49 15.26 ± 1.51 35.86 ± 3.54 35.87 ± 3.54 37.08 ± 6.35 37.08 ± 6.35 
IL-1β 85.81 ± 9.25 87.83 ± 6.63 320.22 ± 
48.96* 
162.16 ± 
15.13* 
241.46 ± 43.61 142.45 ± 28.28 
IL-2 32.94 ± 1.08 31.76 ± 4.06 59.24 ± 5.04 43.92 ± 5.81 83.83 ± 8.98 69.798 ± 9.91 
IL-3 4.31 ± 0.30 4.77 ± 0.53 6.50 ± 0.68 5.77 ± 0.56 12.96 ± 5.05 5.27 
IL-4 OOR OOR OOR OOR OOR OOR 
IL-5 57.34 ± 3.22 55.06 ± 4.23 114.53 ± 
11.24* 
78.4 ± 5.01* 56.76 ± 9.28 46.275 ± 8.23 
IL-6 4.46 ± 0.15 3.82 ± 0.45 193.73 ± 
41.93* 
46.23 ± 13.68* 50.9 ± 18.34 51.1 ± 18.05 
IL-9 OOR OOR OOR OOR 773.84 ± 
145.23 
695.72 ± 
247.94 
IL-10 30.25 ± 0.83 27.87 ± 1.44 66.27 ±5.39* 44.00 ± 2.18* 60.53 ± 8.18 36.22 ± 5.82 
IL-12 (p40) 16.15 ± 2.58 13.32 ± 0.59 34.78 ± 2.57* 21.42 ± 2.17* 44.04 ± 13.10 27.39 ± 4.51 
IL-12 (p70) 39.77 ± 0.39 45.24 ± 3.11 126.99 ± 
7.44** 
86.61 ± 5.82** 92.06 ± 16.27 53.59 ± 6.20 
IL-13 97.86 ± 7.22 93.61 ± 8.81 273.04 ± 
21.37* 
167.49 ± 
14.03* 
253.24 ± 30.77 237.06 ± 44.87 
IL-17 27.07 ± 1.28 24.58 ± 2.02  184.03 ± 
20.69* 
87.78 ± 6.68* 116.05 ± 15.28 62.07 ± 16.17 
Eotaxin 275.12 ± 16.93 208.22 ± 27.24 1154.64 ± 
121.65* 
692.26 ± 
53.71* 
OOR OOR 
Granulocyte 
colony-
stimulating factor 
(G-CSF) 
239.52 ± 44.07 202.82 ± 15.22 438.81 ± 
43.91* 
222.45 ± 
23.94* 
403.2 ± 177.21 184.96 
Granulocyte-
macrophage 
colony-
stimulating factor 
(GM-CSF) 
60.91 ± 4.47 64.26 ± 4.38 209.11 ± 
20.97** 
120.7 ± 4.43** 115.04 ± 
21.47** 
57.09 ± 9.84** 
IFN-γ OOR OOR 21.23 ± 1.21** 14.78 ± 1.36** 36.76 ± 13.13 30.82 ± 7.97 
KC 7.03 ± 0.25 6.72 ± 1.06 621.79 ± 
72.74** 
174.44 ± 
28.89** 
208.04 ± 53.41 180.25 ± 73.03 
Monocyte 
chemotactic 
protein (MCP)-1 
86.46 ± 9.75 72.97 ± 5.46 1519.02 ± 
324.44** 
355.96 ± 
78.53** 
230.77 ± 53.36 129.63 ± 40.49 
Macrophage 
inflammatory 
protein (MIP)-1α 
12.45 ± 0.53 16.07 ± 1.00 59.15 ± 8.80* 30.06 ± 5.08* 40.66 ± 6.11 24.862 ± 4.07 
MIP-1β 20.03 ± 1.50 20.59 ± 1.14 68.93 ± 8.69* 39.56 ± 5.34* 43.02 ± 6.61 31.05 ± 3.66 
RANTES 15.15 ± 4.97 15.17 ± 4.02 176.45 ± 40.02 79.17 ± 25.75 101.84 ± 13.50 51.462 ± 8.40 
TNF-α OOR OOR OOR OOR OOR OOR 
a
values shown represent mean ± SEM for all samples, bolded pairs indicate significant 
differences (C57Bl/6 vs CRAMP); *p < 0.05; **p < 0.01; OOR = out of range (low)  
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Figure 7: UPEC killing by CRAMP-deficient neutrophils is equivalent to wild-type. UPEC 
were incubated with RPMI (media control) or bone marrow-derived neutrophils from C57Bl/6 or 
CRAMP-deficient mice for 1 h, before the neutrophils were lysed and the lysates were plated to 
determine percent survival relative to input. There is no difference in UPEC recovery after 
exposure to wild-type vs CRAMP-deficient neutrophils (p=0.1524). Mean and standard error are 
shown for each treatment. 
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CHAPTER FOUR 
RNA SEQUENCING REVEALS UPEC-SPECIFIC PATHWAY REGULATION  
AFTER SUB-LETHAL EXPOSURE TO CATHELICIDIN 
 
Abstract 
 Antimicrobial peptides (AMPs) are important for defense of many epithelial surfaces, 
including the skin, respiratory system, gut, and urinary tract. The AMP cathelicidin is produced 
by epithelial cells and innate immune cells within the urinary tract at low levels; published data 
support possible in vivo roles both in limiting infection and in promoting inflammation. In order 
to examine the effects of cathelicidin on uropathogenic E. coli (UPEC) in vitro, UPEC were 
treated at various points in growth with increasing concentrations of cathelicidin and plated to 
quantify survival. Surprisingly, UPEC in mid-log phase reproducibly increased in number 
relative to an untreated control after a 1 h treatment with 1 µg/mL cathelicidin. In contrast, the 
laboratory E. coli strain MG1655 exhibited decreased survival after the same treatment. This 
may indicate that UPEC have specifically adapted to better resist cathelicidin. When treated with 
higher concentrations of cathelicidin, UPEC survival decreased in a dose-dependent manner. 
RNA sequencing was employed to interrogate UPEC global transcriptional responses to 
treatment with the murine cathelicidin CRAMP at concentrations of 1 or 3 µg/mL. A limited 
number of genes were significantly upregulated after 1 µg/mL CRAMP treatment and 
approximately half of these upregulated genes are involved in metabolism. Interestingly, another 
subset of upregulated genes encodes known small molecule and peptide transporters. Upon 
exposure to 3 µg/mL CRAMP, almost one fifth of the UPEC genome was differentially 
regulated, including all of the genes upregulated after exposure to 1 µg/mL CRAMP. These data 
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suggest that sensing of cathelicidins in the environment may prompt UPEC to upregulate genes 
that allow for uptake and subsequent breakdown of these peptides. This could function as a 
defense mechanism, and/or to simultaneously promote growth in a nutrient-limited environment. 
Current experiments are elucidating mechanisms through which cathelicidin interacts with the 
cell to induce these alterations in gene expression. 
 
Introduction 
Urinary tract infections (UTIs) are infections of the bladder (cystitis) and sometimes the 
kidneys (pyelonephritis) that most commonly affect otherwise healthy women of child-bearing 
age. More than half of women will experience at least one UTI in their lifetime, and up to 40% 
of infected women will have recurrent UTIs within 6 months that are not eliminated through the 
use of antibiotics [1-3]. Due to the high incidence of these infections (approximately 11 million 
in 2007), there is significant burden on the healthcare system, amounting to upwards of $4 
billion per year in the United States [3]. The most common cause of UTI is uropathogenic E. coli 
(UPEC), which can account for up to 85% of all UTIs [2]. Although the majority of these 
infections will be naturally cleared from the body in 3-4 days, antibiotics are often prescribed to 
help clear these infections, contributing to the epidemic of antibiotic resistance [4, 5]. Much 
work has been done to elucidate the important interactions that occur between UPEC and the 
host during the establishment of infection, but a clearer understanding of the bacterial responses 
to the host environment may help drive the creation of new antimicrobials.  
 The majority of UTIs are thought to originate from seeding of extraintestinal pathogenic 
E. coli (ExPEC), originating from the natural gut microbiota, into the urinary tract [6-8]. 
Behavioral, genetic, and anatomical factors in the host contribute to the incidence of UTI and to 
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the progression from cystitis to pyelonephritis [3]. While there are a number of bacterial factors 
that also influence whether or not a UTI develops, there is not a set of virulence factors that 
“defines” UPEC, as UTI-causing strains are genomically diverse [8-10]. Genes that have been 
identified as important include adhesive fimbriae (type 1, S and P pili), iron acquisition 
molecules (yersiniabactin, aerobactin, enterobactin, among others), and toxins (cytotoxic 
necrotizing factor 1, hemolysin) [11-13]. The identification of other mechanisms that specifically 
promote UPEC infections would help with the design of treatments that would not harm 
important gut flora. A murine model of cystitis has aided in the discovery of a UPEC infection 
cycle, while subsequent clinical studies have confirmed the occurrence of key points in the 
cascade in affected children and adults [14-18]. 
 The urinary tract features a variety of defenses to protect against uropathogens. These 
include mechanical defenses, such as urine flow and exfoliation of the bladder epithelium, and 
limitation of critical nutrients through the expression of molecules such as lactoferrin and 
lipocalin [19]. Most importantly, the innate immune system is comprised of molecules and cells 
that can quickly and broadly eliminate potential pathogens. Within the urinary tract, the 
important cellular components include phagocytes such as polymorphonuclear cells (PMNs; 
neutrophils) and macrophages, mast cells, natural killer cells, and γδ T-cells [20-22]. In addition 
to the molecules that comprise the complement system, antimicrobial peptides (AMPs) are 
produced by innate immune cells and epithelial cells. These peptides have demonstrated 
antimicrobial activity against a range of pathogens. The most prevalent AMPs in the urinary tract 
are cathelicidin, α- and β-defensins, hepcidin, and RNase 7 [23-26]. Previous work has shown 
that  many of these peptides are constitutively expressed within the urinary tract and are up-
regulated in response to bacteria. Therefore, to successfully cause a robust infection, potential 
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pathogens must be able to evade the killing effects of these molecules as soon as they enter the 
urinary tract. 
 Many AMP defense mechanisms have been described in both Gram-negative and Gram-
positive bacteria. These mechanisms range from outer membrane protein modifications that alter 
the surface charge of the bacteria, to the expression of efflux pumps and proteases, and the 
expression and release of proteins that can sequester or break down AMPs [27]. While UPEC 
encode many of the proteins important for these defenses, it is unclear which of these 
mechanisms are most important for survival within the urinary tract. Furthermore, it is likely that 
there are additional resistance mechanisms that have not yet been discovered. We hypothesized 
that UPEC may have specific AMP resistance mechanisms that permit them to cause infections 
in the host, and that we could discover these mechanisms by examining the genes that are 
upregulated in response to AMP exposure. Of the multiple AMPs expressed in the urinary tract, 
we chose to focus first on cathelicidin, as both humans and mice encode a single cathelicidin 
(LL-37 and cathelin-related antimicrobial peptide or CRAMP, respectively) [28, 29]. 
 Here, we created an in vitro assay that would allow us to ascertain mechanisms used by 
UPEC use to resist the killing effects of AMPs, and to approximate the effects that sub-lethal 
exposure to AMPs has on bacteria in the urinary tract. Briefly, pathogenic or non-pathogenic E. 
coli were grown to mid-log phase, treated with murine cathelicidin, and then RNA was isolated 
for RNA sequencing and transcriptomic analysis. While UPEC actually showed augmented 
growth in the presence of a low concentration of CRAMP, non-pathogenic cells were killed by 
the same concentration, indicating that there may be response mechanisms that are specifically 
encoded by uropathogens. RNA sequencing revealed that a limited number of UPEC genes were 
differentially regulated when cells were treated with 1 µg/mL of cathelicidin. These expression 
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patterns suggested that uropathogens may selectively up-regulate genes that enable the cells to 
take up AMPs, increase TCA cycle output, and utilize the peptides as a source of nutrient amino 
acids. Together, these responses would promote growth in the otherwise limiting environment of 
the urinary tract.  
The results shown here may support another mechanism in which UPEC utilize 
uncommon yet available resources in the urinary tract to quickly amplify in number and establish 
infection. Future experiments will directly test the use of cathelicidin by UPEC as a nutrient 
source, and will elucidate the specific roles of the identified genes through in vitro and in vivo 
experiments. We hope that this work will illuminate the biological processes that occur when 
UPEC are introduced into the urinary tract, and will direct the development of new methods for 
inhibiting the growth of UPEC during infection.  
 
Materials and Methods 
Bacterial strains and culture 
The prototypic cystitis isolate UTI89 and the laboratory-adapted K12 E. coli strain MG1655 
were cultured directly from frozen stocks for experiments [30, 31]. Cultures were grown in 20 
mL static cultures overnight at 37°C unless otherwise indicated.  
 
CRAMP survival of stationary phase cultures 
UTI89 and MG1655 were grown in LB Miller broth overnight, pelleted, and resuspended to an 
OD600 = 1 in sterile phosphate-buffered saline (PBS). In triplicate wells of a 96-well plate, 50 µL 
of resuspended bacteria were mixed with 150 µL sterile PBS, along with freshly thawed CRAMP 
to yield the indicated final concentrations. The plate was briefly shaken before static incubation 
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at 37°C for 2 h. Cultures were serially diluted in sterile PBS and plated on LB agar to determine 
survival. The experiment was repeated three times, and significance was determined by Student’s 
t test.  
 
AMP treatment during growth 
CRAMP or LL-37 (Anaspec, Fremont, CA) was resuspended in sterile water and 2 mg/mL 
aliquots were stored at -80˚C until needed. Overnight cultures were centrifuged and resuspended 
in PBS to an OD600 = 1. The resuspended culture was used to subculture fresh LB Luria 1:10, 
and the cultures were grown statically at 37°C until the OD600 reached 0.5. At this point, aliquots 
were removed, centrifuged, and the pellets resuspended in a volume of PBS twice that of the 
original aliquot (1:1 final dilution). Freshly thawed AMP was added to the desired final 
concentration (after 1:10 dilution in sterile water, if necessary), and the samples were incubated 
at 37°C for 1 h before serial dilution in PBS and plating to determine CFU. An untreated sample 
was prepared in parallel to the treated samples for each strain. The experiment was repeated at 
least three times. 
 
RNA isolation and sequencing 
RNA was isolated from CRAMP-treated cultures of UTI89 and MG1655 immediately after 
incubation at 37°C using a QIAgen RNeasy Mini Kit, according to the manufacturer’s 
instructions. Samples were stored at -80°C. Sets of five samples (UTI89 untreated, UTI89 with 1 
µg/mL CRAMP, UTI89 with 3 µg/mL CRAMP, MG1655 untreated, MG1655 with 1 µg/mL 
CRAMP) were prepared on three separate days. Samples were submitted to the Genome 
Technology Access Center for ribosomal RNA depletion (Ribo-Zero rRNA Removal Kit, 
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Illumina), reverse transcription, and sequencing. The samples were sequenced using a single lane 
of a Solexa sequencer, and reads were aligned to either the UTI89 genome or the MG1655 
genome. Read data from individual genes were used for comparisons and downstream 
applications. 
 
Molecular biology 
Electrocompetent cultures of UTI89/pKM208 expressing λ Red recombinase were transformed 
with linear PCR products that contained 20-30 bases of homology to the target gene on either 
side of a chloramphenicol resistance marker [32]. The primers used to prepare these PCR 
products are listed in Table 2. Correct insertion of the chloramphenicol cassette into the gene of 
interest was confirmed in individual colonies using flanking primers, or a primer that recognizes 
the middle of the chloramphenicol cassette (primers listed in Table 3). A single colony with 
PCR-confirmed allelic replacement was selected for each gene of interest and used for further 
characterization. 
 
Growth curves 
Overnight shaking cultures of the desired strains in LB Miller were sub-cultured at 1:100 in fresh 
LB Miller broth and grown to an OD600 = 1. These cultures were diluted 1:10,000 in fresh media, 
and 200 μL was transferred to each well of a 96-well plate, with five wells per strain. The 
cultures were grown at 37°C with shaking in a Synergy 2 microplate reader (BioTek, Winooski, 
VT), and the OD600 of each well was read every 30 min. The experiment was repeated three 
times, and a representative plot is shown.  
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Results 
UTI89 and MG1655 are susceptible to CRAMP-mediated killing. 
 The bactericidal effects of cathelicidin have been touted in many models of disease and 
infection. We first confirmed that the cystitis-derived UPEC isolate UTI89 and the laboratory-
adapted K12 E. coli strain MG1655 were both susceptible to killing in vitro by the murine 
cathelicidin CRAMP. The strains were similarly susceptible to killing at doses <10 µg/mL, 
although MG1655 was significantly more susceptible to killing at both 20 and 50 µg/mL doses 
(**** p < 0.0001; Figure 1). 
 
UTI89 cells grow in response to low-dose CRAMP treatment. 
 Upon introduction into the urinary tract, bacteria are promptly exposed to sub-lethal 
concentrations of AMPs. To determine if E. coli are able to sense and respond to the presence of 
AMPs in their environment, we measured changes in growth rate after treatment with 
cathelicidin. We hypothesized that if bacteria respond by activating AMP resistance 
mechanisms, we would not observe an increase in cell death relative to untreated cells. For these 
experiments, bacteria were grown in low-salt LB Luria in order to more closely replicate the 
environment of the urinary tract. When cultures of UTI89 in early to mid-log phase were treated 
with a 1 µg/mL of CRAMP for 1 h at 37°C, increased growth was observed, relative to an 
untreated sample studied in parallel (Figure 2A). Of note, cells at this point in growth were not 
fully resistant to the killing effects of CRAMP, as treatment with a higher dose of CRAMP (5 
µg/mL) did result in cell death (Figure 2A).  
 We also aimed to identify any UPEC-specific mechanisms important for resistance to 
AMPs. Thus, we studied the laboratory-adapted K12 E. coli strain MG1655 in parallel growth 
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and treatment experiments. In contrast to UTI89, MG1655 cells were susceptible to killing by 1 
µg/mL of CRAMP at all examined points in growth; this susceptibility decreased as the cultures 
approached mid-log phase (Figure 2B). However, MG1655 cells were more susceptible to 
killing by 5 µg/mL of CRAMP at later points in growth than UTI89 (Figure 2B). When these 
experiments were repeated with the human cathelicidin LL-37, there was not an increase in 
growth with 1 µg/mL treatment; UTI89 and MG1655 were equally susceptible to killing at the 1 
and 5 µg/mL doses (Figure 2C). 
 
A subset of UTI89 genes are significantly differentially regulated in response to CRAMP. 
 A global approach was used to investigate the genetic changes that underlie the increased 
growth observed in UTI89 cultures treated with 1 µg/mL of CRAMP. We prepared RNA from 
untreated samples, as well as samples treated with 1 or 3 µg/mL of CRAMP, and analyzed the 
transcriptional profile of these samples by RNA sequencing. An aliquot was removed from each 
of the treated samples before RNA isolation in order to confirm that the survival phenotypes 
were consistent with our preliminary experiments (Figure 3A). A treatment of 3 µg CRAMP/mL 
was used in these experiments to ensure that the cultures contained mostly live cells. Using a 
False Discovery Ratio (FDR) cut-off of 0.05 and a p-value < 0.05, we identified 12 genes that 
were significantly differentially regulated when UTI89 was exposed to 1 µg/mL of CRAMP 
(Table 1). Of the 12 identified genes, six have roles in metabolism, five are identified as 
transporters, and one is a hypothetical protein of unknown function (Figure 3B and Table 1) 
[33]. Three different operons had two genes represented in this set: the dppABCDF operon, 
which encodes an inner membrane dipeptide transporter; the UTI89 homolog of the 
arnBCADTEF operon in MG1655 (annotated as yfbG and yfbH in UTI89), which encodes a 
103
group of transferases; and the malK-lamB-malM operon, encoding an inner membrane maltose 
transport system [33].  
We also treated cells with 3 µg/mL of CRAMP and performed a similar analysis. Using 
the same stringent analysis criteria, 942 genes were significantly differentially regulated under 
these treatment conditions (data not shown), representing almost one fifth of the UPEC genome 
[34]. All 12 genes that were differentially regulated at 1 µg/mL were also differentially regulated 
at 3 µg/mL. The expression of all but two genes (aceA and gatY) was more highly upregulated 
after treatment with 3 µg/mL CRAMP (data not shown). It is important to note that in the 
samples submitted for RNA sequencing analysis, treatment with 3 µg/mL CRAMP resulted in 
measurable cell death relative to untreated samples (66% survival; Figure 3A). It is likely that 
some of the measured changes in gene regulation are associated with lysed or dead cells in the 
samples. 
 
MG1655 genes are not significantly differentially regulated in response to 1 µg/mL CRAMP. 
Cultures of MG1655 treated with 1 µg/mL of CRAMP exhibited decreased survival in 
relation to an untreated control (83% survival; Figure 3A). Even though some bacterial cell 
death was observed at this dose, analysis of RNA sequencing data using the same stringent 
criteria as before did not reveal any significantly differentially regulated genes in MG1655.  
 
Mutants do not have altered growth or CRAMP resistance phenotypes. 
 In order to determine if any of the identified genes have critical roles in normal bacterial 
cell growth, we created in-frame allelic replacements in UTI89 for each of the 12 genes 
differentially regulated upon 1 µg/mL CRAMP exposure. We were able to isolate mutants for 
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each gene, indicating that none of these genes are essential. Mutants for two genes (aceA and 
lamB) had previously been generated (unpublished data). We did not identify any defects during 
growth in rich medium as compared to wild-type UTI89 (Figure 4A). To characterize the ability 
to respond to sub-lethal concentrations of CRAMP, we tested all of the mutants in our CRAMP 
survival assay. Preliminary results indicate that single-gene mutants are not more susceptible to 
killing by 1 µg/mL CRAMP, although further experiments are needed to confirm these 
phenotypes (Figure 4B). 
 
Discussion 
 Cathelicidin antimicrobial peptides have been shown to be exhibit activity against a wide 
range of microorganisms. Here, in relation to urinary tract defense, we sought to identify 
mechanisms by which UPEC (in contrast with non-pathogenic E. coli strains) can respond to the 
presence of cathelicidins in the environment. We confirmed that both the cystitis strain UTI89 
and the laboratory strain MG1655 are susceptible to killing in vitro by the murine cathelicidin 
CRAMP, and were then surprised to find that UPEC in mid-log phase showed increased growth 
after treatment with a sub-lethal concentration of CRAMP (Figure 1, 2A). Non-pathogenic E. 
coli did not display this growth phenotype after exposure to sub-lethal CRAMP (Figure 2B).  
We were interested to determine if there are UPEC-specific mechanisms that promote 
survival and growth in an environment with AMPs. We employed unbiased RNA sequencing 
(transcriptomic analysis) to identify genes that are differentially regulated after cathelicidin 
treatment. This analysis yielded 12 differentially regulated genes in UPEC after treatment with 1 
µg/mL of CRAMP, and nearly 1000 genes after treatment with 3 µg/mL of CRAMP (Table 1). 
The majority of these 12 genes do not represent previously annotated AMP resistance 
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mechanisms, and instead encode membrane-localized small molecule and peptide transporters, as 
well as metabolic enzymes [33]. None of these genes are essential for survival, as in-frame 
deletion mutants were all viable and exhibited normal growth in rich medium (Figure 4A). 
Furthermore, all 12 of these genes are encoded by both UTI89 and MG1655 [33]. 
 The genes dppB, dppC, and oppC encode inner-membrane transporters that function to 
transport peptides from the periplasm into the cytoplasm. DppB and DppC are two of the three 
subunits that make up the DppABC dipeptide transporter [35]. The gene encoding the other 
subunit, dppA, is one of the top 50 genes expressed in pyelonephritis isolate CFT073 when 
grown in human urine in vitro and has also been identified as highly expressed in many clinical 
UPEC isolates [36, 37]. OppC is one of three components that make up the OppABC 
oligopeptide transporter, and the oppA gene is also highly expressed in E. coli isolates from 
patients with active UTI [37-39]. It is particularly interesting that both dpp and opp genes were 
identified in our screen as mutants in dppA and oppA have been shown to promote cystitis in the 
murine model of infection [40]. These proteins had been shown to be highly upregulated during 
growth in human urine [40]. It was further shown that gluconeogenesis and the TCA cycle are 
required for in vivo UPEC infection [40]. It is possible that the opp and dpp operons are 
important for regulating the uptake of peptides that can be fed into these metabolic cycles. 
Finally, the genes lamB and malK occur in an operon along with the gene malM, and encode 
maltose transporters within the outer and inner membranes, respectively [38, 39, 41].  
The other seven genes (aceA, fumC, gatY, glcD, ydcW, yfbG, and yfbH) encode 
cytoplasmic proteins. All but yfbH have well-defined functions, although yfbH likely functions in 
the same pathway as yfbG. YfbG (known as ArnA in MG1655) has a well-defined role in 
resistance to the cationic AMP polymyxin [42]. This protein forms the sugar nucleotide UDP-L-
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Ara40, which is eventually incorporated into Lipid A where it mediates polymyxin resistance in 
E. coli and Salmonella typhimurium [42, 43]. We can use mass spectrometry analysis to 
determine if this Lipid A modification occurs in UTI89 after exposure to CRAMP, and the yfbG 
mutant can be used in a murine model of cystitis to explore the effects of Lipid A modification 
on establishment of UTI.  
The genes aceA, fumC, gatY, glcD, and ydcW encode enzymes that function in 
metabolism, some in the TCA cycle and others in intermediate metabolism. Within the TCA 
cycle, fumC encodes fumarate hydratase, which reversibly converts (S)-malate to water and 
fumarate, while gatY encodes fructose-1,6-bisphophate aldolase, which catalyzes the 
condensation of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate [44-47]. Of note, 
fumC is co-transcribed with fumA, a gene shown to be downregulated  by UPEC in vivo relative 
to expression in growth in human urine in vitro [37]. Furthermore, gatY has been termed as a 
UPEC-specific gene because it was encoded by 8 sequenced UPEC strains, but was not found in 
a set of fecal/commensal isolates; however, this gene is encoded by MG1655 [31, 48]. The 
ydcW-encoded γ-aminobutyraldehyde dehydrogenase is involved in choline and putrescine 
degradation; glcD encodes a glycolate oxidase subunit that helps with small carbon compound 
degradation; and the isocitrate lyase AceA functions in the glyoxylate bypass pathway [49-55]. 
Although these genes represent distinct metabolic pathways, the recurring theme of increased 
metabolic activity is consistent with the growth phenotype that was identified in the preliminary 
experiments. Together, these expression patterns support a model in which UPEC are actively 
upregulating genes that allow for the uptake and subsequent breakdown of CRAMP, potentially 
to use as a source of amino acids. This detection of CRAMP could be triggering the changes that 
occur and which may help prime the bacteria to survive in the urinary tract. 
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 No significantly differentially regulated genes were identified when the treated and 
untreated MG1655 transcriptomes results were compared using stringent criteria. However, 
variation among the three untreated MG1655 samples may affect the sensitivity to changes in 
gene expression. Indeed, if we eliminate one outlying untreated MG1655 from the analysis, a 
single gene (thrL) is significantly upregulated upon CRAMP exposure, based on the p-value 
alone. This gene encodes a 21 aa peptide that controls expression of the thrLABC operon, an 
operon encoding four of the five threonine biosynthesis enzymes [33, 56, 57]. As MG1655 cells 
are dying at this treatment dose, the upregulation of thrL may represent a limited and futile stress 
response to slow the metabolism of the cells as a mechanism of waiting for conditions to 
improve. It should be noted that the FDR ratios for all genes identified in the MG1655 analysis 
are fairly high, and therefore confirmatory qRT-PCR should be done before moving forward 
with additional experiments. Future experiments could use genetic tools to manipulate the 
expression of the differentially regulated UTI89 genes within MG1655 cells before treatment 
with sub-lethal CRAMP. It is possible that the pathways can function in both cell types to 
mediate the growth phenotype, but that MG1655 cells normally are unable to detect the CRAMP, 
or to activate the adaptive pathways. 
 Finally, the RNA sequencing results for both strains were initially aligned to the 
published MG1655 genome before the different treatment groups were compared. Analysis of 
the data generated by this alignment indicated that close to 90% of the genes were differentially 
regulated in UTI89 in response to CRAMP. The sequencing data were re-aligned to the cognate 
genomes for the analysis presented here. However, our initial results underline the importance of 
using robust reference genomes for analysis of sequencing data, and how there can be vast 
differences among strains within the same species. UTI89 and MG1655 are very divergent 
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strains, and MG1655 may not be the best model strain to use in representing non-pathogenic 
strain E. coli. We have access to a collection that contains strains from acute UTI, recurrent 
infections, asymptomatic bacteriuria, and pyelonephritis. It would be interesting to repeat these 
studies with a more closely related non-pathogenic strain, other UPEC strains (both cystitis- and 
pyelonephritis-causing strains), or fecal isolates. 
 Together, though our results do not identify UPEC-specific genes that are important for 
responding to cathelicidin in the environment, our data do reveal a distinct UPEC gene 
expression response to cathelicidin. It is possible that downstream post-translational 
modifications further affect this transcriptional response [58]. Future experiments will explore 
whether cathelicidin AMPs can serve as a source of amino acids for rapidly growing bacteria in 
culture, especially under conditions in which other nutrients are limited or absent. This work can 
be expanded to determine if UPEC can also sense and utilize other cationic AMPs. We will also 
work to ascertain the role of each differentially-regulated gene in the growth phenotype. We can 
test our mutants in an in vivo model of UTI to determine if the identified genes have direct 
effects on pathogenesis. AMP-deficient strains of mice have been created, which would allow us 
to determine the extent to which cathelicidin influences the phenotypes. The individual mutants 
will be used in these experiments, but it may also be necessary to look at full operon mutants, 
and to test these strains under more limiting conditions. We can also examine a strain that is 
mutant for all of the transporters to determine if uptake of the AMP is necessary for the growth 
phenotype. Completion of this work will provide insight into the mechanisms utilized by UPEC 
to persist in the hostile environment of the urinary tract, and may inspire the creation of new 
antimicrobials that can be used to treat UTI. 
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Tables and Figures 
 
 
 
Figure 1: The murine cathelicidin CRAMP is effective against UTI89 and MG1655 in vitro. 
Overnight cultures of UTI89 (green) and MG1655 (blue) are susceptible to killing by CRAMP in 
a dose-dependent manner. Average percent survival at each concentration is shown (± SEM); 
**** p < 0.0001. Each concentration was tested in triplicate, and the experiment was repeated 
three times.  
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Figure 2: UPEC treated with 1 µg/mL CRAMP have increased growth relative to untreated 
samples. Hourly aliquots of samples grown in LB Luria were treated with CRAMP and plated to 
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determine survival. UTI89 (A) and MG1655 (B) were untreated (0) or treated with 1 or 5 µg/mL 
CRAMP. Average percent survival with SEM is shown. The experiment was repeated three 
times. (C) UTI89 and MG1655 grown to OD600 = 0.5 in LB Luria and treated with LL-37 (1 or 5 
µg/mL) or untreated (0). Average percent survival with SEM is shown. The experiment was 
repeated three times. 
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Figure 3: Samples prepared for RNAseq have expected survival profiles and reveal three 
categories of differentially regulated genes. (A) Survival after treatment was determined by 
plating an aliquot of the sample before RNA was isolated for RNA sequencing. The average of 
the three sets of treatments, along with the SEM, is shown. (B) Schematic representation of the 
major functional groups of the differentially regulated genes from 1 µg/mL-treated UTI89 
samples. Genes encoding inner and outer membrane transporters are shown in purple (42%), 
genes encoding proteins involved in metabolism are shown in teal (50%), and one gene of 
unknown function is shown in blue (8%). 
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Table 1: Differentially regulated genes in UTI89 treated with 1 µg/mL CRAMP 
Gene name Putative function
a
 P value FDR log FC 
aceA isocitrate lyase 3.67E-06 0.015033 0.30387 
dppB dipeptide transporter permease B 2.44E-06 0.002994 0.33431 
dppC dipeptide transporter permease C 7.71E-06 0.005681 0.35681 
fumC fumarate hydratase 7.31E-05 0.026907 0.35309 
gatY fructose-1,6-bisphosphate aldolase 1.11E-06 0.002994 0.97178 
glcD glycolate oxidase subunit 1.38E-04 0.045472 0.37146 
lamB maltoporin 7.58E-06 0.005681 0.40872 
malK maltose ABC transporter  
ATP-binding protein 
1.48E-04 0.045472 0.33396 
oppC oligopeptide transport system permease 2.18E-05 0.011487 0.36851 
ydcW γ-aminobutyraldehyde dehydrogenase 2.98E-05 0.013726 0.3368 
yfbG bifunctional UDP-glucuronic acid 
decarboxylase/UDP-4-amino-4-deoxy-L-
arabinose formyltransferase 
1.94E-05 0.011487 0.36143 
yfbH hypothetical protein 2.31E-06 0.002994 0.43178 
a
Putative function identified in the E. coli database Ecocyc[33] 
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Table 2: Primers used to create single gene mutants in UTI89 
Primer 
name 
Primer sequence (5’-3’)# 
dppB-F TATGTTGCAGTTTATTCTCCGACGTTTGGGACTCGTGTGTAGGCTGGAGCTGCTTC 
dppB-R TTACTTCTTATGACGAATACGCGGGTTCACCATATGAATATCCTCCTTAG 
dppC-F ATGTCACAGGTTACTGAAAATAAAGTGATTAGCGGTGTAGGCTGGAGCTGCTTC 
dppC-R TTACTGCTTCAGTTTGGGATCGAGCGCGTCACATATGAATATCCTCCTTAG 
fumC-F TGAGGAGCAGGCCATGAATACAGTACGCAGCGAAAAGTGTAGGCTGGAGCTGCTTC 
fumC-R TTTCATACTGCCGACCATCTGTTCTGGCCGTACATATGAATATCCTCCTTAG 
gatY-F ATGTACGTGGTATCGACAAAGCAGATGCTGGTGTAGGCTGGAGCTGCTTC 
gatY-R TTATGCCCTGCCCTCGCAGCCACAATCGGCAATCACTTTCATATGAATATCCTCCTTAG 
glcD-F ATGAGCATCTTGTACGAAGAGCGTCTTGATGTGTAGGCTGGAGCTGCTTC 
glcD-R TCAGAAACGCTCCAGTTCAGGAAAAGGTAACATATGAATATCCTCCTTAG 
malK-F GTGGAGGATTTAAGCCATCTCCTGATGACGCATAGTGTGTAGGCTGGAGCTGCTTC 
malK-R TTAAACGCCCGGCTCCTTATGCAGTCGACGACATGCCATATGAATATCCTCCTTAG 
oppC-F ATGATGTTAAGTAAGAAAAACAGCGAGACGGTGTAGGCTGGAGCTGCTTC 
oppC-R TTAACGATCTTTCGGGTCGAGGGCATCACGCAACATATGAATATCCTCCTTAG 
ydcW-F ATGCAACATAAGTTACTGATTAACGGAGAACGTGTAGGCTGGAGCTGCTTC 
ydcW-R TTAATGTTTAACCATGACGTGGCGGACGACAGTGTACATATGAATATCCTCCTTAG 
yfbG-F ACCGTCGTTTTTGCCTACCACGATATGGGATGCGTGTAGGCTGGAGCTGCTTC 
yfbG-R TGGTTTATCCGTAAGATCAACGGTGCGCAGGAAGAACATATGAATATCCTCCTTAG 
yfbH-F AAAGTCGGCTTACGCATTGATGTCGATACCTTTCGTGTGTAGGCTGGAGCTGCTTC 
yfbH-R AATTTGTTGGCAACCCAGCCAGCCTTCACGTCATATGAATATCCTCCTTAG 
#
Homology to chloramphenicol cassette is bolded 
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Table 3: Primers used to confirm allelic replacement (flanking primers) 
  
Forward primer (5’-3’) 
 
Reverse primer (5’-3’) 
Expected 
product if no 
insert (bp) 
dppB AATACAGACACGCAGTTCCA AAATAGTGCCAGAACTCCTGTA 1156 
dppC ATGATTATCCTCGTCAACTTGC CCGAAATGCACCGATAATTTAT 1038 
fumC TACATGGCACGAAAGACCAA ACAATGTGCAGCACCGTTAT 1597 
gatY GCCTTTCATTCCTGGATTGATT CTTTATGCCGGGCAATTAAC 1027 
glcD GCTTAATAACTGTTCACAGAAGC TTTATCGCTAATCGCCTGATTC 1637 
malK TACATGACCTCGGTTTAGTTCA CTATCTCCTGAGTCATTGCTT 1350 
oppC GATGTGCTATATGCGGTTATC AATCTTTCACGTTCAGCAGTG 1049 
ydcW GAAGGCGACAATGGTCAATAA CAGTACGCAAGATCATCTCAT 1493 
yfbG TTGTTCAGCAAGTTATCCGTC ATGCTTACTCAAGATTTCCAGC 2112 
yfbH GATATGCAGGAAACCATCGAC GCAGGCAATAAATGCGAAGAG 1009 
pCAT GCGGCATCAGCACCTTGTCG CGACAAGGTGCTGATGCCGC N/A 
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Figure 4: Single mutants have normal growth in rich media, and do not display altered 
CRAMP susceptibility. (A) Single-gene disruptions of the twelve identified genes were created 
in the UTI89 background. Growth in LB Miller was determined by measuring the OD600 of 
cultures every 30 min for 10 h. A representative plot is shown. The experiment was repeated 
three times. (B) Sub-cultured samples of MG1655, UTI89, or the single mutants were treated 
with 0 or 1 µg/mL CRAMP in triplicate and plated to determine survival. This experiment has 
been done once. Average survival and SEM are shown for each strain. 
118
References 
1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic 
costs. Am J Med 2002; 113 Suppl 1A:5s-13s. 
2. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7:653-60. 
3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk 
factors, and disease burden. Infect Dis Clin North Am 2014; 28:1-13. 
4. Little P, Merriman R, Turner S, et al. Presentation, pattern, and natural course of severe 
symptoms, and role of antibiotics and antibiotic resistance among patients presenting with 
suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010; 
340:b5633. 
5. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: 
final results from the North American Urinary Tract Infection Collaborative Alliance 
(NAUTICA). Int J Antimicrob Agents 2005; 26:380-8. 
6. Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic 
isolates of Escherichia coli: ExPEC. J Infect Dis 2000; 181:1753-4. 
7. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 
2:123-40. 
8. Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic 
Escherichia coli. Exp Mol Pathol 2008; 85:11-9. 
9. Marrs CF, Zhang L, Tallman P, et al. Variations in 10 putative uropathogen virulence genes 
among urinary, faecal and peri-urethral Escherichia coli. J Med Microbiol 2002; 51:138-42. 
119
10. Lo Y, Zhang L, Foxman B, Zollner S. Whole-genome sequencing of uropathogenic 
Escherichia coli reveals long evolutionary history of diversity and virulence. Infect Genet Evol 
2015. 
11. Mulvey MA. Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 2002; 
4:257-71. 
12. Justice SS, Hunstad DA. UPEC hemolysin: more than just for making holes. Cell Host 
Microbe 2012; 11:4-5. 
13. Luthje P, Brauner A. Virulence factors of uropathogenic E. coli and their interaction with the 
host. Adv Microb Physiol 2014; 65:337-72. 
14. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by 
type 1-piliated uropathogenic Escherichia coli. Science 1998; 282:1494-7. 
15. Zhou G, Mo WJ, Sebbel P, et al. Uroplakin Ia is the urothelial receptor for uropathogenic 
Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 2001; 114:4095-103. 
16. Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of 
uropathogenic Escherichia coli. Annu Rev Microbiol 2010; 64:203-21. 
17. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular 
bacterial communities in human urinary tract infection. PLoS Med 2007; 4:e329. 
18. Robino L, Scavone P, Araujo L, et al. Intracellular bacteria in the pathogenesis of 
Escherichia coli urinary tract infection in children. Clin Infect Dis 2014; 59:e158-64. 
19. Weichhart T, Haidinger M, Horl WH, Saemann MD. Current concepts of molecular defence 
mechanisms operative during urinary tract infection. Eur J Clin Invest 2008; 38 Suppl 2:29-38. 
20. Song J, Abraham SN. TLR-mediated immune responses in the urinary tract. Curr Opin 
Microbiol 2008; 11:66-73. 
120
21. Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function 
and interstitial cystitis. Ther Adv Urol 2011; 3:19-33. 
22. Spencer JD, Schwaderer AL, Becknell B, Watson J, Hains DS. The innate immune response 
during urinary tract infection and pyelonephritis. Pediatr Nephrol 2014; 29:1139-49. 
23. Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J 
Am Soc Nephol 2007; 18:2810-6. 
24. Becknell B, Spencer JD, Carpenter AR, et al. Expression and antimicrobial function of beta-
defensin 1 in the lower urinary tract. PLoS One 2013; 8:e77714. 
25. Spencer JD, Schwaderer AL, Wang H, et al. Ribonuclease 7, an antimicrobial peptide 
upregulated during infection, contributes to microbial defense of the human urinary tract. Kidney 
Int 2013; 83:615-25. 
26. Zasloff M. The antibacterial shield of the human urinary tract. Kidney Int 2013; 83:548-50. 
27. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr 
Issues Mol Biol 2006; 8:11-26. 
28. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the 
cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758:1408-25. 
29. Gallo RL, Kim KJ, Bernfield M, et al. Identification of CRAMP, a cathelin-related 
antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997; 
272:13088-93. 
30. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli 
reservoir during the acute phase of a bladder infection. Infect Immun 2001; 69:4572-9. 
31. Blattner FR, Plunkett G, 3rd, Bloch CA, et al. The complete genome sequence of Escherichia 
coli K-12. Science 1997; 277:1453-62. 
121
32. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli 
K-12 using PCR products. Proc Natl Acad Sci U S A 2000; 97:6640-5. 
33. Keseler IM, Mackie A, Peralta-Gil M, et al. EcoCyc: fusing model organism databases with 
systems biology. Nucleic Acids Res 2013; 41:D605-12. 
34. Chen SL, Hung CS, Xu J, et al. Identification of genes subject to positive selection in 
uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci 
U S A 2006; 103:5977-82. 
35. Abouhamad WN, Manson MD. The dipeptide permease of Escherichia coli closely 
resembles other bacterial transport systems and shows growth-phase-dependent expression. Mol 
Microbiol 1994; 14:1077-92. 
36. Snyder JA, Haugen BJ, Buckles EL, et al. Transcriptome of uropathogenic Escherichia coli 
during urinary tract infection. Infect Immun 2004; 72:6373-81. 
37. Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HL. Escherichia coli global gene 
expression in urine from women with urinary tract infection. PLoS Pathog 2010; 6:e1001187. 
38. Andrews JC, Blevins TC, Short SA. Regulation of peptide transport in Escherichia coli: 
induction of the trp-linked operon encoding the oligopeptide permease. J Bacteriol 1986; 
165:428-33. 
39. Andrews JC, Short SA. opp-lac Operon fusions and transcriptional regulation of the 
Escherichia coli trp-linked oligopeptide permease. J Bacteriol 1986; 165:434-42. 
40. Alteri CJ, Smith SN, Mobley HL. Fitness of Escherichia coli during urinary tract infection 
requires gluconeogenesis and the TCA cycle. PLoS Pathog 2009; 5:e1000448. 
122
41. Gilson E, Rousset JP, Charbit A, Perrin D, Hofnung M. malM, a new gene of the maltose 
regulon in Escherichia coli K12. I. malM is the last gene of the malK-lamB operon and encodes 
a periplasmic protein. J Mol Biol 1986; 191:303-11. 
42. Breazeale SD, Ribeiro AA, Raetz CR. Oxidative decarboxylation of UDP-glucuronic acid in 
extracts of polymyxin-resistant Escherichia coli. Origin of lipid a species modified with 4-
amino-4-deoxy-L-arabinose. J Biol Chem 2002; 277:2886-96. 
43. Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in gram-
negative bacteria. Annual Rev Biochem 2007; 76:295-329. 
44. Woods SA, Schwartzbach SD, Guest JR. Two biochemically distinct classes of fumarase in 
Escherichia coli. Biochim Biophys Acta 1988; 954:14-26. 
45. Puthan Veetil V, Fibriansah G, Raj H, Thunnissen AM, Poelarends GJ. Aspartase/fumarase 
superfamily: a common catalytic strategy involving general base-catalyzed formation of a highly 
stabilized aci-carboxylate intermediate. Biochemistry 2012; 51:4237-43. 
46. Nobelmann B, Lengeler JW. Sequence of the gat operon for galactitol utilization from a 
wild-type strain EC3132 of Escherichia coli. Biochim Biophys Acta 1995; 1262:69-72. 
47. Nobelmann B, Lengeler JW. Molecular analysis of the gat genes from Escherichia coli and of 
their roles in galactitol transport and metabolism. J Bacteriol 1996; 178:6790-5. 
48. Lloyd AL, Rasko DA, Mobley HL. Defining genomic islands and uropathogen-specific 
genes in uropathogenic Escherichia coli. J Bacteriol 2007; 189:3532-46. 
49. Prieto-Santos MI, Martin-Checa J, Balana-Fouce R, Garrido-Pertierra A. A pathway for 
putrescine catabolism in Escherichia coli. Biochim Biophys Acta 1986; 880:242-4. 
123
50. Nunez MF, Pellicer MT, Badia J, Aguilar J, Baldoma L. The gene yghK linked to the glc 
operon of Escherichia coli encodes a permease for glycolate that is structurally and functionally 
similar to L-lactate permease. Microbiology 2001; 147:1069-77. 
51. Nunez MF, Pellicer MT, Badia J, Aguilar J, Baldoma L. Biochemical characterization of the 
2-ketoacid reductases encoded by ycdW and yiaE genes in Escherichia coli. Biochem J 2001; 
354:707-15. 
52. Maloy SR, Nunn WD. Genetic regulation of the glyoxylate shunt in Escherichia coli K-12. J 
Bacteriol 1982; 149:173-80. 
53. LaPorte DC, Thorsness PE, Koshland DE, Jr. Compensatory phosphorylation of isocitrate 
dehydrogenase. A mechanism for adaptation to the intracellular environment. J Biol Chem 1985; 
260:10563-8. 
54. Matsuoka M, McFadden BA. Isolation, hyperexpression, and sequencing of the aceA gene 
encoding isocitrate lyase in Escherichia coli. J Bacteriol 1988; 170:4528-36. 
55. Rieul C, Bleicher F, Duclos B, Cortay JC, Cozzone AJ. Nucleotide sequence of the aceA 
gene coding for isocitrate lyase in Escherichia coli. Nucleic Acids Res 1988; 16:5689. 
56. Theze J, Saint-Girons I. Threonine locus of Escherichia coli K-12: genetic structure and 
evidence for an operon. J Bacteriol 1974; 118:990-8. 
57. Lynn SP, Gardner JF, Reznikoff WS. Attenuation regulation in the thr operon of Escherichia 
coli K-12: molecular cloning and transcription of the controlling region. J Bacteriol 1982; 
152:363-71. 
58. Cain JA, Solis N, Cordwell SJ. Beyond gene expression: the impact of protein post-
translational modifications in bacteria. J Proteomics 2014; 97:265-86. 
 
124
CHAPTER FIVE 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
  
The overarching goal of this work was to expand our knowledge of host-pathogen 
interactions within the context of urinary tract infections. We chose to focus on components of 
the uropathogenic Escherichia coli (UPEC) outer membrane and on a host peptide (cathelicidin) 
produced by the innate immune system. The UPEC OmpA protein is highly represented in the 
outer membrane and evolutionarily conserved, but is not essential for the bacterium. We find that 
the extracellular loops of OmpA play specific roles in fostering infection in the urinary tract. 
Other outer membrane proteins, as well as outer membrane vesicles, may also influence the 
progression of UPEC infection. Work with human and murine cathelicidin has demonstrated that 
this peptide regulates the uroepithelium and promotes the innate immune response, more 
prominently than in its function as an antimicrobial. Furthermore, UPEC are specifically able to 
respond to the presence of cathelicidins, adaptation which may encourage the establishment of 
infection. This work has uncovered many interesting findings, and has unveiled exciting new 
directions for the UPEC field.  
 
Extracellular loops of UPEC OmpA enhance binding to the uroepithelium 
 The OmpA protein is highly expressed in the outer membrane of E. coli, but its 
expression is also tightly regulated [1]. The protein is composed of an N-terminal β-barrel, with 
eight transmembrane domains that form four extracellular loops and three short periplasmic 
turns, as well as a large C-terminal periplasmic domain with peptidoglycan-binding properties [1, 
2]. The conservation of OmpA throughout E. coli species suggests that the protein may play 
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roles in many settings. This idea is supported by data showing that OmpA is active in 
conjugation, biofilm formation, as an adhesin, and as an immune evasin, but also has roles in 
bacteriocin binding and immune recognition [1, 3]. Of note, OmpA is also required for 
propagation of chronic infection in the urinary tract of C3H/HeN mice [4]. We sought to 
investigate the role of OmpA in a model of acute bladder infection in C57Bl/6 mice, and to 
characterize the functions of the extracellular loops during infection. 
 When matched groups of C57Bl/6 mice were infected with UTI89 and UTI89ΔompA, the 
OmpA mutant strain yielded significantly lower bladder titers 24 hpi. To determine if the 
extracellular loops of OmpA are affecting this phenotype, we created individual loop mutants 
and complemented the full-length ompA knock-out (KO) with these plasmids. The loop mutant 
proteins all localize to the outer membrane and do not affect growth, permeability, or type 1 pili 
expression. However, we find that a LP 2 KO is attenuated in our murine model of infection, and 
results in a level of infection similar to that of the full-length mutant. The LP 2 KO cannot forms 
IBCs, and binding and invasion assays with human bladder epithelial cells (HBECs) indicate that 
the LP 2 KO binds and invades significantly worse than UTI89 or the ompA mutant. Most 
interestingly, the LP 2 KO phenotype is dominant over native OmpA, as a UTI89 strain 
simultaneously expressing the LP 2 KO phenocopies the LP 2 KO. The defect was not 
attributable to the presence of the complementing plasmid, as UTI89/pACYC184 did not have 
altered binding or invasion (Figure 1A, B). Further, episomal expression of the LP 1 mutant in 
UTI89 does not alter the binding and invasion (Figure 1A, B). We do not yet have conclusive 
evidence explaining why the LP 2 KO phenotype is even more notable than that of the full-
length mutant. Global approaches, such as proteomics of the outer membrane, could help to 
determine if other proteins are affected in the mutant strains.  
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 Work in other infection models has identified a specific binding partner of OmpA on the 
surface of host cells and has established that the loops of OmpA can individually affect the 
function of the protein. OmpA was shown to bind specifically to a glycoprotein known as Ecgp 
expressed by human brain microvascular endothelial cells (HBMECs) [5]. After the initial 
binding of type 1 pili bind to the surface of the cells, OmpA binds to Ecgp and promotes 
bacterial cell invasion [6, 7]. Similarly, outer membrane vesicles from adherent-invasive E. coli 
that contain OmpA have been shown to interact with Ecgp on the surface of ileal epithelial cells 
and promote invasion of the bacteria [8]. We will determine if Ecgp is expressed in HBECs and 
in mouse bladder tissue. Immunohistochemistry in human bladder cancer tissue suggests that this 
protein is indeed expressed in bladder uroepithelium [9]. Prasadarao et al showed that after 
initial binding to NMEC to HBMECs, nitric oxide production triggers increased expression of in 
HBMECs, further facilitating uptake of the bacteria [10]. Knowing this, we will also use 
confocal microscopy and cellular fractionation to determine if the localization of Ecgp 
expression in HBECs is altered upon interaction with UPEC. We will use the individual loop 
mutants to explore the effects of loop mutation on Ecgp interaction. However, Ecgp may not 
interact with OmpA in this system; therefore, we will use parallel approaches with purified 
OmpA protein to identify other host cell molecules that can directly interact with OmpA.  
 Preliminary work with individual loop 3 and 4 OmpA knock-outs suggests that these 
loops also contribute to in vivo phenotypes. Both of these strains yielded significantly lower 
bladder titers 24 hpi in the murine model of cystitis. The LP 3 KO is recovered at levels similar 
to the LP 2 KO, while the majority of mice have cleared the LP 4 KO from the bladder at 24 hpi 
(titers < 10
4
) (Figure 2A). However, mature IBCs can be detected by confocal microscopy 16 
hpi in the bladders of mice infected with either of these strains (Figure 2B). This was 
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particularly surprising, as enumeration of IBCs by lacZ stain indicates that very few IBCs are 
found in the bladders of mice infected with the LP 4 KO (Figure 2C). The difference in numbers 
of IBCs found in LP 4 KO-infected bladders is not statistically significant, but a low number of 
mice have been examined thus far. Mice infected with the LP 3 KO demonstrate IBC formation 
approximately the same as both ΔompA-infected mice or LP 1 KO-infected mice (Figure 2C and 
data not shown). In a binding and invasion assay with UTI89 complemented with the LP 3 KO 
and LP 4 KO plasmids, both UTI89/LP 3 KO and UTI89/LP 4 KO bound less avidly than 
UTI89, but only UTI89/LP 4 KO bound less well than the plasmid control (Figure 3A). 
UTI89/LP 3 KO invaded as well as the parent strains, while UTI89/LP 4 KO actually invaded 
better than the parent strains (Figure 3B). When considered together, the binding defect in the 
LP 3 KO likely accounts for the lower titers observed in the bladders of mice 24 hpi.  
As there is not a strict relationship among ability to form IBCs, rate of IBC formation, 
and bladder titers 24 hpi, further experiments should explore the differences in these loop 
mutants. OmpA has previously been shown to play a role in resisting the killing effects of 
complement [11]. Differences in the ability of loop mutant cells to resist the innate immune 
system while exposed in the lumen of the bladder (e.g., during the fluxing and reinfection stages 
of the IBC cycle) could account for the inability of LP 4 KO bacteria to cause a robust infection. 
Experiments that quantify the susceptibility of these strains to killing after exposure to serum can 
help clarify if complement resistance is indeed critical for propagation of infection during 
cystitis. Additionally, a number of experiments, such as the growth, fractionation, and pili 
expression assays done with the other loop mutants, must first be completed in order to ensure 
that the mutations do not result in a confounding phenotype. Interestingly, the LP 4 KO has 
slightly decreased outer membrane permeability, relative to the wild-type and OmpA mutant 
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strains (Figure 4). The diminished binding likely contributes to the lower bladder titers and lack 
of IBC formation with LP 4 KO bacteria, but decreased membrane permeability could affect 
nutrient acquisition and growth.  
Finally, it would also be interesting to compare the sequences of OmpA proteins that 
have been isolated from various niches within the urinary tract, including the urines of patients 
with cystitis or pyelonephritis, the blood of sepsis patients, and commensal fecal strains. These 
data could give us further clues about the roles that OmpA extracellular loops play in promoting 
infection within one or more of these niches, which would be used to inform our future studies. 
To our knowledge, this idea has not been examined in E. coli, let alone in UPEC, although 
studies in Pasteurella indicate that the loops can vary in a host-specific manner [12]. We have 
also begun to compile a library of mutants that contain two or more loop knock-outs. 
Downstream studies with these strains may help elucidate whether interactions involving 
multiple specific loops are required for normal function of OmpA in this system. We plan to 
continue our work revealing the roles that the individual loops of OmpA play during UPEC UTI.  
 
Involvement of other outer membrane proteins during infection 
 OmpA is one example of an outer membrane protein that can allow UPEC to interact 
with the host milieu during infection. The outer membrane protease OmpT is potentially another 
mechanism through which UPEC can modulate the extracellular environment and promote 
infection by resisting the killing effects of AMPs. OmpT is composed of ten antiparallel β-sheets 
that form five long, extracellular loops and four short periplasmic turns [13]. The protein 
recognizes specific sequences of charged residues and cleaves between them [14]. The amino 
acid sequence must include two consecutive basic residues: two lysines, two arginines, or a 
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lysine with an arginine, with flexibility outside of the cleavage site. Enterohemorrhagic E. coli 
(EHEC) and enteropathogenic E. coli (EPEC) can cleave the α-helical antimicrobial peptides 
C18G and LL-37 in an OmpT-dependent manner [15]. ompT mutants in these strains have 
decreased peptide resistance in vitro, likely due to the inactivity of the protease [15]. In addition 
to the proteolytic cleavage of AMPs, OmpT has been reported to modulate outer membrane 
vesicle (OMV) biogenesis in the EHEC strain EDL933 through an unknown mechanism [16]. 
OMVs isolated from ompT mutant EHEC have different lipid and protein profiles when 
compared to wild-type OMVs, which may indicate that OmpT plays a role in the regulation of 
bacterial molecules that are packaged in OMVs [16]. The proteins included or excluded from 
those OMVs could also be affecting the AMP resistance phenotype.  
E. coli OmpT was first suggested as a putative virulence factor in 1992 when Lundrigan 
and Webb identified OmpT in over 50% of E. coli clinical isolates, including 73-76% of 
genitourinary and urine isolates [17]. Later, ompT was found in 83-94% of UTI isolates, 
including first, second, and recurrent UTIs, as wells pyelonephritis strains [18]. A similar study 
in Japan examined the expression of multiple factors in cystitis and pyelonephritis-derived E. 
coli isolates and found that ompT was encoded in over 90% of cystitis and pyelonephritis 
isolates, nearly double the prevalence of the gene in stool isolates [19]. OmpT is expressed in the 
outer membrane of our prototypical cystitis isolate UTI89. This gene is not essential as a knock-
out strain did not display a growth defect (data not shown). Proteolytic cleavage of cationic 
peptides isolated from the urine, mostly thought to be α- and β-defensins, can be mediated by 
OmpT in E. coli K1 strains, but had not been investigated in UPEC [20, 21]. Therefore, we 
sought to determine the effects of UPEC OmpT on cathelicidin resistance in vitro and on the 
progression of infection in vivo. 
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 To determine if the OmpT encoded by UTI89 has proteolytic activity against cationic 
AMPs, live bacterial cells were incubated with biotin-labelled CRAMP or LL-37 for up to an 
hour in PBS. At designated time points, the samples were centrifuged to pellet the bacterial cells, 
and the supernatant was run on 15% SDS-PAGE gels. The AMPs were detected by immunoblot. 
The positive control EHEC strain EDL933 cleaves the 4 kDa AMP, resulting in a band ~2 kDA 
in size. The intensity of this band increases over time (Figure 5). Similarly, UTI89 can also 
cleave cationic AMPs, but this is dependent on expression of OmpT as UTI89 ompT::cat does 
not cleave these peptides (Figure 5). We find that UTI89 OmpT is equally active against LL-37 
and CRAMP in vitro (Figure 5 and data not shown). We were therefore surprised to find that the 
OmpT mutant was not more susceptible to killing by CRAMP when exposed to varying 
concentrations of this peptide in vitro. Specifically, UTI89 ompT::cat was equivalently 
susceptible to killing by CRAMP as UTI89 at concentrations ranging from 1 to 20 µg/mL 
(Figure 6). A recently published paper also found that OmpT in the pyelonephritis-derived strain 
CFT073 can cleave LL-37 in vitro [22]. The mutation of ompT in CFT073 also did not affect LL-
37 resistance in vitro [22].  
 Based on our in vitro results, we were curious if OmpT activity affects virulence in our 
murine model of UTI. We infected C3H/HeN mice with either UTI89 or UTI89 ompT::cat. We 
quantified bladder and kidney titers 1, 6, and 24 hpi, as well as 2 wpi, but did not find any 
significant differences in the bacterial load in these organs (Figure 7). Preliminary results in 
C57Bl/6 also do not indicate a difference in bladder bacterial load 24 hpi (data not shown). 
These data indicate that although OmpT can function to cleave AMPs such as CRAMP and LL-
37 in vitro, this mechanism is not critical for bacterial survival within the murine urinary tract. 
As suggested by the data presented in Chapter 3, the cathelicidin in the urinary tract may not be 
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sufficiently high to cause bacterial killing; it is possible that OmpT would be more important for 
propagating infection if the concentration of AMPs in the urinary tract were higher.  
Additionally, it is likely that the context in which OmpT is expressed is also important. 
He et al recently demonstrated that CFT073 ompT::kan causes limited infection in C567Bl/6 
mice at 12 hpi [23]. This strain is also more susceptible to protamine and cannot bind or invade 
5637 cells as well as the parent strain or a complemented mutant even though type 1 pili 
expression is not altered [23]. It is important to note that a 10-fold higher inoculum dose was 
used for these infections. While these data are interesting, we believe that our data provide a 
more accurate representation of the reality of AMP resistance within the urinary tract. We have 
shown that outer membrane proteins (e.g., OmpT) can have demonstrated roles in vitro, but these 
roles do not necessarily translate to valid functions during infection. It is likely that many other 
UPEC outer membrane proteins will have minimal effects in vivo, even if an in vitro function 
can be demonstrated. These data provide a valuable lesson in studying both in vitro functions of 
proteins as well as the effects within the context of a whole animal infection.  
 
Outer membrane vesicles and infection 
 As the outer membrane is a dynamic interface that is important for the promotion of 
infection, we hypothesized that outer membrane vesicles could also be involved in UPEC 
infection of the urinary tract. Outer membrane vesicles (OMVs) are small (10-200 nm) vesicles 
that are formed when portions of the outer membrane pinch off and are liberated from Gram-
negative bacteria [24, 25]. The precise molecular mechanism behind this process is not well 
understood, but weakened connections between the outer membrane and peptidoglycan likely 
contribute to OMV release [25]. In the context of infection, OMVs can aid the bacteria by 
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delivering toxins to host cells, increasing the reach of antimicrobial resistance mechanisms (like 
proteases), and by functioning as decoys [26]. However, these structures also display PAMPs 
such as OmpA, LPS, and pili, which can alert the host to the presence of the bacterium. We 
believe that isolated OMVs might therefore function as an excellent natural vaccine, if an 
immunizing response is in fact generated in the bladder. To explore that idea further, we first 
needed to understand the role of OMVs during UTI. 
 We began by creating UTI89 mutants that had disruptions in genes that have been shown 
to increase or decrease OMV production. Genes were selected based on previous transposon-
mediated studies in DH5α E. coli [27, 28]. Mutations in degP, degS, ompR, and yieM should 
result in hyper-vesiculating strains, while mutations in pepP and glnA should result in hypo-
vesiculating strains [27]. To confirm the vesiculation phenotypes, we isolated OMVs from 
overnight cultures by removing whole cells through centrifugation and filtration, and then 
concentrating OMVs from the supernatant through ultra-centrifugation (Figure 8A). As some 
loose contaminants (e.g., pilus fragments) could be identified by electron microscopy, we further 
purified some samples using a density gradient (Figure 8B, C). Silver-stained SDS-PAGE gels 
allowed us to compare the protein profiles of the isolated OMVs, and we were able to 
approximate changes in OMV production in vesiculation mutants by performing densitometric 
analyses of major proteins (Figure 8D). We created two hypervesiculating mutants and a 
hypovesiculating mutant in UTI89 by mutating previously identified genes [27]. When we 
isolated the OMVs from cultures of the same size, we found that the mutant strains did have 
altered OMV production (Figure 8D). 
 A recent summer student characterized the effects of degS mutation on in vitro and in 
vivo infection [29]. The DegS protein is an inner membrane protein that functions to degrade  
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incorrectly folded proteins in the periplasm [30-32]. UTI89 degS::cat has a minor growth defect, 
but pili production and outer membrane integrity are not compromised [29]. This mutant does 
produce significantly more OMVs, and there are pronounced differences in the protein content of 
OMVs from wild-type and degS mutant bacteria (Figure 3 from Bradley and Danka reproduced 
as Figure 9) [29]. The increased OMV production is likely due to an accumulation of misfolded 
proteins within the periplasm. In this instance, production of OMVs would be functioning to rid 
the cells of unwanted proteins. These proteins are packaged into the OMVs, and are not observed 
as corresponding to bands in wild-type OMVs when compared by silver-stained gel. 
Complementation of the mutant in trans fully restores wild-type phenotypes [29]. When used in 
a mouse model of UTI, the degS mutant reaches significantly lower bacterial titers in the bladder 
24 hpi even though early and mature IBCs can be identified through confocal microscopy 
(Figures 6 and 7 from Bradley and Danka adapted as Figure 10A, B) [29]. Most interesting, 
when compared in an in vitro binding and invasion assay with 5637 human bladder endothelial 
cells, invasion by the mutant is significantly lower than by the wild-type strain (Figure 8 from 
Bradley and Danka modified as Figure 11) [29]. The mechanism behind this reduced invasion 
phenotype is currently unknown. Future experiments will explore the pathways that may be 
affected by degS mutation or OMV overproduction. However, it is important to note that deletion 
of this protein altered the number of OMVs produced as well as the composition of those OMVs.  
 With DegS as an example, we conclude that hypo- or hyper-vesiculating mutations are 
altering more than just the quantity of OMVs produced such that it is difficult to separate the 
contribution of OMV quantity from other effects of the mutated gene. Thus, future experiments 
will employ add-backs of purified OMVs, either alone or in combination with UPEC, to 
specifically address the role of OMVs during the development of UTI. 
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 We performed preliminary experiments to examine how long OMVs (and the proteins 
contained within them) would remain in the bladders of mice. OMVs were delivered to the 
bladders of mice transurethrally at time 0 and again after 3 h. The mice were sacrificed at 3, 6 or 
24 h after inoculation. Urine was collected prior to inoculation, prior to sacrifice, and at time 
points between delivery and sacrifice. Immunoblots specific to the FimH adhesin of type 1 pili, 
OmpA, and the cytoplasmic chaperone protein GroEL (which is often present in our OMV 
preparations) were used to probe for bacterial protein presence in the bladder. We were surprised 
to find that GroEL can be detected in the tissue homogenates up to 24 h after inoculation (data 
not shown). We did not detect OmpA or FimH within the tissues. As GroEL primarily functions 
as a chaperone, its ability to bind a wide range of proteins may facilitate its persistence in the 
bladder. Immunoblotting of the collected urines did not detect any of these proteins, which was 
not surprising as the OMVs would be highly diluted within the urine. While these experiments 
certainly need to be repeated, the data suggest that some OMV-associated proteins may remain 
in the bladder for a period of time after delivery. Future experiments will specifically determine 
how long OMVs can remain in the bladder, whether the presence of OMVs triggers an innate 
immune response (perhaps preparing the host for subsequent infection), and if an adaptive 
immune response can be elicited by OMVs. 
 
CRAMP modulates epithelial receptivity and immune function during UTI 
 The human and murine cathelicidins LL-37 and CRAMP (respectively) have long been 
thought to be important for proper defense of the urinary tract [33-35]. Multiple groups have 
shown that these peptides can be found in the urines of child and adult patients with UTI, and 
that the expression of these peptides increases after bacterial exposure [36, 37]. However, 
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previous studies with UPEC strains left many unanswered questions. Using CRAMP-deficient 
mice in the C57Bl/6 background, we began to characterize the role of CRAMP in the 
development of, and subsequent response to, cystitis. We first confirmed the antimicrobial 
effects of CRAMP against UTI89 using multiple concentrations of CRAMP in an in vitro assay 
before characterizing the course of infection in wild-type and CRAMP-deficient mice [38].  
When CRAMP-deficient mice are infected with UTI89, the bladder bacterial titers are 
significantly lower than those of infected wild-type C57Bl/6 mice at all examined acute time 
points (1 hpi-48 hpi) [38]. Although IBCs are formed in CRAMP-deficient mice, significantly 
fewer occur in the bladders of these mice. In vivo binding and invasion assays determined that 
CRAMP-deficient mice have significantly fewer bacteria bound in the lumen of the bladder, and 
the urines of these mice contain more bacteria [38]. However, the binding defect does not appear 
to be due to changes in the piliation state of the bacteria [38]. Uninfected CRAMP-deficient mice 
do not seem to have changes in uroplakin quantity or localization, or in the immune state of the 
bladder, as determined by a bead-based 23-plex cytokine array and by quantification of 
myeloperoxidase (MPO; used to approximate neutrophil presence) in uninfected bladder 
homogenates [38]. Additionally, there does not seem to be increased cAMP in the bladders of 
CRAMP-deficient mice immediately after infection, which would lead to internalized bacteria 
being expelled at a higher rate [38]. We conclude from this data that CRAMP is essential for 
normal maintenance of the bladder uroepithelium, and that changes in the uroepithelium result in 
decreased bacterial binding to the bladders of CRAMP-deficient mice.   
As CRAMP is also though to stimulate the innate immune response, we quantified 
cytokine levels and neutrophil influx in the bladders of wild-type and CRAMP-deficient mice 6 
and 24 hpi. We found significantly higher expression of 16 of the 23 measured cytokines, and 
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higher levels of MPO, in the bladders of wild-type mice 6 hpi [38]. Visual inspection of H&E-
stained bladder sections supported a more robust immune response in wild-type mice 6 hpi. By 
24 hpi, the bladders of CRAMP-deficient mice exhibited very little remaining edema, and had 
mostly restored their uroepithelial cells [38]. These data suggest that CRAMP is important for 
amplifying the immune response early during infection. Furthermore, the bladder histology 
demonstrates the detrimental and long-lasting effects of bladder tissue damage caused by a 
robust immune response, and the amount of time needed to recover from such a serious insult. 
We quantified uroplakin expression within the bladder at multiple time points in order to 
examine recovery of the uroepithelium. We found that CRAMP-deficient mice fully restored 
their epithelium by 48 hpi, while wild-type mice still displayed persistent exfoliation at this time 
point [38]. Taken together, our data support a role for CRAMP in maintaining the normal 
uroepithelial surface and in the promotion of an immune response, but do not support a 
prominent antimicrobial function for CRAMP in the urinary tract. 
 We began to address whether CRAMP is playing an important role as a driver of the 
immune response in this system by comparing the cytokine content of bladders with more similar 
bacterial loads. Although low numbers of mice were used in these comparisons – due to the 
disparity in bladder titers – we generally found that wild-type mice had higher cytokine loads 
than CRAMP-deficient mice 6 hpi (data not shown). We believe that such a comparison could be 
informative, but many more infections would be needed to obtain significant numbers of mice 
with similar bladder titers. Of note, recent literature suggests that the “other” functions of many 
AMPs may be more important than their antimicrobial activities. For example, the peptide 
hepcidin was originally described as an antimicrobial peptide but has since been shown to 
regulate iron by limiting export of iron through ferroportin [39, 40].  
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 It is still unknown why binding is disrupted in the CRAMP-deficient host. We were 
unable to overcome the block in the establishment of infection by using a higher inoculum (data 
not shown). However, with two other UPEC strains, CFT073 or NU14, or with UTI89 fimH::kan 
cells, levels of infection were more similar between wild-type and CRAMP-deficient mice (data 
not shown). These data suggested that the specific interaction between type 1 pili and the bladder 
uroepithelium may be disrupted, but that other mechanisms of infection are intact. In an attempt 
to determine if the uroplakin proteins are expressed on the luminal membrane of mutant host 
cells, wild-type and mutant bladders were examined by scanning electron microscopy (SEM). 
The bladders of C57Bl/6 mice have uroepithelial cells with defined cell borders and a wrinkled 
surface (Figure 12A, B). We were surprised to find that the bladders of CRAMP-deficient mice 
appeared to bear a coating of an unidentified substance (Figure 12C). This apparent coating 
obscured the borders between cells as well as the wrinkled appearance of the surface of the cells 
(Figure 12C). Where epithelial cells have been naturally or mechanically exfoliated, smaller 
cells with less-defined shapes can be seen underneath the epithelial layers (Figure 12D). 
However, this coating did not seem very thick and appeared to have been disrupted during 
processing of the tissue in several places. The epithelial cells underneath the coating have a 
wrinkled appearance, similar to that observed in wild-type bladders (Figure 12E, F). These data 
suggest a physical disruption in binding could account for the lower levels of infection seen in 
CRAMP-deficient mice.  
Currently, the make-up of the coating seen on the surface of the bladders of CRAMP-
deficient mice is unknown. It is possible that the charged nature of cathelicidin prevents another 
charged substance from interacting with and coating the surface of uroepithelial cells. Some 
groups have shown that cathelicidin can be internalized and affect gene expression; in this 
138
system, cathelicidin might be downregulating the expression of a molecule that would otherwise 
coat the surface of the bladder. Regardless of the mechanism, we suspect that CRAMP 
expression is important for maintaining normal uroepithelial expression in the bladder. Future 
experiments will confirm this intriguing finding, then focus on identifying the composition of the 
coating on the uroepithelial cells, and describing the mechanism through which cathelicidin 
regulates the presence of this coating. 
 
RNA sequencing reveals specific upregulation of genes after UPEC exposure to CRAMP 
 Cathelicidins are constitutively expressed at low levels by the epithelial cells that line 
many organs in the body [33]. It is therefore likely that bacteria are routinely exposed to sub-
lethal concentrations of these AMPs before, during, and after causing a robust infection. Data 
from other fields suggest that many AMPs can be playing alternative roles within the body at 
concentrations below those required to kill bacteria [41-43]. While this idea opens new fields of 
research into the regulation of host systems, it is unknown how these low concentrations of 
AMPs affect potentially pathogenic bacteria. We sought to determine if UPEC can recognize the 
presence of sub-lethal cathelicidin in their environment, and if they generate a response to the 
peptide upon detection. While we expected that the bacteria to upregulate pathways that would 
function as defense against the AMPs, we instead found that the bacteria increase expression of 
peptide transporters and genes involved in metabolism.  
 We initially found that UTI89, but not MG1655, can grow in response to 1 µg/mL 
cathelicidin when treated in early- to mid-log phase. The bacteria used in these experiments were 
grown in media with lower salt concentrations (0.5 g/L NaCl vs 10 g/L NaCl) to mimic the 
limiting environment of the urinary tract. Untreated and treated samples of UTI89 and MG1655 
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were prepared for RNA sequencing to analyze the global effects of CRAMP treatment. 
Alignment of the resulting reads to the respective genomes demonstrated that there was excellent 
coverage, and that the samples could be grouped by treatment (data not shown). Our results 
indicated that UTI89 cells treated with 1 µg/mL CRAMP differentially regulated twelve genes. 
Of these genes, five represented membrane-associated peptide or small molecule transporters, six 
were involved in a metabolic pathway, and one is a hypothetical protein of unknown function. 
We hypothesize that this indicates that UTI89 are indeed able to detect the presence of CRAMP 
in their environment and then upregulate pathways to take up this peptide, and potentially break 
it down for use as individual amino acids. UTI89 cells that had been treated with 3 µg/mL 
CRAMP experienced increased cell death relative to the 1 µg/mL treatment, and this was 
reflected in the differential regulation of nearly 1000 genes. It is likely that this massive response 
represents a chaotic final attempt to prevent cell death. MG1655 cells did not generate a specific 
response to CRAMP exposure. 
We were able to create individual mutants in UTI89 for each of the identified genes using 
linear recombination. Neighboring genes and nearby proteins within operons were not disrupted. 
When the mutants were tested using our CRAMP-exposure experiment, we did not observe any 
changes in CRAMP resistance and growth of these mutants. Although this will need to be 
repeated, this result may indicate that there are redundant pathways that prevent a single mutant 
from displaying a strong phenotype in this assay. Future experiments will treat cultures of UTI89 
with labeled CRAMP, and analyze these cultures by mass spectrometry at various points post-
treatment to specifically address whether CRAMP is taken up and/or degraded by UPEC. We 
will also test our single mutants in our murine model of cystitis to determine if the genes play a 
role in resistance to CRAMP upon introduction to the urinary tract, and if this affects the 
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establishment of an infection. We may also need to develop other methods in order to thoroughly 
assess the role of each gene in responding to CRAMP treatment. 
Finally, these results might be connected to our earlier findings that less robust infections 
occur in CRAMP-deficient mice. In these mice, the bacteria would not be exposed to sub-lethal 
concentrations of CRAMP, which may function as a signal or as an alternative food source, and 
may not increase their growth rate as rapidly as bacteria that are exposed to CRAMP. This 
proportionally limited growth rate could in turn exacerbate the binding defect in these mice, 
leading to much lower rates of infection. Future experiments will treat bacteria with low doses of 
CRAMP before using these bacteria to infect mice, and will address the direct effects of CRAMP 
on bacteria during infection. 
 
Concluding remarks 
 The work presented here demonstrates that there are unique interactions occurring 
between previously described UPEC factors and host immune factors during urinary tract 
infection. Our findings did not necessarily mirror prior work from other fields and infection 
models, and we therefore expand the breadth of knowledge of UPEC pathogenesis and the innate 
immune system. New techniques were designed to study these interactions, and future 
experiments can further augment the conclusions drawn from these data. We hope that these 
studies will complement other studies that are investigating new UPEC virulence factors, the 
innate and adaptive immune response to infection, changes in the uroepithelium during infection, 
and more. Although much of this work addresses the mechanisms behind the basic biology that 
occurs during UPEC infection, we believe that this work can help direct the development of new 
clinical therapeutics. For example, as OmpA is highly conserved, we envision the design of 
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small-molecule therapeutics that block the specific UPEC OmpA loop-host receptor interaction 
and could be used to treat UTIs. This is but one potential opportunity for downstream application 
of the work presented in this dissertation.  
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Tables and Figures 
 
 
 
Figure 1: Binding and invasion of UTI89 are unaffected by empty vector or OmpA LP 1 
KO expression. (A) Binding of UTI89, UTI89/pACYC184 (empty vector), or UTI89/pLP 1 KO 
to 5637 cells was assessed in vitro. (B) Invasion into 5637 cells is shown as a percentage of the 
bound bacterial cells. For binding and invasion at least three wells/bacterial strain were used for 
each experiment, and the experiment was repeated three times. Mean and SEM are graphed for 
each strain. 
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Figure 2: UTI89 ΔompA/pLP 3 KO and UTI89 ΔompA/pLP 4 KO cause less severe 
infections. (A) Bladder titers of C57Bl/6 mice 24 hpi after inoculation with the indicated strains. 
Geometric mean is indicated by the horizontal bar and the limit of detection is shown by the 
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dashed line. n = 9-10 mice/strain. (B) IBC structure in the bladders of mice inoculated with 
UTI89 ΔompA/pLP 3 KO or UTI89 ΔompA/pLP 4 KO. Nuclei are stained red, bacteria are 
expressing GFP. Representative images are shown. (C) Enumeration of IBCs 16 hpi as 
determined by lacZ staining of bacteria within the bladder. n = 5-13 mice/strain. * p < 0.05, ** p 
< 0.01, *** p < 0.0005 
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Figure 3: Binding and invasion of UTI89/pLP 3 KO and UTI89/pLP 4 KO. (A) Binding of 
UTI89 fimH::kan, UTI89, UTI89/pACYC184 (empty vector), UTI89/pLP 3 KO, or UTI89/pLP 
4 KO to 5637 cells was assessed in vitro. (B) Invasion into 5637 cells is shown as a percentage 
of the bound bacterial cells. For binding and invasion at least three wells/bacterial strain were 
used for each experiment, and the experiment was repeated three times. Mean and SEM are 
graphed for each strain. * p < 0.05, ** p < 0.01 
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Figure 4: UTI89 ΔompA/pLP 4 KO has decreased membrane permeability. Outer membrane 
permeability of UTI89 surA::kan, UTI89, UTI89 ΔompA, UTI89 ΔompA/pLP 3 KO, and UTI89 
ΔompA/pLP 4 KO was assessed by disc diffusion using 30 µg novobiocin. The zone of inhibition 
(including the disc) was measured for each strain. The experiment was repeated three times (2 
discs/strain/experiment). Average and SEM are graphed for each strain.  
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Figure 5: UPEC OmpT can cleave the cathelicidin LL-37. EHEC EDL 933, UTI89, UTI89 
ΔompT were incubated with biotin-labelled LL-37 for up to 1 hr (0, 5, 15, 30, or 60 min samples 
shown for each strain, left to right). Untreated biotin-LL-37 is shown at far left and is indicated 
by black arrow. Presence of cleavage products was detected by separation on SDS-PAGE gel 
and immunoblot against biotin. Cleavage products are denoted by black arrow and asterisk (*). 
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Figure 6: UPEC OmpT is not required for cathelicidin resistance. UTI89 and UTI89 ΔompT 
cells were incubated with 1, 5, or 20 µg/mL CRAMP in PBS for 2 hr at 37˚C. Percent survival 
was determined relative to an untreated control. Mean and SEM are shown for each treatment. 
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Figure 7: UTI89 ΔompT is not attenuated in a murine model of UTI. Age-matched C3H/HeN 
mice were infected with UTI89 (black filled circles) or UTI89 ΔompT (open circles). Bladders 
and kidneys (data not shown) were harvested 1, 6, or 24 hpi, or 2 wpi and the bacterial load was 
determined by serial dilution and plating of organ homogenates. Geometric mean is indicated by 
the horizontal bar and the dashed line shows the limit of detection. n = 4-10 mice/time point. 
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Figure 8: OMVs can be cleanly purified from UPEC. (A) Protein profile of wild-type OMVs 
on silver-stained SDS-PAGE gel after initial purification. Protein marker (M), UTI89 outer 
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membrane prep (1) and UTI89 OMVs (2) are shown. (B) Negative-stained TEM image of UTI89 
OMVs. (C) Density gradient fractions that contain OMVs can be identified on silver-stained 
SDS-PAGE gel. Labelled lanes are: protein marker (M), OMV input, and density gradient 
fractions 1-14. OMVs are concentrated in fractions 5-9. (D) Protein profile of OMVs from 
UTI89 (U), degS::cat (dS; diluted 1:100), pepP::cat (pP), and yieM::cat (yM). Fold change of 
vesicle production was approximated by ImageJ analysis of major outer membrane proteins. 
Vesiculation (fold change) is shown relative to UTI89. 
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Figure 9: OMVs from UTI89 degS::cat are more plentiful and are distinct in composition 
from those of UTI89. (A) OMV-containing pellets of UTI89, UTI89 degS::cat, and UTI89 
degS::cat/pDegS (left to right) vary in size. Pellets are circled in red. (B) Proteins in OMVs 
isolated from UTI89, UTI89 degS::cat, and UTI89 degS::cat/pDegS were separated by SDS-
PAGE and silver-stained. Approximately equal amounts of protein were loaded. Lane 1 is a 
protein marker, OMVs are in lanes 2-4 (UTI89 in lane 2, UTI89 degS::cat in lane 3, and UTI89 
degS::cat/pDegS in lane 4). (Adapted from Figure 3 of Bradley and Danka, 2015) 
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Figure 10: Deletion of degS decreases virulence of UTI89 in mice, but IBC formation is 
unaffected. (A) UTI89 (circles) or UTI89 degS::cat (squares) were used to infect age-matched 
C57Bl/6 mice. Bladders were harvested at 24 hpi and bacterial burdens were determined. 3 
mice/strain were infected in three separate experiments. The geometric mean is indicated by the 
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horizontal line. **** p < 0.0001 (B) Early (top row) and mature (bottom row) IBCs can be found 
in the bladders of mice infected with UTI89/pcomGFP (left column) or UTI89 degS::cat (right 
column). DNA is stained with the red dye Syto 61. IBCs are indicated with white arrows. 
Representative pictures are shown. (Adapted from Figures 6 and 7 of Bradley and Danka) 
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Figure 11: Binding is unaffected by degS mutation, but invasion is severely limited. (A) The 
ability of UTI89, UTI89 degS::cat, UTI89 degS::cat/pDegS, or UTI89 fimH::kan (negative 
control) to bind to 5637 cells was assessed in vitro. (B) The bacterial cells that invaded into the 
5637 cells are shown as a percentage of bound cells. The mean and SEM are shown for each 
strain. * p < 0.05 (Adapted from Figure 8 of Bradley and Danka) 
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Figure 12: CRAMP-deficient mice have an unknown substance coating the uroepithelium. 
Uroepithelial cells have defined borders and a wrinkled surface in C57Bl/6 mice (A, B). 
CRAMP-deficient mice (C-F) have an unknown substance coating the surface of the 
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uroepithelium. Cell shape is similar underneath the coating (E, F), and areas of exfoliation can be 
found (D). Scale bar is 100 µM in A, D, and E; 25 µM in B, C, F. 
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Abstract 
High school students are not often given opportunities to communicate scientific findings 
with their peers, the general public, and/or people in the scientific community, and therefore they 
do not develop scientific communication skills. We present a 9-week course that can be used to 
teach high school students, with no previous knowledge, how to read and write primary scientific 
articles, and to discuss scientific findings with a broad audience. Various forms of this course 
have been taught for the past 10 years as part of an intensive summer research program for rising 
high school seniors that is coordinated by the Young Scientist Program at Washington University 
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in St. Louis. The format presented here includes assessments for efficacy through both rubric-
based methods and student self-assessment surveys. 
 
Introduction 
The Young Scientist Program (YSP; ysp.wustl.edu) at Washington University in St. 
Louis is a science education outreach program that strives to introduce high school students to 
careers in STEM fields and to increase the participation of underrepresented minorities in these 
fields. The Summer Focus program was established within YSP in 2001 as a paid summer 
internship in which high school students would experience authentic, hands-on scientific 
research [2]. Over the past two decades, Summer Focus has grown to incorporate a college 
preparatory course and a scientific communication course [4]. The scientific communication 
course teaches students how to find and read primary scientific literature, how to compose their 
own scientific findings into a journal-style article, and how to present their findings to a broad 
scientific audience. Here, we present the curriculum for this scientific communication course, 
along with tools for assessing students’ learning and examples of student papers and 
presentations. 
We believe that the skills taught in this course should be introduced to students before 
they reach the college level. Although AAAS’s Vision and Change is targeted at undergraduate 
education, some of the goals laid out in the report can be addressed at the high school level [1]. 
For example, Vision and Change calls for students that are “competent in communication and 
collaboration” and have “a certain level of quantitative competency, and a basic ability to 
understand and interpret data” [1]. Skills such as data interpretation are essential for daily life, 
where individuals must be able to understand and interpret data that are presented to them, and 
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make decisions based on their interpretation. Furthermore, students that have mastered these 
skills will likely perform better on standardized tests such as the PSAT, SAT, ACT, and certain 
AP/IB tests, and should increase their chances of winning scholarships and being accepted into 
college. This is particularly important for underprivileged students in St. Louis. In 2009, only 
16% of St. Louis Public School students scored at or above the national average for the ACT 
[10]. Through this course, we aim to improve high school students’ science communication 
skills, writing skills, and ability to understand and interpret basic scientific data. 
 
Intended audience and prerequisite knowledge  
This course has been designed for rising high school seniors participating in an intensive 
summer research experience through the Young Scientist Program at Washington University in 
St. Louis. Students do not need to have prerequisite knowledge before completing this course, as 
it is flexible enough to accommodate students with limited prior knowledge and a range of 
reading and writing abilities.  
A multi-step application process is used to select students for the Summer Focus 
program. The Young Scientist Program has established relationships with high schools 
throughout the greater St. Louis metropolitan area, which includes public and private high 
schools from St. Louis city, the surrounding Missouri counties, and some schools in Illinois. As 
such, the Summer Focus leadership team is able to notify schools when the application opens and 
to remind them to encourage their students to apply. The application includes brief and optional 
demographic data, a short essay addressing their motivation to apply for the program, and 
questions about their extra-curricular activities, job experience, awards, and previous research 
experience. The students also submit two letters of recommendation and an official transcript. 
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Incomplete applications are not excluded. Each application is reviewed and scored by the 
Summer Focus director or assistant director and at least three separate volunteers. Although a 
transcript is part of the application, the student’s grade point average is not taken into account; 
rather, the transcript is used to determine 1) if the student has challenged his/herself 
academically, 2) the availability of advanced placement courses, and 3) regular attendance. 
When evaluating applications, volunteers attempt to identify students that have limited access to 
other research experiences and would therefore benefit from the program. Approximately 30-40 
students are invited for a formal, on-campus interview, where they meet with three pairs of 
interviewers that probe each student’s curiosity, creativity, ability to work as a team, ability to 
work individually, and more. The interviewers meet as a group to discuss which students will be 
given offers. Interviewers consider whether the students can commit to the full program, have 
previous research experience or can pay for a separate experience, want to participate in the 
program, and will benefit from participating in the program. Depending on funding, 
approximately 16 students are offered positions each summer.  
 
Learning time  
As presented here, the course meets weekly for 1.5-2 hours per session, for 9 weeks 
(Table 1); total in-class time is 12-16 hours. Out-of-class homework assignments (e.g., writing 
drafts of various sections of the paper, creating presentations, peer review) build on the material 
that was covered in class that week and prepare the students for class the following week. This 
homework generally does not require more than 1-2 hours per week.  
We also offer 3 optional sessions: one in which the students complete a short pre-
assessment survey and writing assessment (Supplements 2 and 3), and two in which the 
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instructors can hold individual meetings with students to discuss their progress on the final 
paper. Since our program ends with a summer symposium, we ask the students to practice their 
presentations as a group every day during week 9; however, this practice time could be shortened 
to only occur during the scheduled class time. 
 
Learning objectives 
After completing the course, students will be able to: 
1. Identify the major sections of a scientific article and describe the content that each section 
should contain. 
2. Write individual sections of a scientific article. 
3. Analyze simple figures from scientific articles and draw conclusions from these figures. 
4. Effectively peer review another student’s written work. 
5. Communicate original scientific findings to an audience with a diverse knowledge 
background. 
6. Develop an effective presentation style. 
 
Procedure  
Materials, student instructions, faculty instructions, and sample data  
It is best if class sessions are held in a room with a projector and a white/chalkboard, as 
the students give multiple presentations throughout the course and the instructors often use 
projected presentations to augment the lesson of the day. There are no necessary wet lab 
components. 
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The course is taught by two volunteer instructors to divide the workload.  The instructors 
typically are graduate students recruited from our YSP volunteer pool. Each instructor teaches 
the course for 2 years; schedules are staggered so that there is an experienced instructor and a 
new instructor each year. This course also utilizes the volunteer base of YSP in order to hold 
small-group discussions with students at the end of most classes and to objectively assess 
presentations throughout the course. 
The syllabus distributed to the students is shown in Supplement 1. The students do not 
receive credit for their participation in the course or in the summer program. However, they do 
receive a stipend as part of this internship; accordingly, they are expected to attend to all class 
sessions, and to actively participate in each class. Expectations for the students and the 
guidelines for the final paper and presentation are included in the syllabus. We also present a 
schedule with which the students can keep track of their assigned homework and due dates. 
Throughout the summer, the Summer Focus leadership team stresses to the students that they are 
expected to act professionally and to treat their summer experience as a job. The students are told 
at the beginning of the summer that if they do not turn in the required assignments, their stipend 
may be withheld until the work is completed. The students’ research mentors and tutors also 
have access to the class syllabus, and encourage the students to complete their assignments 
during breaks in the lab. We have had very few instances of students not completing the 
assignments.   
As shown in the sample syllabus (Table 1), the first class meeting is the longest and sets 
the students up for a successful summer. Our students come from high schools across the St. 
Louis metropolitan area, and we want them to be comfortable with each other and the instructors; 
therefore, we start off the first class by playing a few ice-breaker games. Once everyone knows 
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the names of their classmates, we introduce basic writing skills, the purpose of scientific writing, 
examples of scientific sources, what plagiarism is and how to avoid it, and the sections of a 
scientific paper. We use a previous student’s paper to ease them into reading scientific literature 
and to show them what they will be able to do by the end of the summer. Many of our students 
know previous participants or attend the same schools as previous participants, and showing our 
students what their peers have achieved helps build self-efficacy (particularly in regard to 
understanding scientific writing and their own writing skills) [11]. Outside of class, the program 
has an intensive research focus, so we also walk all of the students through a literature search 
using PubMed (pubmed.org), before helping them perform individual searches based on what 
they will be studying. If desired, instructors can have students fill out a writing pre-assessment 
(to give the instructors an idea of how much attention an individual student might need) and an 
overall pre-assessment survey at this first meeting (shown in Supplements 2 and 3). Due to the 
structure of our program, the students complete these assessments and other administrative 
paperwork before the summer starts, but they can easily be included at the very beginning of this 
first meeting.  
The classes have a more defined structure for the rest of the summer. A different topic 
(e.g., the format and content of a Materials and Methods section) is covered in each class, and 
the instructors incorporate student discussion, questions for the students, and active learning 
activities (e.g., think-pair-share) into each session [5, 6, 9]. We include examples from previous 
students and current literature as often as possible. The students often complete a preparatory 
reading and a worksheet before coming to class to discuss the topic in-depth with the instructors 
and their classmates, and to participate in an activity. These homework assignments include 
instructions at the top of each sheet, and are shown in Supplement 4.  
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After the topic of the day has been covered, students divide up into small groups for the 
last 10-15 minutes of class to discuss their projects with their peers and a volunteer (graduate 
student, post-doc, etc.). Throughout the summer, when the students are doing group work, we 
place them into groups of 3-4 students that represent many different backgrounds to encourage 
discussion and collaboration among students that may not usually interact. In these discussions, 
each student will describe his/her project and will answer a few questions from their peers and/or 
the volunteer. These sessions informally assess the students’ understanding of their projects, and 
give the students practice communicating with a low-stakes, scientific audience composed of 
their peers. These sessions can also address discrete goals, such as asking the students to describe 
their projects in lay terms, as if they were speaking to a family member or friend not in science, 
instead of using jargon. The volunteers mediate (but do not lead) the discussion, and provide the 
students with constructive feedback.  
There are also multiple opportunities throughout the summer for each student to present 
before a larger group. In the third week of class, students give short presentations in which they 
must explain the project background, their hypothesis, and some of the methods they will learn 
and employ during their time in lab. Volunteers attending this presentation assess the students’ 
presentation skills using a rubric (Supplement 5). Results of these assessments are not shared 
with the students. Students build on this presentation over the course of the summer as they 
create a final presentation on their project and the laboratory work that they completed. During 
the class period in week 8, a complete final presentation is presented to their classmates, 
instructors, and the same volunteer assessors from their first presentation. In our program, these 
final presentations are given during an end-of-summer symposium, and the students intensely 
practice and edit their presentations each day of the ninth week. The daily practice sessions are 
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not required, but we find the students improve their presentations and presenting immensely over 
the course of the week. In addition to feedback from the instructors, the students also take notes 
and give each of their classmates’ critiques. Finally, chalk talks (oral presentations given without 
supporting slides, although a chalk board may be used to draw figures or models) represent a 
distinct way in which work-in-progress is communicated in science. Our students present a short 
chalk talk to the class in the middle of the summer to familiarize them with this format. 
As mentioned in the section on learning time, one-on-one meetings can be included in the 
schedule. Each meeting is short, usually 10-15 minutes, but allots time for an instructor to meet 
with a student (and their mentor and tutor, in our case) to provide feedback on his/her writing. 
These meetings can also be used to assess what the student does and does not understand, and to 
reinforce concepts that have been taught in class.  
 
Suggestions for determining student learning 
 Our course does not provide a grade for students, but our assessments allow us to 
evaluate student learning and our own teaching. Students are given assignments that support the 
topics we have covered in class, and they must implement what they have learned about the 
sections of a scientific paper to write a manuscript describing their own work from the summer. 
Beyond the written sections of a paper that the students turn in, homework assignments help the 
instructors to assess student comprehension and learning with regard to Learning Objectives 1, 2 
and 4. These assignments are not graded, but help the instructors identify any weaknesses in 
individual students. To help ensure that the students work on their papers throughout the 
summer, they are periodically required to turn in individual sections and drafts. This gives the 
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instructors an opportunity to see how much progress each student has made, and what they are 
struggling with, and to provide rewriting suggestions.  
 In order to more formally assess student learning over the course of the summer, we have 
recently added a rubric-based presentation assessment (Supplement 5). As mentioned in the 
instructions above, this assessment is performed at the beginning of the summer and again at the 
end of the summer by volunteers who are not otherwise connected to the course or the students. 
These assessments allow us to examine the extent to which Learning Objectives 5 and 6 are 
addressed. 
 Finally, we have recently designed rubric-based methods for assessing student gains in 
figure analysis. This addition will allow us to better assess Learning Objective 3. We anticipate 
presenting the results of these analysis methods in the future, after we have collected data from 
multiple student cohorts. We expect our students will particularly improve with figure analysis in 
their own field of study. 
Of important note, our students represent a diverse range of abilities and educational 
backgrounds. Most of our students come from urban schools within the St. Louis Public School 
district, although a few students each year come from private schools within the city or from the 
outlying areas. Our students therefore begin the course with distinct individual skills, needs, and 
opportunities for improvement. We believe that this course is helpful for a diverse set of students 
such as ours, and that all students benefit from participation in this course. We acknowledge that 
the students spend the vast majority of their time working in the lab alongside a research mentor. 
As such, these mentors influence what the students learn over the course of the summer, as well 
as student performance on the final assessments. Therefore we also offer a self-assessment that 
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each student can complete at the conclusion of the course, which identifies areas in which each 
student thinks he/she has improved over the summer (Supplement 6). 
 
Sample data 
We have included two sample final paper and two sample final presentations to illustrate the 
products the students have created by the end of this course (Supplements 7 and 8). 
 
Safety issues  
As this course does not entail wet lab work, there are no safety issues to consider when 
implementing this course. 
 
Discussion 
Field testing and evidence of student learning 
High school students participating in the Summer Focus program have been taught 
scientific communication in a similar writing course for 10 years [2, 4]. The course is designed to 
accomplish a number of learning objectives focused on teaching students how to read and write 
scientific articles, and how to present original scientific data. Recently, we have implemented 
straightforward analysis methods, including both student self-assessments and rubric-based 
assessments, which may inform potential modifications to the class. 
 In addition to addressing the described learning objectives, this course brings diversity 
into the classroom, provides students with opportunities to practice working in groups, and 
fosters discussion among peers. For this article, we assessed two separate cohorts of students. 
The first cohort comprised 14 total students, 10 girls (71.4%) and 4 boys (28.6%) (Figure 1A). 
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The second cohort included 16 total students, 10 girls (62.5%) and 6 boys (37.5%); in total, we 
report results from 30 students, 67% of which were girls. Of these 30 students, 14 identified their 
race as Black, 9 as Caucasian, 6 as Asian, and 1 chose “I prefer not to answer” (Figure 1B). 
Furthermore, the students represent a variety of socioeconomic backgrounds and attend different 
types of schools throughout the St. Louis metropolitan area [9].  
 We used informal, pre-assessment surveys that utilize a modified Likert scale to 
determine whether the students were already familiar with the concepts and skills that would be 
taught in this course (Supplement 2) [8]. This scale included responses as follows: 0 represents 
Strongly Disagree, 1 represents Disagree, 2 represents Neutral, 3 represents Agree, and 4 
represents Strongly Agree. Therefore, survey questions with a median response greater than 2 
indicate a positive response. The surveys were completed the first day of class before any 
material had been covered. While 73% of students report having read a scientific paper, 40% 
reported not being able to name the parts of a scientific paper, and the remaining 60% reported 
that they were unsure if they could. Approximately 67% of students report that they have 
previously interpreted basic scientific results, although students feel neither comfortable nor 
uncomfortable doing so (Table 2). Additionally, 67% of students report that they have not 
previously written a scientific paper, and feel neutral about whether they would be comfortable 
writing a scientific paper. The majority of students reported having confidence in their oral 
presentation skills, critical thinking skills, and ability to effectively peer review (Table 2).  
Similarly, post-assessment surveys were used to monitor the students’ own impressions 
of their improvement over the course of the summer (Supplement 6). The results of these surveys 
indicate that students felt they made gains in a number of areas (Table 3). We found that 100% 
of students were confident that they could name the parts of a scientific paper, while only 25% 
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thought they could at the beginning of the summer. Although some students felt that they could 
interpret basic scientific results at the beginning of the summer, the majority of students reported 
that they were comfortable interpreting basic scientific results at the end of the summer (Table 
3). While students report that they felt uncomfortable writing a scientific paper before the course, 
they felt very comfortable writing a scientific paper after taking the course (Table 3). Based on 
the surveys, students felt more confident with regard to their writing and oral presentation skills 
after completing the course (Table 3). Students also indicated that they felt they had developed 
critical thinking skills and could effectively review and critique a peer’s work (Table 3). 
 Finally, the greatest gains are seen in the final papers and presentations that the students 
create by the end of the summer. We do not grade or otherwise quantitatively evaluate student 
papers, so we have provided examples of students’ writing pre-assessment responses (which 
correspond to Supplement 3) and their respective final papers in Supplement 7. The final papers 
that the students create by the end of this course are of very high quality. Our students have won 
awards in national writing competitions, had papers accepted to the Journal for Emerging 
Investigators [3], and have successfully used their papers in college applications and scholarship 
applications. Examples of final student presentations (including edits from a week of practice 
that occurred after the assessment) can be found in Supplement 8. The students improve their 
presenting “style” (including slide design, verbal delivery, and nonverbal delivery) over the 
course of the 9-week program (Figure 2). Additionally, the students create clear, concise and 
polished presentations that include the major sections of a formal scientific presentation 
(background information, methods, results, and discussion) and generally fall between “good” 
and “excellent” when assessed by rubric (Figure 3). The “final” presentation assessment was in 
the second to last week of class, before the students had intensely practiced their presentations. 
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We did not assess the students during the final symposium as we were interested in individual 
gains without the intensive practicing of the final week, but the students continue to improve 
with each practice session. Our data support the idea that students involved in summer research 
programs are more confident in their abilities to perform laboratory science experiments [7]. 
However, we believe that the course described here can be used to augment a summer research 
experience and to effectively teach diverse high school students, with widely ranging previous 
experiences, how to employ the major forms of scientific communication. 
  
Possible modifications  
Although this course was designed for rising high school seniors, it could be used for 
college freshmen, or adapted for use with younger students. The course could also be abbreviated 
to focus on individual skills, such as writing a scientific paper or presenting scientific data to a 
particular type of audience. Each of these focused topics could be presented as stand-alone 
workshops. However, we do not feel that the course in its entirety could be condensed into a 1-2 
day workshop, as students need time to develop ideas and to practice the skills presented in each 
class session – this cannot be accomplished overnight. 
Finally, this course was designed for students that are generating their own data alongside 
research mentors who can help the students outside of class. However, it is feasible that students 
(individually, or in pairs or groups) could write papers or create presentations discussing 
methods and data from case reports, data collected from laboratory exercises done by an entire 
class, or other sources. 
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Supplement 1: Student syllabus 
Supplement 2: Pre-assessment questions 
Supplement 3: Writing pre-assessment 
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Supplement 7: Two sample student writing pre-assessment responses and corresponding final 
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Supplement 8: Two sample student final presentations* 
*due to length, Supplements 7 and 8 are not included here (will be available online at JMBE) 
 
Acknowledgements: Funding was received from the Young Scientist Program Endowment for 
Science Literacy, MidSci, WashU Office of Diversity Programs, WashU Medical School Alumni 
Association, WashU Medical Scientist Training Program, WashU Division of Biology and 
Biomedical Sciences, BioMed RAP, the Howard Hughes Medical Institute, Dr. Will Ross, and 
The BALSA Group. We thank John Russell, Gabriela Szteinberg, David Hunstad, and Katherine 
Chiappinelli for critical reading. We also thank previous Writing Course instructors Hanako 
Yashiro, Elizabeth Tuck, Katherine Chiappinelli, Devjanee Swain Lenz, and Britney Moss for 
creating the original template of this course. The authors do not have any conflicts of interest. 
 
  
178
Tables and Figures: 
Table 1: Example class syllabus. 
Week In-class Assignments due in class 
Pre-SF meeting 
(optional) 
-Writing pre-assessment -Students should know their 
project topic and lab 
 
Week 1 
(3 hrs) 
 
-Ice breakers 
-6 C’s of writing (very briefly) 
-Plagiarism 
-Types of science writing 
-Database searches, practice (NCBI) 
-Sections of a paper (with example) 
-Worksheet with summary of 
lab/project overview focusing on 
main Q, hypothesis and approach 
 
Week 2 (1.5 hrs) 
 
-Critical reading skills 
-Go over example paper (previous 
student’s), discuss 
-Project discussion with volunteers 
-Worksheet to prepare for critical 
reading discussion 
Week 3 (1.5 hrs) 
 
-Give 5 min project presentation focusing on 
background, main Q, hypothesis and 
methods 
-Q’s (students, teachers, volunteers) 
-Peer review previous year’s paper 
-Prepare 5 min project 
presentation for the class 
 
Week 4 (1.5 hrs) 
 
-Format and content of Materials and 
Methods using a real paper (journal club 
style) 
-Project discussion with volunteers 
-Find and read 2 papers related to 
project, summary 
- M&M worksheet 
 
Week 5 (1.5 hrs) 
 
-Format and content of Results section using 
same paper (from last week, journal club 
style) 
-Project discussion with volunteers 
-M&M for their project 
- Results worksheet 
 
Week 6 (optional) 
(10-15 min) 
 
-One on one meetings with student, mentor, 
tutor and teacher 
-Discuss M&M (return edits) and grill them 
for understanding 
 
 
Week 6 (1.5 hrs) 
 
-Format and content of 
Abstract/Intro/Discussion 
-2 min project chalk talk and Q&A from 
students, teachers, volunteers 
-Edited M&M and Results for 
their project (“Draft #1) 
- Ab/Intro/Dis worksheet 
-Prepared chalk talk outline 
Week 7 
(beginning of 
week) 
-Return Draft #1 edits so they can be 
incorporated into Draft #2 
 
 
Week 7 (1.5 hrs) 
 
-Presentation skills (watch, critique a good 
and a bad presentation) 
-How to do Citations and in-text references 
-Project discussion with volunteers 
-Abstract, Introduction and 
Discussion for their project, plus 
Draft #1 (“Draft #2) 
 
Week 8 (optional) 
(10-15 min) 
 
-One on one meetings with student, mentor, 
tutor and teacher 
-Discuss Draft #2 edits and discuss content 
of intro and disc 
 
Week 8 (1.5 hrs) 
 
-Project presentations with critiques from 
classmates and teachers 
-Prepare 5 min project 
presentation 
Week 9 (2 hrs) 
(Every day-
optional) 
-Practice presentations every morning  
 
-Final paper due Thursday, 
Symposium on Friday 
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Figure 1: Gender and race of students participating in the summer program. The self-
identified gender (A) and race (B) of our 2013 and 2014 student cohorts.  
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Table 2: Results of pre-assessment survey. 
 
Median 
score
a, b 
Question 4: I feel comfortable interpreting basic scientific results. 2 
Question 5: I feel confident in my writing skills. 2 
Question 7: I feel comfortable writing a scientific paper. 2 
Question 8: I feel confident in my oral presentation skills. 3 
Question 9: I have strong critical thinking skills. 3 
Question 10: I can review and critique a peer’s work effectively. 3 
a
Answers were ranked on a scale of 0-5, 0 representing Strongly Disagree, 1 representing 
Disagree, 2 representing Neutral, 3 representing Agree, and 4 representing Strongly Agree; 
b
n=15 students 
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Table 3: Results of post-assessment survey. 
 
Median 
score
a, b 
Question 3: Were you able to interpret basic scientific results at the 
beginning of the summer? 
2 
Question 4: Do you feel comfortable interpreting basic scientific results 
now? 
4 
Question 5: Did you feel comfortable writing a scientific paper before 
Summer Focus? 
1 
Question 6: Do you feel comfortable writing a scientific paper after 
completing Summer Focus? 
3.5 
Question 7: Do you feel more confident in your writing now that you 
have completed the Writing Course? 
3.5 
Question 8: Are you more confident in your oral presentation skills now 
that you have completed the Writing Course? 
3 
Question 9: Do you feel you have developed critical thinking skills? 3 
Question 10: Do you feel you can review and critique a peer’s work 
effectively? 
3 
a
Answers were ranked on a scale of 0-5, 0 representing Strongly Disagree, 1 representing 
Disagree, 2 representing Neutral, 3 representing Agree, and 4 representing Strongly Agree; 
b
n=28 students 
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Figure 2: Results of presentation style assessment. Students demonstrated improvements in 
slide design, verbal delivery, and nonverbal delivery between their first presentation and their 
last presentation in class. Each student’s average score from three volunteer assessors was used 
to calculate a median score (n=30 students for first presentation and n=27 students for last 
presentation). Scores are converted to percentages to account for different numerical scales in the 
2013 and 2014 rubrics. The requirements for each category were unchanged. 
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Figure 3: Results of presentation content assessment. Students are able to create presentations 
that thoroughly address important background information, methods, results, and discussion 
sections. Each student’s average score from three volunteer assessors was used to calculate a 
median score (n=27 students). Scores are converted to percentages to account for different 
numerical scales in the 2013 and 2014 rubrics. The requirements for each category were 
unchanged. 
184
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Supplement 1: Student syllabus 
Writing Course Syllabus 
Course Instructors: 
 Name 1  Phone number 
    Email address 
Name 2  Phone number 
    Email address 
Goals: 
While taking this course, you will: 
● Recognize the style, format, and content of scientific papers. 
● Understand your research and present this research to an audience.  
● Understand and discuss others’ research at a basic level. 
● Develop your ability to review others’ work. 
● Appreciate the importance of scientific writing, speaking, and other ways 
communication. 
 
Expectations: 
Skills in writing, oral presentations, and peer review are required for your success in college, 
with further education, and in building and maintaining a career.  This writing course is 
designed to teach you about these life skills, but exactly how much you get out of the class will 
depend on how much time and effort you put into it.  Attendance is mandatory (unless you 
have a valid reason for missing, and you inform the course instructors ahead of time).  We 
expect that you will arrive on time each week and be ready to participate in class, as your 
participation will help you engage and actively think about the writing/editing process. The 
assignments for each week will prepare you for what we will go over in class, as well as 
reinforce in-class topics, so please be thorough and thoughtful when completing them. You will 
receive written comments each week on your assignments from the instructors. We expect you 
to use these comments to improve your writing throughout the summer.  You will thank 
yourself later for the effort spent on writing and editing this summer, as the paper will come in 
handy when the time comes to talk about your research, provide admissions committees with a 
written summary, or compete in a science competition in the future.  
 
We hope that you have a wonderful summer experience!  There is a lot to learn, but we want 
you to enjoy the experience. If you have any problems with the writing course, your labs, or any 
other aspects of the summer, DO NOT HESITATE to inform your instructors, the liaisons, or any 
of the Summer Focus leaders.   
 
Assignments: 
The assignments for each class session are listed in your course syllabus and outline. For the 
first few weeks, you will learn how to read scientific articles and their basic structural format. In 
addition to reading these papers, you will learn to discuss them with other students in the 
format of a journal club. In addition, you will learn to present your project to an audience early 
on in the summer, so you have to become familiar with your project’s main question, 187
background research, hypothesis and methods in the first few weeks. Starting in July, you will 
begin writing your paper.  We will guide you through each section, and each week you will write 
a specific section of your paper and update any previously written sections.  For example, for 
class on July 3, you will write your Materials & Methods section. On July 11, you will turn in 
your first draft of your Results section and improve your Materials & Methods section. You will 
also be asked to discuss your project in a small group (other students and a volunteer) by 
explaining your summer project and the progress you have made for that week. The instructors 
will provide more detailed information on these assignments in class. 
 
Progress charts:  You will be asked to fill in a progress chart each week.  In this chart, please list 
the experiments you performed for the week, why you did them, and what your results from 
these experiments show. Write whether you worked independently, with the help of your 
mentor, or whether you watched your mentor do the experiment. We will review the charts to 
ensure that you are receiving the maximum amount of time at the bench and the best 
experience possible!  Progress charts have been given to you and are in your binder.   
 
Final paper:  A scientific paper on your research project will be due at the end of summer. Your 
paper should be at least five pages long, double-spaced, with 12-point Times New Roman font. 
Formal requirements for formatting your paper will be distributed later. We encourage you to 
write a longer paper if you would like to use the paper for science competitions. A rough draft 
of your entire paper is due on July 18. We realize that some sections may not be complete 
because you may still be working on the experiments. However, you should still have at least 
begun to draft all of the sections of the paper. You will edit and improve this draft until the end 
of the program. The final draft is due August 1 by 5:00pm. Throughout the editing process, we 
encourage you to save each draft as a separate document (e.g. SF Paper-Draft 1, SF Paper-Draft 
2) to at least two different hard drives (e.g. Desktop & USB) in case your computer crashes at 
the last minute (it happens!!).   
 
Final presentation: You will present your research to an audience of all SF students, their family 
and friends, and SF volunteers at an end of SF Symposium on Friday, August 2. This 
presentation will be 5-7 minutes long and will demonstrate why you did your research, what 
your project was, and the main results and conclusions from your work. Your presentation will 
have an outline similar to that of your final paper. We will help you prepare this presentation 
and give you lots of feedback as you practice it over and over! Like your final paper, we 
encourage you to save your final presentation to at least two different sources so that you do 
not lose your hard work unexpectedly. 
 
Writing Course: Detailed Course Outline 
 
Date In-class Due today Due next week 
June 5th 
(Wed.) 
-6 C’s of writing and plagiarism 
-types of science writing 
-summary of 
lab/project overview 
-read example paper 
and fill out critical 
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Boot 
Camp 
-how to do database searches, 
practice 
-sections of a scientific paper 
(main Q, hypo, 
methods) 
reading worksheet 
June 13 
(Thurs.) 
-critical reading skills 
-example paper 
-discuss progress of project 
-critical reading prep 
worksheet 
-find and read 2 
papers for project, 
summarize 
-prepare 5min PPT 
presentation 
June 20 
(Thurs.) 
-5 min project presentations 
(background, main Q, hypo, 
methods) 
-summaries of 2 
papers related to 
your project 
-5min presentation 
-read example 
M&M, fill out M&M 
worksheet 
-prepare 5min PPT 
with group about 
M&M 
June 27 
(Thurs.) 
-format and content of Materials and 
Methods section 
-discuss progress of project 
-M&M worksheet 
-presentation for 
Journal Club 
discussion of format 
and content of 
M&M 
-write M&M for your 
project 
-read example 
Results, fill out 
Results worksheet 
-prepare 5min PPT 
with group about 
Results 
July 3 
(Wed.) 
-format and content of Results 
section 
-discuss progress of project 
-schedule one-on-one meetings 
-M&M 
-Results worksheet 
-presentation for 
Journal Club 
discussion of format 
and content of 
Results 
-read example 
Abs/Intro/Disc, fill 
out worksheet 
-write Results for 
your project 
-chalk talk outline 
July 8 
(Mon.) 
ONE-ON-ONE MEETINGS 
(9AM-12PM Rooms TBA) 
  
July 11 
(Thurs.) 
-format and content of 
Abstract/Intro/Discussion sections 
-2 min project chalk talk 
-Draft #1 (edited 
M&M, Results) 
-Abs/Intro/Disc 
worksheet 
-chalk talk outline 
-Draft #2 (edited 
M&M and Results, 
add in Abstract, 
Introduction and 
Discussion) 
 
 
 
(continued on next page) 
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July 18 
(Thurs.) 
(July 18 
cont’d) 
-presentation skills 
-how to do Citations and in-text 
references 
-schedule one-on-one meetings 
-Draft #2 (edited 
Draft #1 plus 
Abstract, Intro and 
Discussion) 
-5-10min practice 
PPT presentation 
July 22 
(Mon.) 
ONE-ON-ONE MEETINGS 
(9AM-12PM Rooms TBA) 
  
July 25 
(Thurs.) 
-project presentation to class (5-10 
minutes) 
-practice 
presentation 
-final presentation 
and final paper 
July 29-
August 2 
-practice final project presentation 
every morning at 9 AM 
-final presentation -continue editing 
paper and 
presentation 
August 1 
(Thurs.) 
FINAL PAPER DUE BY 5 PM   
August 2 
(Friday) 
SYMPOSIUM: PRESENTATIONS AND 
BANQUET at 6 PM 
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Supplement 2: Pre-assessment questions 
Name:          Number: 
Please read each question and circle the answer that describes your feeling most accurately. 
1) Have you ever read a scientific paper? 
 
 Yes   No  Not sure 
 
 
2) Can you name the parts of a scientific paper? 
 
 Yes  No  Not sure 
 
 
3) Have you ever interpreted basic scientific results? 
 
 Yes  No  Not sure 
 
 
4) I feel comfortable interpreting basic scientific results. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree 
 
 
5) I feel confident in my writing skills. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree 
 
 
6) Have you ever written a scientific paper before? 
 
 Yes   No   Not sure 
 
 
7) I feel comfortable writing a scientific paper. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree 
 
 
8) I feel confident in my oral presentation skills. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree 
 
 
9) I have strong critical thinking skills. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree 
 
 
10) I can review and critique a peer's work effectively. 
 
 Strongly Disagree  Disagree  Neutral  Agree   Strongly agree191
Supplement 3: Writing pre-assessment 
Writing Course   Name: _________________________ 
Pre-course free write     
 
You have 15 minutes to create a response to the following:  
 
Think of a time when you read an article (magazine, newspaper, online source) about a science 
or health topic. What did you learn from this article? Did you consider it to be a credible source 
at the time? Why or why not? What do you think of this article now? If you have changed your 
mind about the article, why did you change your mind? 
 
 
  
192
Supplement 4: Homework assignments  
Lab summary and project overview 
 
Name of PI: 
 
General lab interest: 
 
 
Project topic: 
 
 -why is this interesting? 
 
 
 
Main question of project: 
 
 
 -why is this worth investigating? 
 
 
 
Hypothesis: 
 
 
 
 
 
Approach (what experimental methods will you be using to test your hypothesis? add more if 
needed): 
-Experiment 1: 
 
 
-Experiment 2: 
 
 
-Experiment 3: 
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6 C’s of writing notes 
Effective communication of ideas in written form is an incredibly valuable life skill. The 6 C’s 
of writing provide basic guidelines to successfully present your ideas in a written document. 
The 6 C’s are clarity, conciseness, credibility, completeness, consistency, and coherence. They 
are not presented in a specific order. Each C is essential to the formation of a well written 
composition. The 6 C’s are presented below. 
 
1) Clarity: The goal of writing is to convey your ideas, thoughts, and conclusions to the reader. 
Thus, your writing should be clear, easily understandable, and without errors that will hinder a 
reader’s comprehension of your thoughts. To achieve clarity, the following are essential: 
 Do the simple things right: check spelling and grammar! Proofread extensively.  
 Always use citations where necessary. 
 Be clear about what is fact versus what you hypothesize or present as a potential model 
(especially important for scientific writing). 
 Proper sentence structure is essential. Proofread each sentence individually to yourself 
to assess how well the words flow and the sentence relates your intended meaning.  
 Use active tense when writing (Jen is counting cells) and avoid passive tense when 
possible (The cells are being counted by Jen). 
 Pay attention to verb tenses: past tense for what you did, present tense for what is 
currently being done, future tense for what you plan on doing 
 
2) Conciseness: Your writing should be succinct but comprehensive. The following suggestions 
will help maintain concise writing: 
 Get to the point! Make sure that you are only adding important details.  
 Make statements in simple terms. 
 Remove any unnecessary sentences and words that do not enhance the reader’s 
understanding of your thoughts. 
 A sentence should not be longer than 3 lines. However, do not make sentences 
incomplete when trying to be concise. 
 Conciseness also applies to paragraphs and the paper as a whole: avoid being redundant 
at all times. Proofread to ensure that you do not repeat yourself.  
 
3) Credibility: Your writing must be convincing and trustworthy.  
 How does your reader know that you didn’t just make this up? 
 Detail and context are important. Convince your audience! 
 Cite proper sources to provide the reader with all of your sources. 
 
4) Completeness: Your writing should contain all necessary and appropriate information. To 
make sure that your writing is complete, follow these guidelines: 
 Introduce new information in all appropriate situations to avoid confusing the reader. 
 Finish each thought or phrase in a sentence. 
 Write in paragraphs that continue the flow of your writing and lead to your conclusions.  
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 Give reasoning for statements and justify why those statements are important and true. 
Convince your audience! 
 
5) Consistency: A writing composition should be uniform. Maintaining consistency will ensure 
that the writing is understandable and does not confuse the reader.  
 Check to make sure that everything in your document matches, including: noun/verb, 
verb tenses, pronouns, etc. 
 Introduce the reader to your topic and ideas. 
 Ensure that your sentences and paragraphs flow effectively towards your conclusions. 
 
6) Coherence: Your writing should have a logical, orderly, and consistent flow that will please 
the reader. In addition, the sentences and paragraphs should be logically connected. Logical 
connections and proper flow will make your writing understandable and easy to read. When 
completing your document, assess the following aspects of the writing: 
 Do things follow a logical order, or are you jumping around between topics and ideas? 
 Does your work as a whole make sense? Reading out loud can help with this. You 
shouldn’t need to backtrack and reread any sentence. 
 Check that you have followed the other 6 C’s. 
 Proofreading is a critical aspect of writing. Editing should be performed throughout the 
writing process and multiple times before a document is considered complete.  
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Sources of Scientific Information worksheet 
 
There are many different ways for the average person to find out scientific information. You are 
probably most familiar with popular science sources and textbooks right now, but there are 
other sources of scientific information available. The credibility of these sources varies, and so it 
is always important to evaluate the source and where the information in that source came 
from. A list of some of these other sources is below. 
 
-Pamphlets/Informative Brochures: Brochures for medications, pamphlets on disease 
-Newspaper Articles/News Shows: Articles in the St. Louis Post Dispatch, segments on recent 
developments in the evening news 
-Popular Science Magazines or Books: Popular Science magazine, Discover magazine, Scientific 
American magazine, National Geographic magazines, “Maneater: and Other True Stories of a 
Life in Infectious Diseases” by Pamela Nagami, “The Immortal Life of Henrietta Lacks” by 
Rebecca Skloot 
-Documentaries: National Geographic documentaries, Discovery Channel documentaries, NOVA 
programs 
-References or Text Books: The Merck Manual, “Genes VII” by Benjamin Lewin 
-Science Fiction Books or Movies: “Frankenstein” by Mary Shelley, Jurassic Park, Contagion 
-Special Pieces in Non-Science Magazines: An article about reproductive health in a women’s 
magazine 
-Online: CDC website, TED talks, science blogs, Wikipedia, “The Onion” science page 
-Experts in the field (often oral sources of information): Your PI, collaborators, your doctor 
 
 As you may know, scientific articles are the way that most scientists communicate new findings 
and results within the field. In order to make sure that scientific papers are credible and 
worthwhile, they are subjected to the process of peer review. 
 
What is peer review? 
 
 
 
 
 
 
 
 
Why is peer review important in science? Why is it important in writing? 
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What are the guidelines for peer review? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample paper for practice peer review: 
-use the brief paper below to fill out the table on the following page 
 
Introduction 
Blind people have cataracts. The majority of cataracts are age-related. Cataracts occur when 
crystallins clump together, making the lens cloudy. This causes the light hitting by the lens to be 
scattered. Cataracts can occur at birth, in childhood, or as older adults.   There is increasing 
evidence that age-related cataract has a strong genetic component (Hammond et al., 
2000).  People with cataracts that appear at birth or in childhood usually have a mutation in 
one gene. Some scientists think that studying families with early-onset cataracts will help us 
understand age-related cataracts. 
Methods 
Our lab collected DNA from a family with an autosomal dominant inherited posterior polar 
cataract.  They used linkage analysis to map the family’s disease to chromosome 1p36. I looked 
at the gene Q9UKB5 because it codes for hypothetical protein MOT8. MOT8 may be a member 
of the aldehyde dehydrogenase family of enzymes. ALDH is similar to omega-crystallin 
(Piatigorsky). We think that this gene is important for cataracts because it is similar to a protein 
found in scallop’s eyes. 
Results 
I sequenced Q9UKB5. There are 5 exons. We did this using wild type DNA and DNA from two 
affected individuals. I used the polymerase-chain reaction (PCR) to amplify the exons. I used 2 
microliters of DNA and 1 microliter of primer. A gel was run to look at the polymerase chain 
reaction product.  It was sequenced with the ABI machine using the method.   I printed out the 
data and looked at it to see if there were any mutations.  No one had two peaks. I screened 3 
exons. 
Conclusions 
There aren’t any mutations.  This project isn’t finished because we need to sequence the rest of 
the exons. 197
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Problem 6 C Comment Solution 
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Plagiarism worksheet 
 
Database searches and material given to you by your lab will provide you with lots of 
background information about your project. You will likely refer back to this information as you 
start to put together your paper and your presentation. When you do this, it will be important 
to avoid plagiarism. 
 
Discuss: What is plagiarism? How do we avoid plagiarizing? 
 
 
 
 
 
 
 
 
When do we use citations? What sources need to be cited? Is there ever a time when we do not 
need to cite information? 
 
 
 
 
 
 
 
 
 
Like you have probably learned in your English classes, citation methods vary. There are 
different formatting guidelines for citations in general writing (such as MLA, APA, CMS and IEEE) 
and in science writing. Most peer-reviewed journals have specific guidelines for citations. When 
we discuss how to do citations, we will give you a format to use. 
 
Why have we gone over this? It is important for you to document your sources for when you 
start to write your papers, so save papers that you need (either hard copy or electronically) or 
write down details about the paper (authors, journal, title, etc.) on your notes so that you can 
find the paper later! 
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Peer Review Worksheet 
Fill out this worksheet as you read through your HW article. It was written by a previous 
student! Be sure to read slowly enough to identify the important parts that are outlined here. 
Also, as you read, think about things that the author does well and things that the author could 
have done better. We will discuss this paper in class on Thursday. 
 
Title: 
 
 
Just from the title, what do you think the paper will be about? 
 
 
 
 
After reading the Introduction, what did you learn is the topic of the paper?  
 
 
What is known about the subject? (list at least 3 things) 
 
 
 
 
 
What is not known about the subject? 
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What is the main question that the author is trying to answer? 
 
 
 
 
What is the significance of the question? Are you convinced that this is an important question? 
 
 
 
 
What is the author’s hypothesis?   
 
 
 
How does the author plan on testing the hypothesis? (In other words, what methods will the 
author use during their experiments?)       
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 What are the main results of the paper? 
 
 
 
 
 
List 3 strengths of this paper. 
 
 
 
 
 
 
List 3 weaknesses of this paper. 
 
 
 
What 5 things do you think are the most important for you to consider when you are writing 
your own paper? 
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Materials and Methods 
The Materials and Methods section of a scientific paper can give you lots of information that is 
not available in any of the other sections of a paper. As its name implies, this section tells you 
about the materials (chemicals, buffers, cells, etc.) that the authors used to do their 
experiments and the methods (protocols, etc.) that the authors used to do their experiments. 
You will likely find some things that you are familiar with in this section, as well as some things 
that you have not yet learned about. 
 
For next week, each group will make a presentation to give to the class in which they go 
through the provided Materials and Methods section and discuss any points that they think are 
particularly important. This presentation should be about 5 minutes long. A couple ideas of 
things to consider discussing when making your presentations: 
 
-What is the purpose of this section? 
-What is the format of this section? 
-What voice is used when writing the M&M? 
-How much detail do the authors include? 
-How does this section relate to the other sections of a paper? 
 
This is not a complete list. Please be thorough when analyzing what goes into an effective 
Materials and Methods section! Think about what is helpful and what the author has done well, 
as well as what could be improved. Remember, you will be writing the M&M section for your 
own paper soon! 
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Results section homework handout 
You will analyze the Results section from the old SF paper that you read last week. As you read 
the Results section from that paper, please answer the questions below. Then fill out the final 
question for your summer project. 
 
What is the purpose of the Results section? What is the format of this section? Did the author 
of your paper adhere to this format? 
 
 
 
 
 
Name at least 3 things that should be included in the TEXT of the Results section. 
 
 
 
 
Name at least 5 things that should be included in the FIGURES or FIGURE LEGENDS. 
Distinguish between things that belong in the figure or in the figure legend. 
 
 
 
 
 
 
What did the author do well in their Results section? What could they have done better? 
 
 
 
 
 
 
Write out one or two subheadings that will be included in the Results section of your paper. 
What kinds of figures will these subheadings describe? 
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Abstract/Introduction/Discussion worksheet 
Although the Abstract, Introduction and Discussion sections of a paper each have a different 
purpose, they can give the reader similar pieces of information, so we will learn about these 
three sections of the paper together. 
 
Writing the Introduction: 
 
 
Writing the Discussion: 
 
 
Writing the Abstract: 
It is often easiest to write the Abstract last, since it is a short summary of the entire paper. 
However, you should be very thoughtful when writing your abstract as you have a lot of 
information to convey to your reader in a short space. Readers will often use abstracts to judge 
whether or not a paper is worthwhile, so your abstract should be convincing! 
 
Where in the paper is the abstract placed? Is this important? What is the purpose of the 
abstract? 
 
 
 
 
 
How many sentences of the abstract should be devoted to each of the sections of your paper? 
 1. Introduction: 
 
 2. Materials and Methods: 
 
 3. Results: 
 
 4. Discussion: 
 
 5. Citations: 
 
Write your abstract below. Remember to include all of the parts of the paper. If you want to 
leave out the discussion/conclusion sentence for now, that is fine. 
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Extras! 
-your title should be specific and informative to give any potential readers an idea of what the 
paper describes 
 -can be fairly long, are usually almost a complete sentence 
-important to mention your specific topic (protein or gene of interest, model system, 
general method used) 
-the major conclusion can be included in the title 
-if you choose to include an acknowledgements section, put it at the end of your paper, before 
your citations 
-generally these include people that helped with experimental design, brainstorming 
ideas/conclusions, or paper editing, and funding sources 
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Summer Project Chalk Talk worksheet 
A chalk talk is a quick, informal way of presenting your research to an audience. Instead of using 
a formal, lengthy Powerpoint presentation, you will instead give a much shorter presentation, 
and you will use the white board to draw out concepts, models and/or important points. This 
presentation will only be 3 minutes long! This presentation will include a brief introduction to 
your project’s main question and hypothesis, followed by some brief results that you have 
obtained, and then a summary of what these results mean and how they fit into the big picture. 
You do not have to write everything you are going to say on the board. Fill out the following 
outline to help you prepare for your chalk talk (and use the back of this page to practice 
drawing the models or diagrams that you will show your audience!): 
 
Introduction 
-General topic of research with brief background (relevancy, short previous work): 
 
 
 
 
-Main question: 
 
-Hypothesis: 
 
 
Results (can describe as many as wanted, probably little time for more than 3) 
-Experiment 1: 
 -Methods: 
 
 
 -Results: 
 
 
-Experiment 2: 
 -Methods: 
 
 
 -Results: 
 
 
 
Summary 
-Conclusion based on results: 
 
-Big picture implications: 
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Supplement 5: Presentation assessment rubric 
Directions: Please use this rubric to rate these 7 parts of the students presentation (4 categories focused 
on the parts of the presentation and the organization on the first two pages, 3 categories focused on the 
presentation style on the third page). Indicate your numerical choice for each section on the 
accompanying reporting sheet. You may use in-between numbers and you can write notes to clarify 
decisions (or as you are listening) on the reporting sheet.  
The students will not see or receive these reporting sheets, so please be honest and as critical as you 
would be with any other scientific presentation. 
Thank you for your help with this!! 
Parts of the presentation categories (4): 
Category POOR (0 pts) FAIR (1 pt) GOOD (2 pts) EXCELLENT (3 pts) 
Backgroun
d section 
(includes 
title slide, 
main Q and 
hypo) 
-Section (or key parts) 
missing  
-Main Q and 
hypothesis not 
presented or 
nonsensical 
-Excessive use of 
clipart/unrelated 
pictures 
-Section present but 
has far too much or far 
too little information 
-Text presented as 
paragraphs, no 
citations 
-Extra figures/clipart 
are added when not 
needed 
 
-Section present with 
close to the 
appropriate amount of 
material (1 extra or 
too few slide) 
-Clear main Q and 
hypo 
-Text presented as 
bullet points or 
complete sentences 
Appropriate citations 
included 
-Most figures are of 
value to the audience 
-Section present with 
appropriate amount of 
information 
-Main Q and 
hypothesis are clear 
-Slides have bullet 
points with info, not 
paragraphs  
-Appropriate citations 
included 
-Relevant figures used 
to illustrate key data 
(from other articles or 
constructed) 
Methods 
section 
-Section missing 
-Experiments not 
described or missing 
key points 
-Excessive text 
-Too little explanation 
-Student does not 
understand 
methods/cannot 
explain properly 
-Section present but 
too many experiments 
described/too much 
detail included 
-Too much text on 
slides, mostly 
paragraphs, no 
citations 
-No figures to clarify or 
figures do not aid in 
description 
-Student present 
minimal 
understanding of 
methods 
-Section present with 
close to the 
appropriate amount of 
material (every step 
not described in 
detail) 
-Novel or complicated 
experiments are 
described, maybe with 
figure 
-Mostly bullet points 
or complete phrases, 
no paragraphs, 
citations included 
where needed 
-Student 
demonstrates solid 
understanding of 
methods used 
-Section present with 
appropriate amount of 
information 
-Key experiments 
explained 
-Slides have bullet 
points with info, not 
paragraphs, citations 
included 
-Figures used to clarify 
complex methods  
-Student 
demonstrates full 
understanding of 
methods used 
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Results 
section 
-Section missing 
-Figures presented 
without labels (axis, 
samples, units) 
-No accompanying 
text with figures 
-Significance not 
indicated 
-Section present with 
some figures that are 
mostly appropriate for 
the data they are 
displaying 
-Too many/too few 
figures 
-Many labels are 
missing 
-Figures are 
complicated or require 
a lot of interpretation 
-No flow/consistency 
between figures 
-Accompanying text 
not sufficient or 
significance missing 
-Section present with 
appropriate figures to 
display data 
-Figures are labeled 
(may be missing 1 or 
2) 
-Figures are generally 
easy to read and 
interpret 
-Figure style is mostly 
consistent 
-Accompanying text is 
brief, but includes 
significance 
-Section present with 
appropriate figures 
chosen 
-Figures used to 
present data including 
labels, titles, units and 
keys 
-Figures are easy to 
read (size, coloring) 
and style is consistent 
through talk 
-Accompanying text 
highlights key findings 
-Significance is 
indicated 
Discussion 
section 
(includes 
conclusions 
and 
acknowled
gements) 
-Section (or key parts) 
missing 
-Results repeated, no 
conclusions or analysis 
-No future directions 
-No 
acknowledgements 
-Student did not 
understand the 
purpose of their 
research 
-Section present, but 
missing one key part 
(no conclusions or no 
future directions or no 
acknowledgements) 
-Results repeated 
without stated 
conclusions 
-No future directions 
or no 
acknowledgments 
-Student 
demonstrates minimal 
understanding of the 
broad purpose of their 
research 
-Section present with 
appropriate summary 
of conclusions and 
significance/interpreta
tion 
-Results are needlessly 
repeated 
-At least one future 
experiment described 
-Lab/mentor are 
acknowledged 
-Student 
demonstrates solid 
understanding of their 
research as whole 
-Section present with 
appropriate amount of 
information 
-A summary is given 
with the main 
conclusions and 
significance 
-Model presented for 
clarity 
-Future directions are 
described 
-Lab/mentor are 
thanked 
-Student 
demonstrates 
complete 
understanding of their 
research project 
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Presentation style categories (3): 
Category POOR (0 pts) FAIR (1 pt) GOOD (2 pts) EXCELLENT (3 pts) 
General 
slide design 
-Font size is too large 
or small 
-Font is hard to read 
-Color scheme is 
distracting or hard to 
read, lots of distracting 
animation 
-Too many words and 
little use of visual 
cues/support on most 
slides 
-Font size mostly okay 
-Appropriate font 
chosen 
-Color scheme not 
consistent or is 
distracting at times, 
animation occasionally 
detracts from 
presentation 
-Extensive use of 
words on most slides 
-Font size is 
appropriate 
-Font is easy to read 
-Color scheme is easy 
to read and consistent, 
some animation 
included in 
presentation 
-Predominantly 
appropriate mix of 
words and images on 
most slides 
-Font size is 
appropriate 
-Easy to read font 
chosen 
-Color scheme makes 
presentation easy to 
follow and is 
consistent, animations 
are used to emphasize 
points 
-Appropriate mix of 
words and images on 
every slide 
Verbal 
delivery 
-Student did not plan 
out what they wanted 
to say 
-Student was not able 
to convey purpose of 
presentation to 
audience, may have 
been confused about 
the conclusions 
-Many fillers used 
-Thoughts left 
unfinished 
-Not loud enough for 
audience to heard, 
trails off while 
speaking, minimal 
enunciation 
-Pitch, rate and 
emphasis not varied 
-Student had rough 
outline for what they 
wanted to say, used 
notes whole time 
-While presenting the 
student was easily 
distracted and prone 
to tangents, hard to 
follow along to 
definite conclusion 
-Fillers used often 
-Some complete 
thoughts, but some 
trailing off speech 
-Pitch, rate and 
emphasis are 
occasionally varied 
-Correct pronunciation 
used most of the time, 
some enunciation 
-Student planned out 
what they wanted to 
say, occasionally 
glanced at notes 
-Presentation rarely 
strayed from topic, 
audience understood 
the conclusion 
-Fillers used a few 
times 
-Most statements are 
complete thoughts 
-Voice is clear and 
strong with good 
enunciation and 
pronunciation 
-Audience is engaged 
by some changes in 
pitch, rate and 
emphasis 
-Student planned out 
what they wanted to 
say, notes were not 
used 
-Presentation was 
focused and the 
audience understood 
the conclusion 
-Minimal filler 
-Statements delivered 
as complete sentences 
-Strong, loud, clear 
speaking voice with 
enunciation and 
correct pronunciation 
-Pitch, rate and 
emphasis varied to 
engage audience 
Nonverbal 
delivery 
-Back mostly to the 
audience, or head 
down to avoid 
audience 
-Reads from the board 
and/or points to every 
word 
-Gestures are 
distracting or 
inappropriate 
-Occasionally turns 
back to the audience 
while speaking 
-Pointer not used or 
used ineffectively 
-Gestures are 
distracting or 
inappropriate 
-Faces the audience 
for the majority of the 
talk, some eye contact 
-Pointer occasionally 
used effectively 
-Appropriate gestures 
used 
-Faces the audience 
and “interacts” via eye 
contact 
-Use of pointer to 
emphasize material 
-Appropriate gestures 
while speaking 
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Supplement 6: Post-assessment questions 
Name:           
Please read each question and circle the answer that you feel is most accurate. 
 
1) Could you name the parts of a scientific article before this summer? 
 Yes   No 
2) Can you name the parts of a scientific paper now? 
 Yes  No 
3) I was about to interpret basic scientific results at the beginning of the summer. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly Agree 
 
4) I feel comfortable interpreting basic scientific results now. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
5) I felt comfortable writing a scientific paper before Summer Focus. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
6) I feel comfortable writing a scientific paper after completing Summer Focus. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
7) I am more confident in my writing now that I have completed the Writing Course. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
8) I am more confident in my oral presentation skills now that I have completed the Writing  
Course. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
9) I feel that I have developed critical thinking skills. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
 
10) I feel that I can review and critique a peer's work effectively. 
 
Strongly Disagree  Disagree   Neutral   Agree   Strongly agree 
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APPENDIX TWO 
CHARACTERIZATION OF A UPEC DEGS MUTANT IN VITRO AND IN VIVO 
 
India C. Bradley
1,2
 and Elizabeth S. Danka
3
 
 
1 
Cardinal Ritter College Prep High School, 
2
 Young Scientist Program Summer Focus, 
3 
Division of Biology and Biomedical Sciences, Washington University in St. Louis 
 
Modified from Bradley and Danka (2015) Journal for Emerging Investigators. 
 
Abstract 
The Escherichia coli DegS protein is an integral inner membrane protein that breaks 
down incorrectly assembled proteins and helps to regulate the σE stress response pathway. When 
degS is deleted, approximately 200-fold more outer membrane vesicles (OMVs) are produced. 
As OMVs contain sections of the outer membrane and proteins from the periplasm, they may 
play a role in the virulence of E. coli. To test whether degS or OMVs play a role in 
uropathogenic E. coli virulence, we characterized a degS mutant. We found that degS mutation 
did not affect the morphology of the bacterium, but did result in decreased virulence in vivo and 
in vitro. When we tested our mutant in a murine model of cystitis, mice infected with degS::cat 
bacteria had 100-fold decrease in bacterial titers in the bladder at 24 hours post-infection. In vitro 
binding and invasion assays showed no difference in ability to bind to host cells, but a significant 
decrease in the ability of mutant bacteria to invade into cells. Together, these data suggest that 
degS::cat decreases the virulence of E. coli, and increased OMV production may be a detriment 
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to virulence. Future studies can separate the role of degS and OMV production in UPEC 
virulence. 
 
Introduction 
The bacterium Escherichia coli is widely distributed and occupies many niches, including 
the intestines of humans and other animals. It is a rod-shaped, Gram-negative, and facultative 
anaerobic bacterium. While most strains are harmless, some are capable of causing disease in 
humans. One such species is uropathogenic E. coli (UPEC), the causative agent of over 85% of 
urinary tract infections (UTIs) [1]. UTIs can affect the bladder, termed cystitis, or can spread to 
cause a kidney infection, termed pyelonephritis. Some infections will affect both the bladder and 
the kidneys. Over 50% of women will develop at least one UTI in their lifetime, and many of 
these women will have recurrent infections that affect their quality of life [1]. While there are 
likely many host factors that contribute to the occurrence of UTI, UPEC are characterized by the 
expression of specific virulence factors such as type 1 pili, flagella, hemolysin and siderophores 
[2, 3]. These virulence factors aid the bacteria in binding to the host bladder epithelial cells. 
Bound bacteria can be internalized where they are protected from antibiotics and the immune 
system [3]. Virulence factors help the bacteria acquire necessary nutrients and grow to high titers 
within the cells. Some of these intracellular bacteria will remain hidden for up to 6 months 
before emerging from the cells and causing a recurrent infection [3]. In addition to the 
intracellular bacteria, bacteria are also able to persist in the lumen of the bladder, and can ascend 
up the ureters to cause kidney infection. The discovery of additional UPEC virulence factors 
could lead to strategies for prevention of UTIs in humans and the development of more effective 
drugs for treatment of E. coli infections.  
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degS of E. coli encodes a 355 residue protein that is a homolog of the DegP protease [4]. 
The DegS protein is an integral inner membrane protein with an active site in the periplasm [5]. 
This protein is able to detect and break down misfolded proteins in the periplasm so that they can 
be cleared from the cell [5]. Additionally, DegS provides proteolytic cleavage of the RseA anti-
sigma factor when misfolded proteins are detected to regulate σE activity in E. coli cells [5]. 
Activity of the σE pathway is essential under conditions of envelope stress as well as in non-
stress conditions in order to maintain homeostasis within cells [6]. When degS is mutated in 
bacteria, thousands of outer membrane vesicles (OMVs) are produced in what is likely a 
response to the stress of accumulated misfolded proteins [7]. Previous work from the Kuehn lab, 
as well as unpublished work from our lab, has shown that approximately 200-fold more OMVs 
are produced in a degS::cat mutant strain [7].  
OMVs are nano-sized (~10-300 nm in diameter), spherical, bilayered proteolipids that are 
produced when small portions of the bacterial outer membrane bulge away from the cell, break 
off, and release [8]. OMVs can present virulence factors to host cells, but it remains uncertain 
whether OMVs are liberated by membrane instability or through a more directed process. The 
production of OMVs has been described as a bacterial stress response, but experimental evidence 
suggests that OMVs play a role in pathogenesis and are associated with virulence factors and 
toxins [9, 10]. OMVs bear components that are thought to impact the course of infection and are 
likely to play a significant role in the virulence of Gram-negative bacterial pathogens [9, 10]. 
To investigate the role that degS and OMVs have on the virulence of UPEC, we 
characterized a degS::cat UPEC strain. We aimed to determine if degS mutation affects the 
virulence of UPEC. We hypothesized that degS::cat would be more virulent due to the increased 
production of OMVs, which can play an important role during infection. If degS::cat was more 
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virulent, it would suggest that OMVs do increase virulence, but that degS is not essential for 
UPEC virulence. Conversely, if the wild-type strain was more virulent, this could mean that an 
increase in OMV production is detrimental to virulence, or that degS is essential for virulence in 
UPEC. We used a variety of in vitro and in vivo assays to compare our strains and to test the 
virulence of our mutant. Our results indicated that the mutation of degS slightly impairs growth 
of the bacteria, but does not change the morphology or protein expression in the membranes. 
Furthermore, degS::cat was less virulent than wild-type UPEC both in vitro and in vivo, 
demonstrating that mutation of degS, accompanied by an increase in OMVs, decreases the 
virulence of UPEC. 
 
Materials and Methods 
Bacterial Strains 
The model uropathogenic E. coli strain UTI89 was used as the wild-type strain for all studies. 
This strain was originally isolated from the urine of a patient with cystitis [11]. A degS::cat 
mutant (UTI89 degS::cat) was previously made by replacing the degS with a chloramphenicol 
resistance cassette using lambda red mutagenesis [12]. Strains were grown in fresh LB without 
antibiotics, unless otherwise indicated. 
 
Molecular Biology 
A degS complementation plasmid was created by amplifying degS from UTI89 genomic DNA (F 
primer: 5’-CCATCATGTTTGTGAAGCTCTTACGTTCCGTTGCGATTGG-3’, R primer: 5’-
TTAGTTGGTCGCCGGATATTCCTGAATGGTGACCTGC-3’).The product and the plasmid 
vector PTRC99A were digested with XbaI and HindIII and then ligated together. The resulting 
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plasmid was transformed into TOP10 cells. Colony PCR identified colonies that contained the 
plasmid with the insert, and these colonies were sent for sequencing. Once the sequence was 
confirmed to be correct, the plasmid was electroporated into UTI89 degS::cat cells. The 
complemented mutant strain is termed UTI89/pTRC99a-degS degS::cat, and is referred to as 
pdegS in this document. 
 
Growth in Rich Media 
UTI89, UTI89 degS::cat and UTI89 degS::cat/pdegS were cultured in a shaker overnight at 37°C 
in 3 mL LB broth (with 100 µg/mL Amp for pdegS). The next morning, cells were sub-cultured 
1:100 into fresh LB media with or without antibiotics as appropriate and grown ~2 h until the 
OD600  = 1 (approximately 2 x 10
9
 CFU/ml). The cells were diluted to 2 x 10
5 
cells/mL. 
Approximately 2000 cells were added to 200 µL of LB per well. Strains were plated in triplicate 
wells in LB media with or without Amp as appropriate. Cells were grown at 37°C and the optical 
density was recorded every 40 min for 12 h in a temperature controlled microplate reader 
(Synergy 2, Biotek). Triplicate wells of LB and LB-Amp served as blanks and controlled for 
contamination. The experiment was repeated three times.   
 
Transmission Electron Microscopy (TEM) 
UTI89 and UTI89 degS::cat cells were grown in LB overnight; replicates for each strain were 
grown under shaking or static conditions. The cultures were centrifuged at 5000 x g for 2 min 
and the pellets were resuspended in fresh PBS. Samples were then fixed and negative-stained 
with uranyl acetate before analysis on a JEOL 1200EX transmission electron microscope (JEOL 
USA, Peabody, MA) [13].  
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 Membrane Isolation 
Overnight cultures of mutant and wild-type strains were sub-cultured and grown in LB until they 
reached an OD600  = 0.8. Cells were pelleted and the pellets were stored at -20°C. The pellets 
were resuspended in 10mM Tris pH 8.0 with 100mM RNase and DNase. Cells were lysed in the 
Stansted Pressure Cell Homogenizer (model SPCH-10, United Kingdom). Whole cells were 
removed by centrifugation at 3000 x g for 15 min at 4˚C. The cytosolic and membrane proteins 
were resuspended in 50 mm Tris. Membranes and cytosol were separated by centrifugation at 
82,500 x g for 80 min at 4˚C. The supernatant containing the cytosolic and periplasmic contents 
was removed and saved and the pellet containing the membranes was resuspended in 50mM Tris 
and centrifuged at 82,500 x g for 80 min at 4˚C. The supernatant containing the inner membrane 
fraction was removed and saved, while the pellet containing the outer membrane fraction was 
resuspended in 10mM Tris. All samples were stored at -20°C for use in downstream 
applications.  
 
Protein Expression Analysis 
SDS-PAGE analysis was used to compare the proteins in whole bacteria, inner membrane, outer 
membrane and cytosol from the wild-type and mutant strains. Approximately equivalent amounts 
of protein from each sample were separated on a 12% SDS-PAGE gel. Gels containing whole 
cell lysate, outer membrane, and cytosolic fractions were Coomassie-stained for 30 min and then 
destained with 6:3:1 water: methanol: acetic acid until bands could clearly be seen. To visualize 
the inner membrane proteins of the wild-type and mutant strain, a Pierce Silver Stain Kit was 
used according to manufacturer’s instructions (Thermo Scientific).  
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 Bacterial Outer Membrane Vesicle Isolation and Protein Expression Analysis 
Wild-type, degS::cat, and pdegS strains were grown in 100mL LB overnight, before 
centrifugation for 10 min at 5000 x g at 4°C. Supernatant was filter sterilized with 0.2 µm filter 
and ultracentrifuged for 2 hours at 40,000 RPM (100,000 x g). The pellet was resuspended in 
200ul of Dulbecco’s phosphate buffered saline (Gibco) with 0.2M NaCl. A BCA protein assay 
was performed according to manufacturer’s instructions (Pierce). The samples were separated by 
SDS-PAGE and silver-stained to compare the proteins in the OMVs.  
 
Antibiotic Susceptibility 
UTI89 and UTI89 degS::cat were cultured in a shaker overnight at 37°C in 5 mL LB broth. 
Strains were sub-cultured the next morning and grown to an OD600 = 1. The cells were diluted 
1:10 in sterile PBS.  The cultures were then spread evenly across the entire plate with a sterile 
swab. Using sterile tweezers, three antibiotic-impregnated disks were placed onto each agar 
surface. A single strain and antibiotic combination was used per plate. The antibiotics for each 
disk were as follows: ampicillin (10 µg/disc), chloramphenicol (30 µg/disc), kanamycin (30 
µg/disc), novobiocin (30 µg/disc), spectinomycin (100 µg/disc), and tetracycline (30 µg/disc). 
The plates were incubated overnight at 37°C, and the zone of inhibition around the disk was 
measured. The experiment was repeated three times. 
 
Mouse Infections 
C57BL/6 (Jackson Laboratories, Bar Harbor, Maine) mice were used for infections; all mice 
were female and aged matched at 8-10 weeks. UTI89 and UTI89 degS::cat were grown in 20mL 
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LB overnight under static conditions. Catheters were made with 30 gauge needles and 0.28mm 
polyethylene tubing and sterilized with UV light in tissue culture hood overnight. Overnight 
cultures were spun down at 2000 x g for 10 min, resuspended in sterile PBS to OD600 = 1. 
Resuspended bacteria were diluted 1:1 with PBS for the inoculum. Under isoflurane anesthesia, 
mice were infected transurethrally with 50 µL of bacteria (~1 x 10
7 
bacteria/mouse). Bladders 
were harvested 24 hours post-infection (hpi) using sterile technique, homogenized in sterile 
phosphate-buffered saline (PBS) and plated on LB agar in order to enumerate colony forming 
units (CFU)/bladder. The experiment was performed three times with three mice/bacterial 
strain/group.  
 
Confocal Microscopy 
Mice were infected with 50µl of UTI89/pcomGFP or UTI89 degS::cat/pcomGFP (2 
mice/bacterial strain) as described above. Mice were sacrificed 16 hpi and bladders were 
harvested, bisected, and stretched. Bladders were fixed in 2.5% paraformaldehyde in PBS, 
permeabilized with 0.1% Triton X-100 in PBS and stained with Syto 61 nucleic acid stain 
(1:1000 in PBS, Life Technologies). Stained bladders were washed 3 times with PBS, mounted 
on slides with ProLong Gold antifade reagent (Invitrogen) and imaged on a Zeiss LSM510 
inverted confocal microscope.  
 
Human Bladder Epithelial Cell Culture 
5637 cells (ATCC HTB-9) were maintained in RPMI 1640 medium (Gibco) supplemented with 
10% fetal bovine serum (FBS, Sigma). Cells were grown at 37°C in a humidified atmosphere 
with 5% CO2.  
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 In vitro Binding and Invasion Assays  
Binding and invasion assays were performed as described previously, with modifications [14]. 
Four strains were compared: UTI89, degS::cat, pdegS and UTI89 fimH 
-
 (negative control). 
Overnight static cultures of each strain were centrifuged and resuspended in sterile PBS to OD600 
= 1. Binding, input, and invasion wells with confluent 5637 cells were prepared in triplicate for 
each strain in 24-well tissue culture plates (TPP). Old medium was aspirated and 1 mL of fresh 
medium was added to each well. The desired bacterial suspension (10 µL) was added to each 
well. Plates were spun at 325 x g for 3 min at room temperature and returned to the incubator. 
Binding and input wells were removed after 30 min. Supernatants were aspirated from the 
binding wells and cells were washed five times with 1X PBS before lysis in 0.1% Triton X-100 
(in PBS) at room temperature for 15 min. Input wells were not washed before cells were lysed 
with 10uL of 10% Triton X-100. Each well was scraped and examined under the microscope to 
ensure that all cells released. Lysed cells and bacteria were serially diluted and plated on LB agar 
plates to enumerate CFU. The invasion plates were removed from the incubator after 60 min and 
wells were washed once with 1X PBS. Gentamicin (10 mg/mL in media) was added to each well 
and the plate was returned to the incubator for 90 min. After gentamicin treatment, wells were 
washed three times with 1X PBS before lysis in PBS with 0.1% Triton X-100. Lysed cells and 
bacteria were scraped, serially diluted, and plated. The LB agar plates were incubated overnight 
at 37°C and colonies were enumerated the following day.  
 
Statistical analysis 
Significance was determined by a Student’s t test, with values less than 0.05 considered  
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significant. For the mouse infections, significance was determined by the Mann-Whitney U 
statistical analysis as performed by GraphPad Prism 5 software. 
 
Results 
Wild-type, degS::cat and pdegS strains do not have significantly different growth in LB. 
Growth curves of UTI89, UTI89 degS::cat and UTI89 pdegS were developed to compare 
the effects that degS mutation has on bacterial growth. Cells were cultured in LB, and the optical 
density was measured every 40 min for 12 h to create growth curves (Figure 1). Strains had 
similar growth at all time points. Overall, the mutant cultures were less dense than the wild-type 
or complemented strains at most time points; this difference was not significant.  
 
degS::cat does not have altered morphology under aerated or nonaerated conditions.  
Transmission electron microscopy was used to examine the effects that shaking and static 
growth conditions have on the size, shape, and pili of bacterial cells from the wild-type strain or 
degS::cat. Shaken cultures of either strain produced bacterial cells that were coccoid with few 
pili (Figure 2B, D). Conversely, cells from static cultures were rod-shaped with lots of pili 
(Figure 2A, C). The wild-type and mutant strains had similar morphological characteristics in 
both the static and shaken cultures, indicating that degS::cat does not alter morphology under 
either condition. 
 
Protein composition of membranes and cytosol is similar between strains.  
SDS-PAGE gels were used to compare the protein content of whole cell lysates of wild-
type and mutant cells to see if degS mutation affects the expression of other proteins.  There were 
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no observable differences in the protein composition of whole cell lysates from wild-type or 
mutant cells when stained with Coomassie blue (Figure 3A). Cellular fractionation and SDS-
PAGE gels were used to more closely examine the composition of the inner membrane, outer 
membrane and cytosol of the two strains. We did not see any differences in the proteins in the 
outer membranes of our two strains (Figure 3B). Surprisingly, we found that degS::cat was 
missing a high molecular weight protein band that appeared in the cytosol from wild-type 
bacteria; however, we were not able to identify this protein (arrow, approximately 200 kDa, 
Figure 3B). Finally, silver stained SDS-PAGE gel was used to analyze the protein expression in 
the inner membrane (Figure 3C). We did not note any major differences in the protein content of 
the inner membrane between the two strains.  
 
degS::cat results in increased production of outer membrane vesicles.  
In order to confirm that degS::cat produces more outer membrane vesicles (OMVs) than 
the wild-type strain, OMVs were isolated from overnight cultures of the wild-type, degS::cat, 
and pdegS strains. Visual inspection of the pellets of the OMVs recovered after 
ultracentrifugation revealed a much larger pellet in the degS::cat compared to either the wild-
type or complemented strain (Figure 4A). This was confirmed by resuspending the pellets in 
equal volumes and determining the protein content in each (UTI89 = 31 µg/mL, UTI89 degS::cat 
= 910 µg/mL, pdegS = 51 µg/mL). TEM confirmed that these pellets contained mostly intact 
OMVs, with minimal amounts of cellular debris (data not shown). A silver-stained SDS-PAGE 
gel was used to analyze variations in OMV protein content in each strain. We found that OMVs 
isolated from degS::cat contained many different proteins than OMVs from the wild-type or 
complementated strains, and that some of the proteins that were common between strains varied  
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in amount (see asterisks for examples, Figure 4B).  
 
degS::cat does not alter antibiotic susceptibility. 
An antibiotic disk diffusion assay was used to compare the antibiotic susceptibility of the 
wild-type strain and the degS::cat. This method was used as a simple way to assess changes in 
essential pathways (DNA replication, protein synthesis, cell wall synthesis, etc.). The assay 
showed no significant differences in susceptibility to ampicillin, kanamycin, novobiocin, 
spectinomycin, or tetracycline (p = 0.10, 0.09, 1.0, 0.07 and 0.34, respectively; Figure 5). We 
therefore conclude that degS::cat and increased OMV production does not alter antibiotic 
resistance, and that most essential pathways are intact. There was a significant difference in 
susceptibility to chloramphenicol (p < 0.000001, Figure 5). As a resistance cassette for this 
antibiotic was used to replace the degS in the mutant, chloramphenicol functioned as our positive 
control for the assay. 
 
degS::cat bacteria cause less severe infections in a murine cystitis model. 
Female C57BL/6 mice were infected using a well-established murine model of cystitis in 
order to compare the virulence of wild-type and mutant strains. Mice inoculated with degS::cat 
had approximately 100-fold fewer bacteria in the bladder than mice inoculated with UTI89 by 24 
hpi (p < 0.0001, Figure 6).  
 
degS mutation does not alter intracellular growth in vivo. 
Fluorescent confocal microscopy was used to examine the growth of wild-type and 
mutant strains within murine bladder epithelial cells to investigate a potential cause for the 
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differences in bladder titers 16 hpi. Although the importance of intracellular bacterial growth was 
originally defined in a mouse model of UTI, intracellular growth and formation of intracellular 
bacterial communities (IBCs) have been described in human patients with active cystitis [15]. 
The bladders of C57BL/6 mice were inoculated with UTI89/pcomGFP or degS::cat/pcomGFP. 
Bladders were harvested 16 hpi and stained for microscopy. We found both early stage and 
mature IBCs, indicating that the strains were equally capable of growth within bladder cells 
(Figure 7). It should be noted that IBCs were more difficult to identify in mice infected with the 
mutant strain, as all bacteria seemed to have lost the GFP-expressing plasmid for an unknown 
reason.  
 
degS::cat has decreased ability to invade host cells. 
Binding and invasion assays were conducted in order to compare how well the wild-type, 
degS::cat and pdegS strains bound and invaded 5637 human bladder epithelial cells in vitro. We 
found that degS::cat bound to 5637 cells as well as the wild-type (p = 0.47, Figure 8A). 
However, the degS::cat strain invaded into cells significantly less than the wild-type strain (p = 
0.01, Figure 8B). We found that only 0.1% of the degS::cat bacteria that bound to cells actually 
invaded, as compared to 0.59% of wild-type bacteria (Figure 8C). pdegS was able to bind and 
invade as well as the wild-type strain (p = 0.83 and 0.58, respectively, Figure 8A, B). degS::cat 
bound similarly to the complemented strain (p = 0.28, Figure 8A), but invaded significantly less 
(p = 0.001, Figure 8B). A strain that is unable to produce pili (UTI89 fimH 
-
) functioned as a 
binding mutant and our negative control. As expected, UTI89 fimH 
- 
was unable to bind to host 
cells, and, as a result, invaded significantly less than the wild-type strain (p = 0.04, 0.02, 
respectively; Figure 8A, B).  
224
 Discussion 
To investigate the role that degS and OMVs have on the virulence of UPEC, we 
characterized a degS mutant strain. This mutant has the degS gene replaced with a 
chloramphenicol antibiotic resistance cassette. We predicted that degS::cat would be more 
virulent because of the increased production of OMVs. OMVs have previously been shown to 
contain outer membrane proteins, toxins and other factors that can be delivered to host cells, 
which may in turn enhance infection [9, 10]. However, our results demonstrated that degS may 
instead be necessary for virulence and that increased numbers of OMVs did not promote 
infection.  
Our experiments with degS::cat demonstrated that while degS mutation does not alter the 
morphology of the bacteria under static or shaking growth conditions, the mutant has slightly 
impaired growth in rich media in early log phase. This difference is no longer significant by mid-
log phase, although the mutant does grow at a slightly decreased density. Complementation of 
the mutant restores the wild-type growth phenotype. These data may indicate that increased 
OMV production early in growth modifies nutrient allocation and limits the speed at which 
bacteria can replicate. Similarly, DegS function may be most important in early log phase, when 
proteases can easily be overwhelmed by misfolded proteins that accumulate as the bacteria 
rapidly synthesize proteins necessary for growth. In contrast to this idea, comparison of isolated 
membranes did not reveal major changes in protein content. However, in the cytosol, a high 
molecular weight protein was missing in the degS::cat which could be related to a change in 
virulence.  
We were able to confirm that degS mutation results in increased OMV production, and  
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were able to restore wild-type production of OMVs by complementing the mutant with the wild-
type gene. Interestingly, in addition to increased numbers of OMVs, the mutant also had changes 
in the proteins contained within those OMVs. In line with the previous suggestion, these likely 
represent misfolded proteins that have accumulated in the periplasm due to the lack of functional 
DegS. This could be confirmed by isolating and comparing the periplasm of our three strains. 
Interestingly, the variability in the protein content of the OMVs and the whole cells demonstrates 
the efficiency for packing misfolded proteins specifically into OMVs to clear them from the 
cells. However, it is possible that one or more of those proteins could be negatively affecting the 
virulence of the mutant in vitro and/or in vivo. The degS::cat and wild-type strains also had 
similar antibiotic susceptibility, indicating that the basic processes through which these 
antibiotics function are not affected by increased OMV production or the presence of extra 
misfolded proteins present in the outer membrane and periplasm due to the decreased DegS 
activity. 
In vitro binding and invasion assays and mouse infections showed that degS::cat is less 
virulent than wild-type. The binding and invasion assays demonstrated that degS::cat cells were 
able to bind to host cells just as well as the wild-type strain, indicating that degS::cat does not 
alter pili production or function. This confirmed our TEM result showing no obvious change in 
the number of pili produced by the mutant under static conditions. Surprisingly, degS::cat was 
not able to invade into the cells. A complemented mutant strain was able to bind and invade as 
well as the wild-type strain. However, the degS::cat strain bound and invaded significantly less 
than its complement. This confirms that the deletion of degS specifically leads to decreased 
ability to invade. These results may mean that degS is important for the invasion mechanism in 
this model, or that increased production of OMVs is detrimental to mutant cells. Past research 
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has shown that UPEC invade host cells via an HDAC6 modulated microtubule dependent 
pathway; because degS::cat was not able to invade host cells this may mean that excess numbers 
of OMVs can disrupt this pathway [16]. Alternatively, degS mutants may have limited ability to 
produce important virulence factors due to energy wasted on misfolded proteins and OMV 
production. 
In a mouse model of cystitis, we found that mice infected with degS::cat had 100-fold 
fewer bacteria in their bladders at 24 hpi. Consistent with our results, past research has also 
shown that degS is necessary for virulence
 
in a murine model of peritonitis, and that σE regulation 
is essential for UTI [17, 18]. We did not find any differences in intracellular growth of the 
bacteria when we assessed the bladders for IBC formation. However, IBCs seemed to occur less 
frequently in mice infected with degS::cat (observation by the authors). Future experiments 
could quantify IBC formation in mice infected with the wild-type and mutant strains to 
determine if there is an invasion defect in vivo as well. Additional experiments could also 
confirm that the complemented strain is able to rescue the infection defects. 
The function of the DegS protein is relatively well understood. Previous studies have 
indicated that DegS functions as a protease in vivo, contributes to the regulation of σE activity, 
and clears incorrectly assembled proteins out of the periplasm of the cell [4-6]. When degS is not 
present, OMV production increases, likely as a result of stress on the cell envelope [7]. In our 
strain, OMV production may be using more of the available energy which could explain why 
degS::cat grew a little bit slower than wild-type. Although OMVs have been shown to positively 
impact infection, our results showed that knocking out degS decreased virulence [9, 10]. This 
suggests that increased OMV production in UPEC could be stressing the cell instead of aiding in 
infection. Alternatively, the extra vesicles present in mice infected with degS::cat could increase 
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the activation of the host immune system, resulting in faster clearance of the mutant bacteria. 
Finally, our experiments do not conclusively determine whether the altered virulence is a due to 
greater numbers of OMVs, or to a different factor specific to the degS mutant. Further research 
can be done to focus solely on the effects of OMVs in UPEC virulence. Specifically, wild-type 
UPEC can be tested in vitro and in vivo with exogenous OMVs to determine whether OMVs 
alter virulence.  
By investigating bacterial virulence factors and important bacterial genes, we can better 
understand how bacteria function. This can allow chemists to create drugs that are more effective 
against specific bacteria, and help doctors determine how best to treat infections. E. coli persists 
throughout our bodies and our environment, so an in-depth understanding of UPEC virulence 
could aid in reducing UTI occurrence and recurrence, as well as associated healthcare costs. 
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Tables and Figures 
 
 
 
Figure 1: Growth of UTI89, degS::cat, and pdegS in LB. The OD600 was measured every 40 
min during growth at 37ºC. UTI89 is shown in blue, degS::cat is shown in red and pdegs is 
shown in green. LB and LB-Amp (used as blanks) are shown in purple and orange, respectively. 
Error bars represent standard deviation. 
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Figure 2: TEM images of UTI89 and degS::cat. Representative images from UTI89 and 
degS::cat cells under shaken and static growth conditions. The scale bar represents 500 nm.  
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Figure 3: Protein expression of whole cells and cellular fractions. (A) Coomassie stain was 
used to show the protein expression in whole cell lysates from both strains. (B) Coomassie stain 
was used to show protein content in the outer membrane and cytosol of both strains. Arrow 
indicates a missing high molecular weight protein in the cytosol of degS::cat. (C) Silver stain 
was used to show protein content of the inner membrane of the two strains. Marker indicates the 
approximate protein size in kDa.  
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Figure 4: Protein expression in isolated OMVs. (A) Pellets of OMVs after ultra-centrifugation 
of sterile O/N supernatants. Pellets are circled in red. (B) A silver-stained protein gel revealed 
difference in protein composition of OMVs. Examples are denoted with asterisks (*). Marker 
indicates the estimated protein size in kDa.  
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Figure 5: Antibiotic susceptibility. The antibiotic susceptibility of the wild-type and mutant 
strains was determined by disc diffusion assay. The average zone of inhibition was graphed; 
error bars show the standard deviation.  
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Figure 6: Bladder bacterial titers from infected mice. Colony-forming units (CFU) recovered 
from mouse bladders 24 hpi. Horizontal lines indicate the geometric mean.  
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Figure 7: Confocal microscopy images of IBCs. Bladders of mice infected with 
UTI89/pcomGFP or UTI89 degS::cat were harvested at 16 hpi. IBCs in the bladders were 
visualized at 63X. Nucleic acids are stained red. IBCs are indicated with an arrow.  
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Figure 8: Binding and invasion into 5637 human bladder epithelial cells. (A) The average 
percent of UTI89, degS::cat, pdegS or UTI89 fimH 
-
 (negative control for binding) that was able 
to bind to host cells. (B) The average percent of each strain that was able to invade into the host 
cells. (C) The average percent of bound bacteria that invaded into host cells. Error bars are used 
to show the standard deviation; * p < 0.05, relative to UTI89.  
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